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Abstract 
 
Introduction: A proper nutrition can contribute to adequate glucose control in patients 
with type 2 diabetes. The analysis of the association between glycaemia and socio-
demographic characteristics, nutrition recommendations compliance and meal 
composition can contribute to the discussion of the optimal nutrition therapy for 
patients with type 2 diabetes. 
Aims: This thesis analysed the associations between several clinical and psychometric 
variables that can determine glycaemic control: nutritional intake, barriers to nutrition 
therapy adherence, postprandial glycaemia, and diabetes complications perception. 
Methods: A group of 66 patients previously diagnosed with type 2 diabetes mellitus was 
recruited and categorized into patients with HbA1c below 7% (proper glycaemic control) 
and patients with HbA1c of 7% or above (poor glycaemic control).  
All subjects were interviewed and offered a nutritionally controlled breakfast. Glucose 
response to the experimental breakfast was monitored for 120 minutes after the meal. 
Results: The results show that subjects with adequate glycaemic control have a better 
compliance of nutrition recommendations, but all patients have excess intakes of 
energy, total cholesterol, saturated fatty acids, and sugars.  
There are no significant differences in postprandial glycaemia between patients with 
adequate glycaemic control and those with poor glycaemic control,  
Patients with poor glycaemic control have a more biased opinion of their likelihood of 
personal disease risk.  
Younger age, high body mass index, and biased personal disease risk perceptions are 
important predictors of glycaemic control. 
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Discussion: This work identified several determinants of glucose control and shows that 
some patients are unaware that they exceed the recommended rise in postprandial 
glucose, and thus may be at a higher than expected risk for macro and microvascular 
events. 
Conclusions: As self-monitoring is the only practical way to detect postprandial 
hyperglycaemia, efforts should be made to promote regular glucose self-monitoring. 
Health professionals need to consider specific patient characteristics in order to provide 
proper continued medical care, and nutrition education should be structured and 
tailored to the perceptions of patients. 
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1.1. Background and significance 
Osteoporosis, type 2 diabetes mellitus (T2DM), several types of cancer, and coronary 
disease are considered high-prevalent diseases, related with obesity and overweight 
(WHO/FAO 2003). There is a growing concern with the burden associated with these 
non-communicable diseases and T2DM may even be considered the greatest epidemic 
in human history, with over 190 million affected individuals worldwide and an estimated 
300 million more with pre-diabetes (Zimmet 2005).  The mortality attributed to diabetes 
in the year 2000 was around 2.9 million deaths (5.2% of all-causes mortality), placing 
diabetes as the fifth leading cause of death (Roglic et al. 2005).  Diabetes is also 
responsible for 2-7% of the expense of health services in Western countries (ADA 
2003a).  
Treatment and prevention approaches for T2DM focus on achieving glycaemic control, 
in order to manage the disease and to prevent or slow down its complications. General 
management of diabetes consists of patient education, medical nutrition therapy, 
physical activity, and pharmacological therapy combined with oral hypoglycaemic 
agents or insulin (Nyenwe et al. 2011). 
Recently, the role of postprandial glycaemia (PPG) in overall glycaemic control and as a 
risk factor for cardiovascular complications has been discussed, as patients with good 
glycaemic control can show elevated postprandial hyperglycaemia (PPHG). According to 
the American Diabetes Association (ADA), glycated haemoglobin (HbA1c) levels below 
or around 7% are associated with long-term reduction in macro-vascular disease (ADA 
2013a), and a reasonable goal in HbA1c for T2DM adult patients is 7%. HbA1c reflects 
the average plasma glucose concentration over prolonged periods of time and a 2009 
review (Peter et al. 2009) suggests that the relative contribution of PPG for the overall 
glycaemic control is around 70% in patients with HbA1c below 7.3%, independently of 
the timing of the meal during the day.  
PPHG seems to be common in T2DM patients, even in those who are considered to have 
good overall glycaemic control, and achievement of target HbA1c and fasting plasma 
glucose levels does not necessarily indicate that good glycaemic control is continuous 
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throughout the day (Ceriello 2010). A meta-analysis by Coutinho and colleagues 
(Coutinho et al. 1999) reports an exponential relationship between the incidence of 
cardiovascular events and elevated glycaemia two hours after a meal, resulting in an 
increased mortality risk, that is also reported in a large European patient sample  (Ning 
et al. 2010). A 2010 review (Ceriello 2010) suggests that PPG values one hour after 
breakfast are predictive of all-cause mortality and reports that PPHG is associated with 
increased cardiovascular risk, independent of fasting hyperglycaemia. This adds to the 
evidence indicating that PPG may be a more dominant cardiovascular risk factor than 
fasting hyperglycaemia. 
The International Diabetes Federation (IDF) has developed specific clinical guidelines for 
PPG and recommends that two hour post-meal glucose levels are kept below 140 mg/dl 
(IDF 2007), and that the difference between pre-prandial and post-prandial glycaemia 
should normally be between 30 and 50 mg/dl (Slama et al. 2006). Furthermore, the 
management and treatment of T2DM must consider PPG (Tibaldi 2009), as its variations 
throughout the day and between different meals are inﬂuenced by the blood glucose 
level before the meal, the nature and quantity of carbohydrate consumed, or the anti-
diabetic treatment (Ceriello 2010).  
Although the goals and objectives for treating T2DM are known, their translation into a 
daily routine seems difficult. Studies that have evaluated adherence do dietary 
recommendations have shown poor results, especially those with T2DM patients 
(Thanopoulou et al. 2004; Toeller et al. 1996), who appear to have high intake of calories 
and saturated fat, accompanied by low intake of fibre (Rivellese et al. 2008). Self-
reported adherence to treatment in T2DM is higher for pharmacological therapy than 
for a proper diet, even if weight loss trough diet and exercise also results in an improved 
glycaemic control (Vijan et al. 2005). Despite the recognized success of medical nutrition 
therapy, patients treated with diet alone, in a general practice setting, have significant 
rates of complications, and are less likely than those on medication to be adequately 
monitored (Julia and Pringle 2004). This can imply that compliance with dietary 
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recommendations can be improved in a general practice setting, and that patient 
education strategies should be assessed. 
A proper patient education is something that needs to be addressed as to overcome 
barriers to chronic disease self-management (Jerant et al. 2005). Daly and collaborators, 
(Daly et al. 2009), identified the type and duration of diabetes,  other illnesses or 
conditions, psychosocial factors, medication use, following of meal and exercise plans, 
and also glucose testing at home as factors that inﬂuence diabetes treatment and 
management. Research with a focus group design (Gazmararian et al. 2009) identified 
as barriers to diabetes care the emotional toll following diagnosis and the lifestyle 
changes needed to treat the disease. The same study also reports that patients fail to 
recognize the risks and consequences of a condition that is asymptomatic for most of its 
natural history, but believe that there is a lack of follow-up on patient education 
interventions (refresher courses and support group discussions, for example), and that 
different education modalities could be available.  
The Diabetes Attitudes Wishes and Needs (DAWN) (Martha M Funnell 2006) and 
DAWN2 studies (Peyrot et al. 2013), which include a large international sample of 
patients and analysed psychosocial issues in diabetes and person-centred diabetes care, 
showed that patients with diabetes report low rates of self-management behaviours, 
especially for diet and exercise, allowing to conclude that there are still significant 
challenges in self-management, adherence, access to support and involvement in care. 
Results from these studies show that patient distress with the disease is common and 
interferes with self-management (Peyrot et al. 2005a). The DAWN2 study shows that 
patients report important prevalences of negative impact of diabetes in all life and 
lifestyle aspects investigated, ranging from 20.5% on relationship with family/friends to 
62.2% on physical health. Only 48.8% of subjects had participated in diabetes 
educational programs to help manage the disease (Nicolucci et al. 2013). 
Few studies have specifically examined the reasons for the low adherence to dietetic 
recommendations or examined how patients view dietary restrictions, but it is known 
that interventions aimed at improving patients ability to modify their diet need to 
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consider preferences and barriers when setting goals for treatment (UKPDS Study Group 
1995b).  
This knowledge, together with the multiple determinants of food intake make the case 
for the need of further research, in order to successfully translate the benefits of 
interventions in controlled research environment to individuals in the community (Vijan 
et al. 2005).  
The health risks of poor diabetes care are well known by the scientific community, but 
the general population is yet to fully appreciate the hazards of this condition (Nyenwe 
et al. 2011). Assessing patients’ characteristics and their motives and motivations to 
comply with nutrition therapy may offer some insight into the skills and adjustments 
needed to promote the adequacy of current nutrition therapy guidelines in a clinical, on 
the field, setting. Additionally, considering the effect of PPG in glycaemic control, the 
fact that it provides immediate feedback on the effect of foods and meals, and its role 
as a cardiovascular risk factor (Jovanovic 2009), an investigation analysing the 
associations between PPG and socio-demographic characteristics, nutrition 
recommendations compliance and meal composition, could contribute to the discussion 
of the optimal nutrition therapy in T2DM and to the design of strategies to reduce the 
burden of diabetic complications. A comparison of PPHG using a case-control design, 
with patients who believe they currently have achieved a good glycaemic control and 
patients who fall above the HbA1c cut point defined for this metabolic state, may help 
to understand the role of HbA1c in the education, counselling, and treatment of T2DM, 
and also to quantify the odds of achieving good glycaemic control based on different risk 
factors. 
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1.2. Overview of diabetes, insulin secretion and insulin action  
Diabetes mellitus is a condition that encompasses a group of metabolic diseases 
characterized by hyperglycaemia (ADA 2013b). Its clinical features have been 
documented since antiquity, with records from around 1550 BC detailing references to 
a condition now believed to be diabetes mellitus (Sanders 2002). The term diabetes has 
been traced to Egypt, in 230 BC, when Apollonius of Memphis used the Greek word 
meaning siphon or “to pass through” to describe patients’ symptoms. Around 150 AD, 
Aretaeus of Cappadocia provided a clinical description of a condition characterized by 
increased urine ﬂow, thirst and weight loss, noting that the onset commonly followed 
acute illness, injury or emotional stress (Bilous et al. 2010). Although physicians in India, 
contemporary of Apollonius of Memphis, named this condition “madhumeha” or “honey 
urine” after observing that urine from patients attracted ants and flies, the term 
mellitus, from the Greek and Latin for honey, was only firmly established after 1769, on 
account of an elaborate classification on human diseases published by William Cullen, a 
British physician. This was the first time a distinction was made between “diabetes 
mellitus”, which was applied to cases were the urine presented sweet smell and flavour, 
and “diabetes insipidus”, applied to cases with limpid but not sweet urine (Bilous et al. 
2010; Sanders 2002). 
Currently, diabetes mellitus is considered a heterogeneous multi-etiologic disorder, 
characterized by chronic hyperglycaemia and disturbances of carbohydrate, fat and 
protein metabolism, caused by pathophysiological mechanisms linked to insulin 
synthesis, insulin metabolic regulation or both (ADA 2013b). 
Insulin is a hormone synthesised within the β-cells of the islets of Langerhans in the 
endocrine part of the pancreas and is essential for the regulation of carbohydrate and 
fat metabolism.  Carbohydrate metabolism plays a major role in energy production and 
glucose, a monosaccharide naturally occurring in its D-form and metabolized by nearly 
all known organisms, is considered the most important carbohydrate. Glucose and fat 
(in the form of fatty acids) can provide energy for all the body’s needs (Holt et al. 2011).  
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Glucose comes directly from food intake by breakdown of glycogen in the liver, or by 
the formation of glucose in the liver and kidneys, from other carbon compounds such as 
lactate, pyruvate, amino acids, or glycerol. Although glucose is used by all cells, free fatty 
acids act as the main fuel for most organs, due to the greater energy yield potential of 
fatty acids: when oxidized, one gram of fatty acids produces approximately nine 
kilocalories, while the same weight in carbohydrate produces approximately four 
kilocalories. The brain constitutes the exception to this fuel predominance, as glucose 
serves as the only metabolic fuel for this organ under normal physiologic conditions. The 
brain’s inability for synthesizing glucose or to store more than a relatively small amount 
of glycogen, together with the limitations of transport across the blood-brain barriers 
and with the low circulating concentration of alternative substrates, signify that a 
continuous supply of glucose is needed to maintain normal organ function (Szablewski 
2011).  
Glucose is extremely important in muscle cells, as its conversion into energy is faster 
than energy production from fatty acids; this can account for the need for a steady 
concentration of glucose, managed by a process of glucoregulation that aims to maintain 
glycaemic homeostasis. Homeostatic arterial glucose levels is achieved by a regulatory 
mechanism involving insulin, that acts in skeletal muscle, adipose tissue, and liver, 
promoting uptake and storage of carbohydrate, fat, and amino acids, while 
simultaneously antagonizing the catabolism of these nutrients (Holt et al. 2011).  
In skeletal muscle, insulin induces glucose transport and glycogen storage, as well as 
glycolysis and tricarboxylic acid cycle activity. In the liver, insulin lowers glucose output 
by inhibiting glycogenolysis and gluconeogenesis, and also promotes glycogen synthesis. 
In adipocytes, insulin promotes glucose uptake, glycerol synthesis, and triglyceride 
formation (Holt et al. 2011).  
In healthy individuals, glucose homeostasis maintains glycaemia at an average of 
approximately 90 mg/dl within a 24h period, with a maximal concentration usually not 
exceeding 165 mg/dl, after a meal. A decrease in plasma glucose to around 70 mg/dl will 
signal for the suppression of insulin release and will also lead to a decrease in glucose 
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uptake in certain areas in the brain where glucose sensors are located; this, in turn, will 
activate the release of counter regulatory hormones. Conversely, a 10 mg/dl increment 
in plasma glucose will stimulate insulin release. Glycaemia below 55 mg/dl impairs 
cerebral function, while more severe and prolonged hypoglycaemia causes convulsions, 
permanent brain damage, and even death (Szablewski 2011). 
The regulatory neuro-hormonal system depends on adequate insulin secretion, 
controlled by the function of the islets of Langerhans in the pancreas. The β-cells in this 
organ detect changes in circulating nutrients and respond by initiating an insulin 
secretory response. 
The pancreas is mainly an exocrine gland, responsible for the secretion of digestive 
enzymes, but its endocrine part regulates nutrient homeostasis and metabolism. The 
endocrine portion of the pancreas accounts for approximately 2% of the total organ’s 
mass and comprises approximately two million clusters of cells of at least four types: α-
cells, β-cells, δ-cells, and pancreatic polypeptide (PP) cells. These cells can be classified 
by their secretion: α-cells secrete glucagon, β-cells secrete insulin, δ-cells secrete 
somatostatin, and PP cells secrete pancreatic polypeptide (Shrayyef and Gerich 2010). 
Insulin is synthesized only within the β-cells and consists of two polypeptide chains 
linked by disulﬁde bonds. It regulates carbohydrate and fat metabolism by direct and 
indirect actions, in order to maintain nutrient homeostasis. Insulin, through binding to 
its receptors in the liver, kidney, muscle, and adipose tissue, enables a signalling 
pathway which involves a number of protein kinases and regulatory proteins and causes 
suppression of glucose release from the liver and kidneys, the translocation of glucose 
transporters in muscle and adipose tissue to increase their glucose uptake, and the 
inhibition of free fatty acids (FFA) release due to the suppression of lipase activity and a 
simultaneous increase in their clearance. Insulin also promotes glycogen accumulation 
by inhibiting glycogenolysis and stimulating glycogen synthase, the key enzyme in 
glycogen synthesis. Besides these actions, glucose levels are also lowered by the 
suppression of glucose output from the liver through inhibition of gluconeogenesis, 
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which has an effect on circulating FFA levels, since FFA promote gluconeogenesis and 
reduce glucose transport into the cells (Gerich 2000). 
Insulin secretion is characterized by dephosphorylation and phosphorylation that, in 
specific sites, create recognition domains that will allow the formation of multimolecular 
complexes. At the same time, scaffolding or adaptor proteins are formed that target 
enzymes to speciﬁc intracellular locales where critical substrates reside (Shrayyef and 
Gerich 2010). 
Insulin secretion occurs in two phases – a fast first secretory response, lasting for about 
10 minutes, in which insulin secretion rises rapidly, followed by a prolonged and steady 
secretion second phase, that lasts for as long as the blood glucose remains elevated. The 
ﬁrst phase involves the plasma membrane fusion of a readily releasable pool of insulin 
granules that discharge their contents in response to nutrient and non-nutrient 
secretagogues. Second-phase secretion is promoted exclusively by nutrients, mainly 
glucose, directed into β-cells by transporters (GLUT 1, GLUT 2 and GLUT 3) that enable 
an equilibrium between extracellular and intracellular concentrations. In the cells, 
glucose is phosphorylated by glucokinase, which modulates insulin secretion to the 
glucose levels (Holt et al. 2011). Glycolysis and mitochondrial metabolism produce 
adenosine triphosphate (ATP), which closes ATP-sensitive potassium (KATP) channels. 
This, in turn, causes depolarization of the β-cell plasma membrane, which leads to an 
inﬂux of extracellular calcium that triggers granule translocation and exocytosis (Ciaraldi 
2010). Glucose levels below 5 mmol/L (90 mg/dL) do not affect insulin release and 
glucose must be metabolised within the β-cell to stimulate secretion (Szablewski 2011).  
When there is no extracellular glucose, the β-cell membrane potential is maintained in 
potassium equilibrium by the efflux of potassium ions through ATP sensitive potassium 
channels. The presence of ATP in the cytosolic surface of β-cell membrane result in 
rapid, reversible inhibition of resting membrane permeability to potassium ions. ATP 
generation following glucose metabolism, along with lowering ADP levels, leads to 
closure of the ATP sensitive potassium channels which promotes depolarization of the 
β-cell membrane and influx of calcium ions. The increase of calcium ions starts the 
Chapter 1: Literature review 
10 
 
insulin secretory response, with the exocytosis of insulin secretory granules. Intracellular 
calcium is a principal effector of the nutrient induced insulin secretory response, linking 
depolarization with exocytosis of insulin secretory granules. Elevations in intracellular 
calcium are sufficient to initiate insulin secretion, and conditions that elevate 
intracellular calcium usually stimulate insulin release. Conversely, preventing calcium 
influx by removal of extracellular calcium or by pharmacologic blocking calcium channels 
inhibits nutrient induced insulin secretion (Codario 2010; Holt et al. 2011). 
Insulin secretion is mainly determined by the concentration of nutrients in plasma, 
mainly glucose, but some amino acids, such as leucine, lysine and arginine, can stimulate 
insulin secretion in the absence of glucose (Szablewski 2011). Leucine enters islets by a 
sodium independent transport system and affects β-cell membrane potential and ion 
fluxes, resulting in an insulin secretion similar to those of glucose, albeit in a smaller 
scale. Lysine and arginine cross the β-cell plasma membrane via a specific transport 
system for cationic amino acids and is believed that the accumulation of these positively 
charged molecules directly depolarizes the β-cell membrane, leading to a calcium influx 
(Holt et al. 2011).  
Insulin secretion in response to nutrient concentrations can be enhanced or inhibited by 
the action of several neurotransmitters and different hormones. Islets are innervated by 
cholinergic, adrenergic and peptidergic autonomic nerves and it is know that the 
autonomic innervation of the islets is important in regulating insulin secretion. An 
increased insulin output follows the activation of parasympathetic nerves and decreased 
insulin secretion follows increased sympathetic activity (Codario 2010). 
The autonomic nervous impact on hormone secretion is thought to be involved in insulin 
secretion during feeding, in coordinating islets to generate oscillations of hormone 
secretion, and in the regulation of secretory responses to metabolic stress. The 
parasympathetic nerve fibres that innervate islets are postganglionic, and acetylcholine, 
the major postganglionic parasympathetic neurotransmitter, stimulates the release of 
insulin and glucagon. In β-cells, acetylcholine ultimately amplifies the effects of glucose 
by elevating cytosolic calcium and activating the enzyme protein kinase C. Acetylcholine 
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also depolarizes the plasma membrane by affecting sodium ions’ conductivity, causing 
an increase in cytosolic calcium (Opara 2005). 
Islets also have an extensive sympathetic innervation, and norepinephrine, the major 
sympathetic neurotransmitter, has both secretion stimulatory (due to β2-
adrenoreceptors) and inhibitory effects (via α2-adrenoreceptors), depending on the 
relative levels of expression of the receptor subtypes (LeRoith et al. 2004).  
Pancreatic islets have a complex innervation and capillary network, receiving signals 
from other hormones and allowing islets to integrate the hormonal response and 
function as a coordinated secretory unit. The influence of other islet endocrine cell 
secretions has been studied and it is known that glucagon, a peptide hormone secreted 
by pancreatic α-cells, and somatostatin, secreted by δ-cells, have important effects on 
insulin secretion. The physiologic action of pancreatic polypeptide, which is the 
secretion of the fourth type of islet cell, is not completely know, although PP levels seem 
to rise after a meal composed of mixed nutrients, and its secretion is often elevated in 
patients with pancreatic tumours (Holt et al. 2011).  
Glucagon acts almost exclusively in the liver and plays an opposite role to insulin in 
glucose and nutrient homeostasis, promoting catabolism and making energy available 
to tissues when nutrients from food are less available. Glucagon activates adenylate 
cyclase, resulting in an intracellular cAMP increase, enhancing glycogenolysis as a result 
of phosphorylase stimulation. This response diminishes after several hours and is 
followed by an increase in gluconeogenesis.  In the liver, a low insulin to glucagon ratio 
signals energy utilization, resulting in glycogenolysis, gluconeogenesis, and fatty acid 
oxidation (Giugliano et al. 2008). Glucagon is a potent stimulator of hepatic glucose 
production and its secretion is influenced by hypoglycaemia, by sympathetic nervous 
input, by cholecystokinin secretion and by the presence of arginine and alanine 
(Ramnanan et al. 2011). 
The glucagon precursor, proglucagon, produces several peptides with different 
receptors and biologic activities. Among these, two glucagon-like peptides (GLP-1 and 
GLP-2) are identified. GLP-1 is produced in intestinal L-cells by cleavage of proglucagon 
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and secreted in response to carbohydrates, lipids and protein in the intestinal lumen. 
GLP-1 stimulates production and secretion of insulin and somatostatin, and inhibits 
glucagon (Szablewski 2011). 
GLP-2 is produced by the same process that results in GLP-1 and promotes growth of 
the intestinal mucosa and nutrient absorption, while inhibiting motility in the intestine. 
GLP-1 in classified as an incretin, referring to a group of intestinally secreted peptides 
released in response to the presence of nutrients, which enhance glucose-stimulated 
insulin secretion (Amori Re 2007).  
GLP-1, glucose–dependent insulinotropic peptide (GIP), and cholecystokinin (CCK) were 
identified as the main incretins associated with an elevated insulin response to nutrients 
after food intake and, currently, it is know that GIP is released from K-cells in the 
duodenum and jejunum in response to the absorption of glucose, to other actively 
transported sugars, amino acids, and long-chain fatty acids. Although GLP-1 and GIP 
both enhance insulin output, GIP stimulates glucagon secretion and inhibits GLP-1 
release. CCK is released in the gastrointestinal tract in response to fat and protein but 
its role in insulin secretion has not been completely explained due to the fact that high 
concentrations are required to assess its effects, and it is possible that its main function 
is in digesting nutrients in the duodenum (Rijkelijkhuizen et al. 2010). 
As stated, homeostatic regulation of body energy primarily involves insulin actions in 
skeletal muscle, adipose tissue, and liver. Generally, insulin promotes carbohydrate, fat 
and amino acid uptake and storage at the same time it antagonizes catabolism. Insulin 
promotes glycogen synthesis in muscle, adipocytes, and liver by activating glycogen 
synthase, which adds activated glucosyl groups to growing polysaccharide chains, 
enhancing the final step in glycogen synthesis (Szablewski 2011). Nonetheless, tissue-
specific insulin action occurs, mainly due to different expression of effector systems in 
target cells (Holt et al. 2011). 
In skeletal muscle, which accounts for the majority of glucose uptake, insulin stimulates 
the glucose transport effector system, promoting glucose storage as glycogen, as well 
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as promoting glycolysis and tricarboxylic acid cycle. Glucose transport proteins allow the 
creation of pores in cell membranes that allow for facilitative diffusion of 
monosaccharides, although each of the identified transporter isoforms has a specific 
role in glucose metabolism, determined by physiologic conditions and by substrate 
specificity and affinity (Szablewski 2011). 
In the liver, insulin lowers glucose output through modifications of enzymes, such as 
phosphorylation, and through changes in gene expression; hepatic metabolism inhibits 
glycogenolysis and gluconeogenesis and enhances glycogen synthesis, all of which 
determine glucose output (Holt et al. 2011). 
Insulin augments availability of both glycerol and fatty acids for triglyceride synthesis 
and activates lipogenic and glycolytic enzymes. This means that, in adipocytes, insulin 
promotes glucose uptake, glycerol synthesis, and triglyceride formation, while at the 
same time having an antilipolytic effect. Lipolysis in adipose tissue is regulated to assure 
that metabolic fuels are adapted to energy needs so that, during fasting, lipolysis is 
enhanced to allow that FFA will be available for oxidative fuel for the liver, the heart, 
and skeletal muscle. FFA are metabolized by the liver into ketones that replace glucose 
as the main fuel for the nervous system tissue. After nutrient intake, lipolysis is 
decreased and adipocytes store triglycerides, regulated by the antilipolytic action of 
insulin in adipose tissue (Opara 2005). 
The final responses in insulin action are directed at glucose transport and glycogen 
synthesis, while glucose entry into the primary insulin target tissues occurs by facilitated 
diffusion, mediated by the glucose transport proteins. The most important transporters 
with regard to insulin action appear to be GLUT1 and GLUT4. GLUT1 exists in all target 
tissues, residing primarily on the cell surface, and GLUT4 exists in some intracellular 
vesicles present in adipose tissue and cardiac and skeletal muscles. There is a recycle of 
GLUT4 between the plasma membrane and intracellular vesicles and insulin increases 
the rate of GLUT4 exocytosis at the same time transporter endocytosis is slowed (Bilous 
et al. 2010; Ciaraldi 2010). 
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The tissue selectivity of insulin responsiveness is modulated, in large part, by cell-speciﬁc 
expression of different elements of the signalling pathways or of ﬁnal effectors. Despite 
this, there are several principles in the organization of insulin action. These principles 
include the phosphorylation/dephosphorylation cascades initiated by the insulin 
receptor kinase, the formation of multimolecular complexes involving speciﬁc 
recognition domains on adapter proteins, and the targeting of signalling and effector 
molecules to appropriate intracellular locales. Impaired insulin action in diabetes most 
often involves defects in insulin receptor kinase and kinase activation but it is unlikely 
that mutations in individual elements of insulin signalling are responsible for the 
majority of instances of insulin resistance (Bilous et al. 2010). 
Each of the elements involved in insulin action can represent a site of possible defects 
that lead to insulin-resistant states, which can be caused by alterations in protein 
turnover, activity or expression.  
In diabetic patients, the initial events in insulin signalling, hormone recognition, and 
receptor kinase activation are impaired and can contribute to insulin resistance (Ciaraldi 
2010). An example of this is the reduction in insulin receptor binding that has been found 
in skeletal muscle and adipose tissue in diabetic patients (Hunter and Garvey 1998). This 
may be an acquired defect, resulting from hyperinsulinemia, as reductions were also 
recorded in obese, non-diabetic individuals, but it is common for the insulin-stimulated 
kinase activity of the receptor to be impaired in diabetes (Ciaraldi 2010). 
Several nucleotide polymorphisms have also been linked to diabetes pathophysiology. 
Polymorphisms in GLUT1 and in GLUT4, linked to the regulation of protein expression, 
appear to be significant in obese (Bonadonna 2004). The total cellular complement of 
GLUT4 appears to be reduced in 40-50% in subcutaneous adipocytes of diabetic patients 
and this impairment seems to be sufﬁcient to account for the reduction in maximal 
insulin-stimulated adipocyte glucose transport. In muscle tissue, an impairment in 
insulin-stimulated GLUT4 translocation is also documented (Bonadonna 2004; Ciaraldi 
2010). 
 
Chapter 1: Literature review 
15 
 
1.3. Diabetes classification, epidemiology and pathogenesis  
Due to the fact that diabetes mellitus is a group of diverse metabolic disorders 
characterized by hyperglycaemia and different complications, classification of the 
disease has evolved from a classification based on clinical findings such as age of onset 
or treatment modalities (insulin-dependent and non-insulin-dependent diabetes) to a 
classification based on the cumulative knowledge of the aetiology and pathogenesis of 
these metabolic disorders. 
The current classification of diabetes mellitus, adopted and endorsed by the ADA 
(2013a), IDF and World Health Organization (WHO) (WHO/IDF 2006), includes four types 
of clinical manifestations, according to their different aetiology. These types are type 1 
diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes 
mellitus (GDM). 
 
1.3.1. Type 1 diabetes mellitus 
Type 1 diabetes results from a progressive destruction of the pancreatic islet cells in 
susceptible individuals, leading to complete insulin deficiency and thus requiring lifelong 
treatment with insulin.  The underlining pathophysiologic mechanisms trigger 
autoimmunity from islet cell autoantibodies that gradually kill β-cells. Following the loss 
of first-phase insulin release, autoimmunity impairs secretory function of β-cell, leading 
to glucose intolerance and hyperglycaemia. This type of diabetes, where circulating islet 
cell antibodies suggest autoimmune destruction of β-cells, is classified as type 1 
autoimmune diabetes mellitus. Around 10% of all cases of type 1 diabetes seem strongly 
inherited and, despite presenting β-cell destruction, have no evidence of autoimmunity 
or detectable islet cell autoantibodies. These cases constitute a type 1 diabetes subtype 
labelled “idiopathic” (ADA 2013b). 
Younger patients often present ketoacidosis as the ﬁrst manifestation of the disease 
(Kitabchi et al. 2009). This results from a metabolic imbalance due to the combination 
of insulin deficiency and the increase in counter regulatory hormones, like 
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catecholamines, cortisol and glucagon, which leads to metabolic acidosis, 
hyperglycaemia and high total body ketone concentration. In diabetic ketoacidosis, 
hyperglycaemia besides resulting from impaired insulin action, develops as a 
consequence of increased gluconeogenesis and glycogenolysis (Kitabchi et al. 2006). The 
combination of insulin deficiency and increased counter regulatory hormones also leads 
to the release of free fatty acids into the circulation, and to their oxidation into ketone 
bodies of hepatic fatty acid, originating the ketonemia and metabolic acidosis (Kitabchi 
et al. 2006; Kitabchi et al. 2009). Due to the metabolic work required to compensate for 
the hyperglycaemia and the acidosis, diabetic ketoacidosis is life-threatening, with 
patients experiencing vomits, dehydration, difficulties in breathing, confusion, and 
coma. 
While some patients with type 1 diabetes present ketoacidosis as the ﬁrst manifestation 
of the disease, others have fasting hyperglycaemia that can change to severe 
hyperglycaemia or ketoacidosis in the presence of some form of stress, like an infection. 
In some patients, islet cell function is retained at a sufficient degree as to prevent 
ketoacidosis for many years (Holt et al. 2011). 
Susceptibility to type 1 diabetes is influenced by genetic factors, particularly human 
leukocyte antigen genes, and it is believed that a link exists to environmental factors and 
that some gene-environment interactions occur, although its role in the onset of this 
type of diabetes is yet unknown. Genetic factors may help to accelerate the failure of β-
cell secretion in response to exogenous environmental factors and there are reported 
associations between type 1 diabetes and viral infections, toxins, nutritional factors, 
perinatal factors, and postnatal growth. However, no definite causal environmental 
factor for type 1 diabetes has yet been identified (Bilous et al. 2010). 
Type 1 diabetes can occur at any age, but its highest incidence rates are reported during 
childhood and adolescence, increasing steadily from birth to peak at around puberty 
(10-15 years). The incidence rate in most populations is lower among 15 to 29 year-olds 
than among younger individuals. The peak in incidence rate occurs slightly earlier in girls 
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than it does in boys, suggesting an eventual influence of puberty (Diamond Project 
Group 2006; IDF 2011).  
A multicentre prospective registration study in 17 countries, during the 15-year period 
between 1989 and 2003 (Patterson et al.), showed significant yearly increases in 
incidence, ranging from 0.6% to 9.3%, with an overall annual increase of 3.9% (95% CI 
3.6–4.2). The reported increases in the 0–4 years, 5–9 years, and 10–14 years groups 
were 5.4% (4.8–6.1), 4.3% (3.8–4.8), and 2.9% (2.5–3.3), respectively. The authors of this 
study also report that mean (M) age of onset is decreasing and estimate that if present 
trends continue, by 2020 there will be a doubling of incidence in children under the age 
of 5 and a more even distribution of incidence across age groups below 15 years of age. 
Furthermore, this study reports that prevalence under 15 years of age is predicted to 
rise 70% between 2005 and 2020. 
Evidence also suggests that there is a significant worldwide variation in standardized 
incidence among 0-14 year-olds. During the period of 1990-1999, the age-adjusted 
incidence ranged from 0.1/100,000 in Zunyi (China) to 37.8 in Sardinia and 40.9 in 
Finland (Diamond Project Group 2006). In Europe there is an approximately 10-fold 
difference between highest and lowest incidence countries, with the lowest rate being 
reported as of 3.6/100,000 in Macedonia during 1989–1994 and the highest being 
30/100,000, reported in Sweden (Patterson et al. 2005). In Portugal, France, Italy and 
Spain, age-adjusted incidence rates ranged from 10 to 15/100,000 (Diamond Project 
Group 2006; Macedo et al. 2003; Serrano Ríos et al. 1990).  
In the Portuguese region of Algarve, the age-adjusted incidence rate between 1985 and 
2005 was estimated as being 15/100,000. Based on this data, incidence for 2010 was 
predicted as being 16.2/100,000 (Gomes et al. 2008). 
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1.3.2. Type 2 diabetes mellitus  
In T2DM, autoimmune destruction of islet cells does not occur. This form of the disease 
is characterized by a combination of resistance to insulin action and an inadequate 
insulin secretory response (Codario 2010). 
Insulin resistance can be defined as the inability of insulin to produce its usual biologic 
actions in normal individuals. This inability leads to impaired suppression of endogenous 
glucose production and to reduced glucose uptake. Insulin resistance also signifies that 
the ability of insulin to suppress the production of very low density lipoprotein 
cholesterol (VLDL) decreases, leading to an increase in circulating serum triglycerides 
(Codario 2010). 
The pathogenesis of T2DM is still unclear, as patients have a combination of varying 
degrees of insulin resistance and relative insulin deficiency (Stumvoll et al. 2005). Both 
these factors contribute to T2DM and can arise through genetic or environmental 
influences (Pratley and Weyer 2001). It is believed that impaired β-cell function is the 
primary underlying defect, probably genetic, followed by tissue insulin sensitivity 
(Schofield and Sutherland 2012). In most individuals who will develop T2DM, the 
pathogenesis process starts in early life, when glucose homeostasis is normal. 
Individuals are at risk for T2DM on account of genetic polymorphisms, or on account of 
an environment that limits the ability of their pancreatic β-cells to adjust for insulin 
resistance (Pratley and Weyer 2001). 
The UK Prospective Diabetes Study (UKPDS) found that β-cell function was reduced by 
50% at the time of T2DM diagnosis and that there was subsequent further deterioration, 
regardless of therapy (UKPDS Study Group 1995a).  Impaired β-cell function seems to 
occur in non-afflicted but genetically predisposed individuals, even when no insulin 
resistance is apparent (Costes et al. 2013; Pratley and Weyer 2001). As pathogenesis 
evolves, decreases in insulin sensitivity occur, usually as a result of unhealthy lifestyles, 
and these are balanced by an increase in β-cell secretion in order to achieve glucose 
homeostasis. Sometime after, the secretory function of β-cells deteriorates but remains 
sufficient to maintain normal fasting glycaemia. Further deterioration is due, at least in 
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part, to toxicity resulting from hyperglycaemia following meals, which can also reduce 
insulin sensitivity. Fasting plasma glucose concentrations increase on account of an 
increase in basal endogenous glucose production. Finally, as a result of even further 
impairment in β-cell function, glycaemia rises to levels consistent with the 
hyperglycaemia that characterizes diabetes (LeRoith et al. 2004). 
T2DM is a complex polygenic disorder, as genetic susceptibility to the disease appears 
to be determined by many common variants in multiple gene loci. Although at least 36 
diabetes-associated genes were identified, they explain only 10% of the estimated 
inheritability of T2DM (Herder and Roden 2011). This suggests a strong role of acquired 
or environmental factors in impairing β-cell function and in the risk of developing T2DM. 
Malnutrition in utero and in early childhood, as well as in utero exposure to 
hyperglycaemia, have been linked to an increased risk of T2DM later in life (J. P. Burke 
et al. 2004; Lawlor et al. 2006; Schellong et al. 2012). A meta-analysis reports that low 
birth weight (below 2500 g) was associated with increased risk of T2DM, with an odds 
ratio (OR) of 1.32 (95% CI 1.06-1.64) (Harder et al. 2007). It is proposed that malnutrition 
in utero and during the first few months of life may damage β-cell development and that 
nutritional deficiency at this stage may limit β-cell ability to adapt to overnutrition 
(Pratley and Weyer 2001; Stumvoll et al. 2005). Not all individuals with early life 
malnutrition develop T2DM, even if they become obese; thus these findings must be 
viewed as one risk factor among many that can influence disease susceptibility.  
Taylor, in a literature review, (Taylor 2013), reports that it seems apparent that β-cell 
defect, not solely hepatic insulin resistance, may be reversible by weight loss at least 
early in the course of type 2 diabetes. Even if formal recommendations on how to 
reverse type 2 diabetes in clinical practice must await further studies, the evidence for 
T2DM reversibility from studies after bariatric surgery (Dixon et al. 2008; Guidone et al. 
2006; Holst 2011) or in patients that underwent a calorie restriction diet (Lim et al. 
2011), suggests that T2DM can be understood as a potentially reversible metabolic 
state,  precipitated by chronic excess of pancreatic and liver triacylglycerol stores. Taylor 
(Taylor 2013) suggests that although a cause-and-effect relationship between excess 
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intraorgan fat and metabolic effect has not yet been proven, data are highly suggestive 
for a causal link. Furthermore, obesity, linked to overnutrition, seems the most 
predictive acquired risk factor for development of T2DM (Codario 2010). 
Chronic overnutrition with a diet rich in fat and sugars originates an accumulation of 
body fat which is considered the primary cause of chronic inflammation in obese 
patients, which may promote the development of systemic insulin resistance. Obesity 
causes metabolic disturbances associated with insulin secretion and insulin action, 
particularly in liver, muscle and adipose tissue, that lead to T2DM in susceptible 
individuals (Codario 2010).  
There is evidence that an increased supply of fatty acids from adipose tissue competes 
with glucose utilization, particularly in muscle, which oxidizes the largest proportion of 
glucose. The mechanism underlying this process is an inhibition of the glycolytic 
enzymes pyruvate dehydrogenase, phosphofrutokinase, and hexokinase, which reduce 
the rate of glucose oxidation. The increased fatty acid turnover is accompanied by an 
increased release of glycerol from adipose tissue which is then used in hepatic glucose 
production, further increasing the imbalance of glucose metabolism (Szablewski 2011). 
Reports that obese subjects and those with T2DM have a high intramyocellular lipid 
accumulation suggest that the increased availability of fatty acids, further enhanced by 
chronic overnutrition with a high dietary fat intake, may be the most important factor 
in disturbing insulin action in obesity. A chronic exposure of β-cells to excessive fatty 
acids is also associated with marked impairment of glucose-stimulated insulin secretion 
and to a decrease in insulin biosynthesis (Bray et al. 2003). 
Adipose tissue also acts as a secretory organ, producing and releasing several factors 
that may contribute to insulin resistance. These factors include resistin, leptin, adipsin, 
amylin and TNF–α, a multifunctional cytokine which is a mediator role of tumour 
necrosis factor α, first found to be expressed in adipose tissue and which is related to 
several catabolic effects (Bray et al. 2003). 
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The distribution of body fat also seems to be important in the association between 
obesity and T2DM. Fat distribution was found to be an independent risk factor for T2DM, 
as subjects with a more abdominal body fat distribution have an increased risk of T2DM 
and other metabolic and cardiovascular complications due to the metabolic effect of 
adipose tissue (Wang et al. 2005). Intra-abdominal adipocytes are more active than 
subcutaneous adipocytes and exhibit greater accumulation of lymphocytes and 
macrophages, which indicates a more active pro-inflammatory role. Visceral adipocytes 
also have higher vascularization and nerve density, which signifies greater metabolic 
activity (Bray et al. 2003; Codario 2010). 
Waist circumference (WC) has become a common assessment tool for estimating the 
risk of T2DM (Klein et al. 2007), because body fat distribution pattern strongly predicts 
the risk for diabetes (Qiao and Nyamdorj 2009) and the majority of T2DM patients show 
a visible abdominal accumulation of excess body fat. WC is encouraged to be used as a 
surrogate marker of abdominal fat mass (Klein et al. 2007; Zhu et al. 2002) since precise 
measurement of abdominal fat requires the use of radiological imaging techniques  
(Klein et al. 2007) and correlates with subcutaneous and intra-abdominal fat (Pouliot et 
al. 1994). 
The specific cut-points applicable to WC of European men and women which, according 
to the WHO (WHO 2011), are associated with increased risk of metabolic disease are 
presented in table 1. 
 
Table 1. Waist circumference and correspondent classification of metabolic and cardiovascular risk for Europeans, adapted 
from WHO (2011) Waist Circumference and Waist-hip Ratio: Report of a WHO Expert Consultation, Geneva, 8-11 December 
2008, World Health Organization. 
Gender Waist circumference (cm) 
 
Increased metabolic and 
cardiovascular risk 
Substantially increased metabolic 
and cardiovascular risk 
Men >94 >102 
Women >80 >88 
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Studies in different populations suggest that there are significant differences in adiposity 
throughout specific ethnic groups and, thus, some researchers have proposed specific 
cut-off points for WC its association with and metabolic risk. On the overall, when 
compared to Europeans, Asians have greater visceral adipose tissue, while African 
populations and, possibly, Pacific Islanders have less visceral adipose tissue or 
percentage of body fat at any given WC (WHO 2011). 
Asian populations, probably due to higher levels of body fat and abdominal adipose 
tissue, appear to have an increased metabolic risk at lower WC than Europeans, and 
research indicates a lower WC for Asians, set at 85 cm for men and 80 cm for women 
(Diaz et al. 2007; Huxley et al. 2008). Oksun et al. (Okosun et al. 2000) recommend 
setting the waist circumference cut-off points at  75.6 cm and 80.5 cm for men, and 71.5 
cm and 81.5 cm for women of Nigerian and Cameroon origin, and suggest that cut‐off 
points based on Europeans provided low sensitivity with respect to metabolic risk 
factors for the Hispanic population. Sánchez‐Castillo et al. (2003) recommend a waist 
circumference of 90 cm for men and 85 cm for women in Hispanic populations, and Lear 
et al. (2009), in a sample of participants of South American origin, recommended waist 
circumference cut‐off points of 88–90 cm for men, and 83–84 cm for women. 
WC above the proposed cut-off points has been associated with increased risk for T2DM 
(Djoussé et al. 2013; Guh et al. 2009; Klein et al. 2007), and allow to infer that 
maintaining a healthy weight can have an important role in T2DM prevention and 
control. 
A review of published analysis shows that waist-to-height (WtH) ratio is an appropriate 
tool  for assessing adult cardiometabolic risk (Ashwell et al. 2012) and there is evidence 
that WtH ratio is superior to waist circumference as a risk discriminating tool  (Browning 
et al. 2010). Waist-to-height ratio levels above a cut-point of 0.5 are good predictors of 
cardiometabolic risk (Ashwell et al. 2012).  
Besides WC, nutritional status and adiposity can be assessed by the body mass index 
(BMI), the usual index for obesity diagnosis and classification. 
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BMI is a simple anthropometric index calculated from body weight and height (a 
person’s weight in kilograms divided by his squared height in meters), independent of 
body height and correlated with body fat mass, that is considered a fast and non-
invasive way to assess short and long term nutritional status (Donini et al. 2013; Prentice 
and Jebb 2001). High BMI is associated with an increased risk of coronary disease, 
hypertension and T2DM (T.A. Wadden and Stunkard 2004). 
The WHO established categories to classify BMI (WHO 2000), defining obesity with an 
index of 30 kg/m2 or above, and subdividing this classification further, as BMI increases 
with the severity of body fat excess. A BMI in the range of 25–29.9 kg/m2 represents 
overweight, associated with an increased risk of comorbidities related to excess fat, 
albeit a smaller risk than that of obese individuals (table 2).   
 
Table 2. Categories of body mass index classification, adapted from WHO (2000) Obesity: preventing and managing the 
global epidemic, World Health Organization. 
Classification BMI (kg/m2) 
Underweight <18.5 
Normal weight 18.5 – 24.9 
Overweight 25 – 29.9 
Obesity grade I 30 – 34.9 
Obesity grade II 35 – 39.9 
Obesity grade III ≥ 40 
 
In Europe, the trends in obesity prevalence point out to an increase in adult individuals, 
with rates between 15–30%. Data from Portugal for 2003-2005, collected in individuals 
aged 18-64 years, allow to identify 45.2% of overweight men, from which 15% are obese. 
Overweight prevalence in women was reported as 34.4% and obesity prevalence as 
13.4% (Do Carmo et al. 2008). Worldwide, in 2010, it was estimated that approximately 
475 million adults were obese, one billion adults were overweight. At the same time, in 
the 27 member states of the European Union, 60% of all adults were overweight or 
obese (IOTF 2010). The incidence of obesity has been rising in the last decades to the 
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extent that is now considered a pandemic and constitutes an important cause of death 
in industrialized countries (Rippe and Angelopoulos 2012). 
Excess weight is an established risk factor for T2DM, with a relative risk (RR) of 2.7 (95% 
confidence interval (CI) between 2.1 - 3.3) reported in a prospective cohort study in 
women who gained 8.0 to 10.9 kg. This study concludes that the excess risk for diabetes 
is substantial, even with modest and typical weight gain in adults (Colditz et al. 
1995).  Other reports, also from a prospective cohort study, claim that a gain of 1 kg/m2 
between the ages of 25 and 40 years increases the relative risk of T2DM by 25% 
(Schienkiewitz et al. 2006). Additionally, data from a USA populational follow-up 
between 2000 and 2004 suggest that the increase in obesity was an important 
determinant of the increase in diabetes prevalence (Gregg et al. 2007). A meta-analysis 
of nine prospective cohort studies of the general population of Western countries (Guh 
et al. 2009) further strengthens this inference, showing that elevated BMI and WC were 
significantly associated with T2DM in men and women, with reports of pooled relative 
risks (RR) across BMI categories ranging from 2.40 to 6.74 in men and from 3.92 to 12.41 
in women. 
Although there is accumulating evidence that even modest weight reduction can 
improve glycaemic control and reduce diabetes risk (Djoussé et al. 2013), the 
pathogenesis linking obesity and diabetes needs to be further clarified. Several 
mechanisms have been proposed to link obesity to T2DM risk, including the increased 
production of adipokines, resistin, and retinol-binding protein 4, or ectopic fat 
deposition and mitochondrial dysfunction (Deng and Scherer 2010). Impaired 
mitochondrial mass and/or function in overweight individuals results in an insulin 
sensitivity decreased and a compromised β-cell function (Rippe and Angelopoulos 
2012). It was also recently suggested that the link between obesity and diabetes can be 
due to the role of a protein that controls the differentiation and function of immune 
cells (Stolarczyk et al. 2013), due to endoplasmic reticulum stress, or to complex genetic 
interactions (McCarthy 2010). Despite these findings, neither the relative importance of 
the described links is clearly defined nor are the connections between obesity and 
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T2DM explored in a conclusive way. Nevertheless, both clinical trial and populational 
studies on obesity and its modifiable lifestyle risk factors identify adiposity as a major 
determinant of diabetes. The association between obesity and T2DM has also led to the 
suggestion that a shared pathogenesis underlies both diseases, implying that life styles 
that give rise to progressive weight gain and metabolic impairment also contribute to β-
cell impairment (Eckel et al. 2011). Hotamisligil and Erbay have suggested that long term 
cell exposure to nutrient concentrations that exceed energy requirements can lead to 
endoplasmic reticulum stress, excess production of reactive oxygen species, 
mitochondrial dysfunction, and triglycerides accumulation (Hotamisligil and Erbay 
2008). These authors also suggest that obesity-associated cellular injury can activate an 
immune response that originates tissue inflammation and, concomitantly with cell 
responses to excess energy, contributes to the pathogenesis of insulin resistance. 
Obesity-induced metabolic impairment can favour insulin resistance and progressive β-
cell dysfunction that, in turn, contribute to enhance the excess nutrient problem. 
Nutrient excess triggers inflammatory responses, leading to insulin resistance and 
placing a greater demand on the β-cell. As β-cell function declines, the toll taken by 
nutrient excess increases. However, since not all obese individuals develop T2DM, an 
underlying abnormality of the β-cell must coexist with nutrient excess, to promote this 
pathogenic cycle (Kahn et al. 2006).  
It is reported that individuals with obesity or with excessive abdominal fat deposition 
account for about 80% of all T2DM patients and, although the specific link is still not 
clear, it is known that a decreased insulin sensitivity is frequent in obese and overweight 
adults. Decreased insulin sensitivity has been established as an independent risk factor 
for the development of T2DM and is positively correlated with BMI (Kahn et al. 2006). 
There is evidence that decreased insulin sensitivity progressively increases with time, 
constituting a late step in the development of T2DM, after years of normal glycaemia in 
the presence of insulin resistance (C. Day and Bailey 2011). 
Ultimately, obesity arises due to an excessively positive energy balance, created by a 
complex set of interrelated factors, as its determinants involve sociocultural, genetic, 
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physiologic, metabolic, behavioural and psychological components. It is believed that 
there is an underlying genetic susceptibility to the disease, which is heavily modified by 
environmental circumstances and individual lifestyle choices (McCarthy 2010). The 
decline in manual occupation, the rise of motorized transport, and increasingly 
sedentary leisure activities, have reduced overall energy needs. The rise in the 
proportion of food consumed out of the household, the offer of energy dense foods, 
and the increased usual portion sizes, also had an effect in the incidence of obesity 
(Rippe and Angelopoulos 2012). The risk of T2DM further increases with other 
environmental and lifestyle factors, like physical inactivity, excessive alcohol intake, or 
smoking, which have an effect in insulin sensitivity (ADA 2013a; Reis et al. 2011).  
A meta-analysis of 10 prospective cohort studies reported a lower risk of T2DM 
associated with regular moderate physical activity (RR=0.69, 95% CI 0.58-0.83). These 
results are maintained after adjustment for BMI, suggesting an independent effect of 
exercise on glucose metabolism (Jeon et al. 2007). The Pre-diabetes Risk Education and 
Physical Activity Recommendation and Encouragement (PREPARE) study, examining 98 
overweight or obese individuals with impaired glucose tolerance, suggests that the 
benefits of moderate physical activity are sustained after 24 months (Yates et al. 2011), 
with subjects who underwent a 3h structured education session with personalized 
pedometer use showing a significant reduction in 2h post exercise plasma glucose, when 
compared with a control group. 
Alcohol consumption seems to present an association with the risk of developing T2DM 
in the form of a U or J curve, implying  that a modest alcohol consumption reduces the 
incidence of T2DM and that an excessive alcohol intake is related to an increase in 
incidence (Pietraszek et al. 2010). A systematic review and meta-analysis, comparing 
lifetime abstainers with individuals with different daily alcohol consumption patterns, 
reports that alcohol intakes above 60 g/day in men and above 50 g/day in women 
increase the risk for T2DM (Baliunas et al. 2009). There are some conflicting results 
regarding the daily alcohol intakes that become deleterious, but this may be due to 
different drinking patterns, beverage preference, or health behaviour (Pietraszek et al. 
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2010). The association between alcohol and T2DM also seems BMI-dependent, as both 
moderate and excessive alcohol intake increase T2DM risk in men with low BMI, 
whereas moderate alcohol consumption appears to have a protective effect in men with 
a higher BMI (Reis et al. 2011). 
Cigarette smoking also increases the risk of T2DM. According to a meta-analysis of 
prospective cohort studies, smokers have a pooled adjusted RR for T2DM of 1.4 (95% CI 
1.3-1.6) compared with non-smokers (Willi et al. 2007). Data from a physicians' health 
study (Manson et al. 2000) suggest that approximately 10% of the incidence of T2DM 
may be attributable to smoking. 
The risk of developing T2DM increases with age (particularly after 45 years) and the 
disease is also more common in individuals with a family history of diabetes, in women 
with history of diabetes during pregnancy, in certain ethnic groups (African American, 
Hispanic), and in women with polycystic ovarian syndrome (UKPDS Study Group 1995a). 
Furthermore, most patients with T2DM present a cluster of clinical features of insulin 
resistance named metabolic syndrome. In non-diabetic individuals, this cluster of clinical 
features confers substantial additional risk for cardiovascular and metabolic 
complications. The cluster of features confers a risk of T2DM that is above the risk 
associated with each individual clinical feature. 
According to a study group of IDF researchers (Alberti et al. 2005), a person is diagnosed 
with metabolic syndrome if central obesity is present (assessed by increased waist 
circumference with ethnic-specific WC cut-points), together with any two of the 
following:  
 Serum triglycerides above 150 mg/dL (1.7 mmol/L) or treatment for elevated 
triglycerides; 
 Serum HDL cholesterol below 40 mg/dL (1.03 mmol/L) in men or below 
50 mg/dL (1.29 mmol/L) in women, or treatment for low HDL; 
 Systolic blood pressure above 130, diastolic blood pressure above 85, or 
treatment for hypertension; 
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 Fasting plasma glucose above 100 mg/dL (5.6 mmol/L) or previously diagnosed 
T2DM; 
  An oral glucose tolerance test is recommended for patients with an elevated 
fasting plasma glucose, but not required. 
Based on the results from 16 cohort studies, the RR for T2DM in individuals with four or 
more clinical features from the metabolic syndrome ranged from 10.9 to 24.4 (Ford et 
al. 2008), suggesting that the metabolic syndrome has a strong association with diabetes 
incidence. 
T2DM prevalence varies substantially from one geographical region to the other, as a 
result of environmental and lifestyle risk factors. The IDF (2011) estimated that 
worldwide diabetes prevalence for 2012 would correspond to 371 million people with 
diabetes between 20-79 years old. Approximately half of those cases were expected to 
be undiagnosed. As it is believed that T2DM makes up for 85% to 95% of all cases of 
diabetes in high income countries and that it may account for an even higher percentage 
in countries with lower incomes (WHO 1994). 
Western Pacific, Middle East, and North African countries have the highest prevalence 
of all types of diabetes. The Federal State of Micronesia, in the Western Pacific region, 
has the highest reported adjusted prevalence, with 37.7%. Europe shows marked 
differences in prevalence. The Russian Federation is the country with the highest 
prevalence (9.7%) and the Republic of Moldova the country with the lowest prevalence 
(2.7%). Portugal is reported as the country with the second highest prevalence in Europe 
(9.6%). This rate is above the estimated proportion of diabetics for the USA (9.4%), which 
is the country with the third greater number of diabetic individuals (preceded only by 
India and China). The estimated prevalence for Portugal in 2012 is significantly higher 
than the prevalence of its only neighbour country, Spain (7.15%)(IDF 2011). 
Data from a national prevalence study in Portugal (Gardete-Correia et al. 2010) point to 
an age-adjusted T2DM prevalence of 11.7% in 2009, corresponding to an estimated 
900,000 patients. The age-adjusted prevalence reported for the Algarve in 2009 was 
11%. In 2011, the global diabetes prevalence for Portugal was estimated as 12.7%, in an 
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increase that, according to the authors, was also due to population ageing (Gardete 
Correia et al. 2013). The same study analyses previous data on diabetes, and reports an 
increase in incidence of 79.6% between 2002 and 2011. 
In the United Kingdom, the Quality and Outcomes Framework reports an average 
prevalence of diabetes of 4%, representing around 2.6 million individuals (Health and 
Social Care Information Centre 2012). Approximately 85% of those were T2DM cases. 
IDF data for the United Kingdom shows a 4.5% prevalence of T2DM in 2012 (IDF 2011). 
T2DM is also increasingly observed among children, adolescents, and younger adults, 
accompanying the obesity increase in paediatric age. Evidence suggests that the 
progression of insulin resistance to T2DM is faster in obese children than in adults 
(D’Adamo and Caprio 2011). 
All the trends in T2DM prevalence indicate that the disease will increase further in the 
next two decades, and much of the increase will occur in developing countries where 
the majority of patients are aged between 45 and 64 years (L. Chen et al. 2012). 
 
1.3.3. Gestational diabetes mellitus and other specific types of diabetes  
Insulin resistance and hyperinsulinemia are common during pregnancy, due to placental 
secretion of hormones that are considered diabetogenic, including growth hormone, 
corticotrophin releasing hormone, placental lactogen, and progesterone. The inability 
to secrete additional insulin to overcome the diabetogenic effect, along with increased 
adipose deposition, higher caloric intake, and reduced physical activity, predispose 
some women to develop a form of diabetes during pregnancy that, in most cases, 
subsides after the delivery (ADA 2013b; Crowther et al. 2005).  
This form of diabetes deriving from a glucose intolerance with onset or first recognition 
during pregnancy is classified as gestational diabetes (ADA 2013b; WHO/IDF 2006) and 
its prevalence is associated with a higher incidence of preeclampsia, macrosomia, and 
caesarean delivery (Landon et al. 2009). 
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In Europe, although practices related to its detection are inconsistent, gestational 
diabetes is estimated to occur in 2 to 6% of pregnancies, with a trend for lower 
prevalence in the North of Europe and higher prevalence in the South (Buckley et al. 
2012).  
In Portugal, estimates for 2011 using a sample of 77 431 deliveries within the National 
Health Service, report a 4.9% prevalence of gestational diabetes (Gardete Correia et al. 
2013). 
Other specific types of diabetes include several conditions that can cause some degree 
of impairment in insulin production or secretion. These conditions include genetic 
defects of the β-cell, genetic defects in insulin action, genetic syndromes such as Down 
or Prader-Willi syndromes, diseases of the pancreas (cystic fibrosis or pancreatitis), and 
endocrinopathies such as acromegaly or hyperthyroidism. Furthermore, diabetes can be 
caused by the administration of drugs such as glucocorticoids, due to infections like 
congenital rubella, or due to uncommon conditions that lead to autoimmune forms of 
the disease (ADA 2013b). 
Patients with these specific types of diabetes present a widely variable extent of glucose 
intolerance, often simulating type 1 diabetes mellitus or T2DM (Ewald et al. 2012). 
Specific types of diabetes represent about 1% to 2% of all cases of diabetes (IDF 2011).  
 
1.4. Diagnosis of diabetes mellitus  
The diagnosis of diabetes mellitus is made through various clinical and biochemical 
features, mainly by cut points in fasting plasma glucose (FPG) levels, or plasma glucose 
levels 2h after an oral glucose tolerance test (OGTT), consisting in the ingestion of a 
glucose solution containing the equivalent to 75g anhydrous glucose dissolved in water 
(ADA 2013b). Additionally, the diagnosis can be aided by the observation of classic 
symptoms of hyperglycaemia: thirst, polyuria, weight loss, and blurry vision.  
Recently, HbA1c has been considered as a measure of glucose control, as it correlates 
closely with a complete measure of average glycaemia over a period of  8 to 12  weeks 
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(Nathan et al. 2007), and both the WHO and the IDF (WHO/IDF 2011) recommend that 
HbA1c can be used as a diagnostic tool if quality control of the test can be assured. 
The current diagnosis criteria for diabetes are based on the revised report of the 
WHO/IDF Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 
(WHO/IDF 2006), which resulted from the analysis of epidemiological data. The ADA, 
upon further reviews of the evidence from observational and analytic studies, 
recommends a set of slightly different diagnosis criteria (ADA 2013b) that are widely 
used. In Portugal, the Direção Geral de Saúde (DGS  - National Health Directorate), under 
its National Program for Prevention and Control of Diabetes, issued normative diagnosis 
criteria (DGS 2011b) based on the WHO/IDF Expert Committee report, that also 
integrate the ADA standards for diabetes care (ADA 2013a) and diagnosis criteria. 
The current diagnosis criteria adopted in Portugal (DGS 2011b) state that an individual 
has diabetes mellitus if he presents one of the following:  
 HbA1c ≥ 6.5%; 
 FPG ≥ 126 mg/dl (7.0 mmol/l); 
 2h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during a OGTT; 
 Presence of classic hyperglycaemia symptoms and a random plasma glucose ≥ 
200 mg/dl (11.1 mmol/l). 
These criteria consider that the fasting period for FPG analysis must be of at least 8 hours 
and the Direção Geral de Saúde advises that if an individual is asymptomatic for 
hyperglycaemia, the diagnosis should not be made only through HbA1c.  
The detection of gestational diabetes follows a standardized practice of performing a 
75g OGTT at 24-28 weeks of gestation on women not previously diagnosed with 
diabetes. Diagnosis of gestational diabetes is made if one of three plasma values is 
exceeded: 
 Fasting plasma glucose ≥ 92 mg/dl (5.1 mmol/l); 
 1 hour plasma glucose ≥ 180 mg/dl (10.0 mmol/l); 
 2 hours plasma glucose ≥ 153 mg/dl (8.5 mmol/l). 
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The prevailing clinical guidelines affirm the need to classify the disease according to one 
of the four types of diabetes (type 1 diabetes mellitus, T2DM, gestational diabetes, other 
specific types of diabetes). The diagnosing physician must decide the type of diabetes 
according to the circumstances at the time, and the pathogenesis and hyperglycaemia 
that can be identified for the disease. 
Besides the four types of diabetes, the Expert Committee on the Diagnosis and 
Classification of Diabetes (ADA 2003b) and the position statement from WHO and IDF 
(WHO/IDF 2006) propose additional classification categories for increased risk for 
diabetes, identifying a group of individuals whose glycaemia does not meet diagnostic 
criteria for diabetes but is significantly higher than the usual glycaemia in non-diabetic 
individuals. These individuals are defined as having impaired fasting glucose (IFG) or 
impaired glucose tolerance (IGT). Both the presence of IFG or IGT are referred as pre-
diabetes and these conditions should not be viewed as individual clinical entities but 
rather as an intermediate stage in the disease process leading to one of the four types 
of diabetes. The classification categories for pre-diabetes used in Portugal represent the 
WHO/IDF criteria and are presented in table 3. 
 
Table 3. Pre-diabetes diagnosis criteria, adapted from WHO/IDF (2006) Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva, World Health Organization. 
Pre-diabetes 
condition 
Diagnosis criteria 
IFG Fasting plasma glucose from 110 mg/dl (6.1 mmol/l) to 125 mg/dl (6.9 mmol/l) 
IGT 
2 hours  plasma glucose between 140 mg/dl (7.8 mmol/l) and 199 mg/dl (11.0 
mmol/l) during a OGTT 
 
The use of glycated haemoglobin for the diagnosis of diabetes was not formally 
translated to categories for pre-diabetes diagnosis, but it is know that there is a 
continuum of risk according to all glycaemic control measures, and that individuals with 
HbA1c levels slightly below the diagnostic cut point for diabetes are at very high risk of 
developing the disease (WHO/IDF 2011).  
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Observational studies show consistent results indicating that a stronger correlation of 
HbA1c with diabetic retinopathy than with FPG (Sabanayagam et al. 2009; Tapp et al. 
2008). A systematic review of 16 cohort studies concludes that, compared with an 
HbA1c of 5%, individuals with HbA1c between 5.5 and 6.0% have an increased risk of 
diabetes with the five-year incidence ranging from 9% to 25%. Individuals with HbA1c 
ranging from 6.0% to 6.5% have a five-year risk of developing diabetes between 25% 
and 50%, and a RR 20 times higher compared with the HbA1c of 5.0% (X. Zhang et al. 
2010b). In a study of non-diabetic adults, HbA1c was found to be have a stronger 
association with the incidence of diabetes and cardiovascular events than that of fasting 
glucose (Selvin et al. 2010). Based on this association and also on further evidence from 
prospective cohort studies supporting these findings, the ADA infers that it is reasonable 
to consider an HbA1c range of 5.7–6.4% to identify individuals with pre-diabetes (ADA 
2013b). Despite this recommendation, HbA1c is not formally used for the diagnosis of 
pre-diabetes in Portugal. 
HbA1c was proposed as a diagnosis tool for diabetes considering that the chronic 
hyperglycaemia that leads to diabetes complications could be assessed by a laboratory 
method that reflects long-term glycaemic exposure. It was proposed that this method 
could provide a better marker for the presence and severity of the disease than single 
measures of glycaemia (International Expert Committee 2009).  
HbA1c is formed through the non-enzymatic binding of circulating glucose to 
haemoglobin, a process defined as glycation. HbA1c is measured as the ratio of 
glycosylated to non-glycosylated haemoglobin, and higher levels represent a higher level 
of glycation due to higher levels of blood glucose. As glycation occurs over the entire 90 
to 120 day lifespan of the red blood cell, HbA1c can be interpreted as an indicator of 
blood glucose during that time (Peterson et al. 1998).  
HbA1c  can  be  used  as  a  diagnostic  test  for  diabetes, provided  that  quality  assurance  
tests  are  in  place, and  assays  are  standardised  to  criteria from international  
reference  values (WHO/IDF 2011). This marker also presents a lower variability than 
that of FPG, with day-to-day within-person variation of 2% for HbA1c, and 12–15% for 
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FPG (Playle et al. 1999). Furthermore, several practical advantages support the use of 
HbA1c to diagnose diabetes, like the fact that samples for HbA1c testing can be obtained 
at any time, requiring no patient preparation or fasting. Data also suggest greater pre-
analytical stability, and less day-to-day variations during periods of stress and illness 
(Bonora and Tuomilehto 2011). 
 
1.5. Public health impact of diabetes mellitus  
There is evidence that diabetes related to mortality is underestimated, due to the fact 
that death certificates in diabetes patients frequently do not mention the underlying 
disease as a cause of death. The immediate cause of death in a considerable portion of 
patients is cardiovascular disease, but this condition would not have developed if 
diabetes was not present (Roglic et al. 2005). It is believed that cardiovascular disease is 
responsible for 50% of all deaths in diabetes patients (Zimmet 2003). 
According to the IDF, in 2011, 4.6 million deaths were attributed to diabetes in 
individuals aged 20-79 years old, corresponding to a proportional mortality of 
approximately 8.2% (IDF 2011). In Portugal, the age-adjusted diabetes mortality rate and 
the proportional mortality for diabetes have been slowly rising since the year 2000. The 
proportional mortality for diabetes was reported as 4.2% in 2002 and 4.4%, in 2011, 
while the age-adjusted mortality rate in 2010 was 24.9/100,000, similar to the rate in 
2002 (Gardete Correia et al. 2013). In Portugal, each death attributed to diabetes 
corresponds to seven years of potential life lost (YPLL) below the age of 70 years old. 
This represented, in 2010, a rate of 59 years of potential life lost (YPLL) for every 100,000 
inhabitants (INE 2011).  
The impact of diabetes on hospital care has also been estimated. If hospital stays of less 
than 24 hours are excluded, in Portugal, for 2010, individuals who were hospitalized due 
do diabetes symptoms or complications associated with the disease had a mean of 10.5 
days of hospitalization. This value is significantly higher than the mean for all-causes 
hospitalization, estimated at 7.5 days (Gardete Correia et al. 2013). 
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Health economic analyses in the USA have suggested that a 50 year-old patient who is 
recently diagnosed with diabetes has an annual medical expenditure that is 4,174 US 
dollars higher than the expenditure of an identical person without diabetes. 
Furthermore, each additional year with diabetes increases the annual medical 
expenditure by 158 US dollars above the increases in medical costs attributable to 
ageing (Trogdon and Hylands 2008). 
In 2011, the morbidity and mortality of diabetes is believed to have represented, in 
Portugal, 0.8% of the gross domestic product (GDP), and 8% of all health related 
expense. In 2001, the IDF World Atlas proposed that each diabetes patient had an 
estimated mean cost of 2,522 US dollars (IDF 2011). If this estimate is applied to 
Portugal, the direct costs with diabetes will rise to 1% of GDP and to 10% of all of the 
government expense with health. Zhang and colleagues, analysing the expenditures for 
193 countries, reported that, globally, 12% of all health expenditures was expected to 
be due to diabetes (P. Zhang et al. 2010a). This expenditure estimate does not include 
indirect costs of diabetes, like the effects of work absenteeism and lack of productivity 
due to diabetes related complications, which means that the real expenditure with the 
disease may be higher. It is believed that the complications of diabetes are associated 
with a substantial number of absent days from work, and that the avoidance of these 
complications would benefit both patients and society (Sorensen and Ploug 2013). 
The major complications of diabetes are cardiovascular disease, nephropathy, 
neuropathy, retinopathy, and cataracts (Carl Asche et al. 2011b; Pollreisz and Schmidt-
Erfurth 2010). 
Ischemic heart disease among diabetes patients between 45 and 64 years old is 
approximately three times more prevalent than in non-diabetics (14.3% versus 4.7%), 
and diabetes also raises 1.5 to 2 fold the RR of death after myocardial infarction 
(Engelgau et al. 2004). In a European study involving 7 countries, patients with diabetes 
were more likely to have limb weakness (P<0.02), dysarthria (P<0.001), ischemic stroke 
(P<0.001), and lacunar cerebral infarction (P=0.03) (Megherbi et al. 2003).  
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Although cardiovascular and cerebrovascular disease are major complications of 
diabetes, the diabetic foot, a predominant peripheral neuropathy, is the most common 
cause of hospitalization in patients with diabetes and responsible for at least 33% of the 
direct costs with the disease (Driver et al. 2010). This implies a considerable economic 
burden in healthcare services, as the cost of care for patients with a foot ulcer is 5.4 
times higher in the year after the first ulcer episode than that of diabetic patients 
without foot ulcers. Patients with diabetic foot ulcers require more frequent emergency 
department visits, are more commonly admitted to hospital, and require longer length 
of stays. A retrospective cohort study  with data from 7,758 patients concludes that the 
progression of nephropathy was strongly associated with higher subsequent medical 
care cost (Driver et al. 2010). 
Diabetes can also lead to multiple eye pathologies, including retinopathy, which is the 
leading cause of blindness in people between 20 and 64 years old, accounting also for 
12% of all new cases of blindness (Engelgau et al. 2004). A Swedish population-based 
study with 252 386 individuals found a diabetic retinopathy prevalence of 41.8% (95% 
CI 38.9–44.6) for patients with type 1 diabetes and of 27.9% (27.1–28.7) for patients 
with T2DM (Heintz et al. 2010). Retinopathy was sight-threatening in 12.1% and 5.0% of 
the type 1 and T2DM populations, respectively. This study concluded that the annual 
cost for diabetic retinopathy was €106,000 per 100,000 inhabitants, with the costs 
increasing considerably with the severity of this complication. 
Overall, it is believed that most of the expenditure with diabetes is associated with the 
disability and the YPLL resulting from the disease and its complications (L. Chen et al. 
2012; P. Zhang et al. 2010a). In fact, it is estimated that about half of the expenditure 
with diabetes is allocated to the treatment of its complications and, due to the rise in 
incidence of the disease, the related costs are expected to at least double in the next 
two decades if no significant changes in public or private strategies for prevention and 
control are put in place (E. S. Huang et al. 2009). 
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1.6. Metabolism and postprandial glycaemia in type 2 diabetes mellitus  
The main role of the pancreatic hormones is to regulate the uptake and release of 
metabolic fuels from the hormone-sensitive tissues: liver, muscle, and fat. After meals, 
when nutrient levels in the blood are high, insulin secretion is stimulated, glucagon 
secretion is inhibited, and the high insulin to glucagon ratio promotes nutrient storage. 
But the regulation of glucose concentration after a meal is determined by the extent to 
which glucose entering the systemic circulation exceeds or is exceeded by the rate at 
which glucose leaves the systemic circulation (Standl et al. 2011). PPHG is primarily 
caused by a reduced glucose disappearance, due to the fact that the insulin secretion in 
response to higher glucose concentrations after a meal is impaired in individuals with 
IFG and T2DM (Bock et al. 2006). 
In healthy individuals, PPG is usually below 120mg/dl and rarely exceeds 140mg/dl, 
prompting PPHG to be defined as a plasma glucose level exceeding 140mg/dl (IDF 2007). 
This is one of the earliest abnormalities of glucose homeostasis associated with T2DM, 
and progresses to fasting hyperglycaemia as the condition worsens (Monnier et al. 
2007). 
The impairment in insulin action and insulin secretion associated with diabetes led to 
suspect that PPHG is common in most patients, and today it is believed that PPHG 
contributes significantly to the overall glycaemic control. In fact, the postprandial state 
is the norm for individuals who consume at least three meals a day at relatively fixed 
times, and during the postprandial period insulin secretion does not fully compensate 
for insulin resistance in T2DM (Standl et al. 2011).  
According to van Dijk et al. (2011), who conducted a study with 60 male patients with 
T2DM and 24 age and BMI-matched normal glucose tolerant controls during a three day 
period of continuous glucose monitoring, hyperglycaemia is highly prevalent throughout 
the day, even in patients with diabetes presenting a HbA1c level well below 7.0% and 
receiving adequate medical care. In this study, T2DM patients with a standardized diet 
experienced hyperglycaemia more than nine hours per day.  Even those patients with 
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apparent good glycaemic control, measured by HbA1c below 7.0%, experienced PPHG 
for nearly six hours per day. 
Data gathered in non-insulin treated patients with T2DM also suggests that at HbA1c 
levels below 7.3%, postprandial glucose contributes approximately 70% to elevated 
HbA1c levels, and at HbA1c levels of 7.3% to 8.4%, approximately 50% of the HbA1c 
contribution comes from postprandial glucose (Monnier et al. 2003).   
PPHG also seems most common after breakfast. Data from 200 non–insulin-treated 
patients with T2DM suggest that high plasma levels over morning periods after breakfast 
seem to occur independently of BMI, HbA1c, therapy, and residual β-cell function. 
Monnier et al. (2002) suggest that this can likely be attributable to an elevated hepatic 
glucose output in the early morning. 
According to the evidence of long term prospective cohort studies and clinical trials 
(DCCT/EDIC Study Research Group 2005; Levitan et al. 2004; UKPDS Study Group 1995b), 
there is a strong correlation between glycaemic control and the incidence of 
microvascular and macrovascular complications. The DECODE study, which analysed 13 
prospective European cohort studies (DECODE Study Group 1999), suggests that fasting-
glucose concentrations alone do not identify individuals at increased risk of death 
associated with hyperglycaemia. This study reports that during the follow-up period the 
largest number of excess deaths was observed in subjects who had impaired glucose 
tolerance but normal fasting blood glucose levels and concludes that the glucose level 
two hours after the start of a meal is a better predictor of deaths from all causes and 
cardiovascular disease than is fasting blood glucose. 
PPHG seems associated with an increased risk of retinopathy, impaired cognitive 
function, and with increased carotid intima-media thickness. PPHG is also identified as 
a causal factor in oxidative stress, inflammation, and endothelial dysfunction (Ceriello 
et al. 2008).  
Diabetes treatment aimed at lowering postprandial blood glucose reduces vascular 
events, and there is strong evidence that, especially for patients with very poor control 
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over the disease, targeting both PPHG and FPG is an important strategy for achieving 
optimal glycaemic control (Standl et al. 2011). These treatment strategies should be 
initiated at any HbA1c level (Ceriello et al. 2006).  
The importance of targeting PPHG is accepted by the leading diabetes organizations, 
which currently include in their treatment and management guidelines 
recommendations for the monitoring of blood glucose in the period of two hours 
following meals, in order to assess glycaemic control (ADA 2013a; IDF 2007). 
It is proposed (Ceriello et al. 2008; IDF 2007) that two-hour postprandial plasma glucose 
should not exceed 7.8 mmol/l (140 mg/dl), as this is considered a reasonable and 
conservative target, and argue that currently the most practical method to measure 
postprandial glycaemia is patient self-monitoring. The ADA recommendations are based 
on the correlation with HbA1c values, and it is proposed that in order to achieve an 
HbA1c of 7%, the peak postprandial capillary blood glucose that usually occurs one hour 
to two hours after the start of a meal, should be below 180 mg/dl (10.0 mmol/l). It is 
believed that these targets may help to lower HbA1c to 7% or below, which has shown 
to reduce microvascular complications of diabetes, and, if achieved soon after the 
diagnosis of the disease, is associated with long-term reduction in macrovascular 
disease (ADA 2013a). 
Data on the prevalence of PPHG is limited, and although target values exist for 
postprandial glycaemia, most practitioners and clinicians rely solely on HbA1c and FPG 
concentrations to evaluate and adjust therapeutic strategies. (Bonora and Tuomilehto 
2011; Ceriello et al. 2008; Hanas and John 2010). FPG and HbA1c are easy to measure, 
and the latter is especially used in the clinical setting to monitor diabetes, and to 
establish the degree of metabolic control. Deviation from individualized HbA1C targets 
prompts physicians to modify treatment strategies (Bonora and Tuomilehto 2011). 
Nevertheless, the accumulating evidence on PPHG allows to infer that by focusing solely 
on HbA1C or FPG levels, clinicians may miss opportunities to help patients to meet 
glycaemic targets, and minimize glucose variations which can have negative effects on 
long-term outcomes (Standl et al. 2011; van Dijk et al. 2011). 
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1.7. Treatment and management of type 2 diabetes mellitus  
The chronic nature of diabetes and its associated complications, as well as their potential 
for impact on the overall quality of life of those affected, confirm the need for adequate 
treatment and management of the disease, preferably from a team that may include 
physicians, nurses, dietitians, pharmacists, and mental health professionals with 
expertise and a special interest in diabetes. individuals with diabetes should also assume 
an active role in their care, for the therapeutic plan to succeed (ADA 2013a). 
Diabetes care should be achieved by an integrated team approach, and the 
management of the disease should be a collaborative therapeutic alliance among the 
healthcare team and the patients and their families (Arterburn and O’Connor 2012). At 
the same time, the goals and management plan should be individualized in order to take 
into account the patient’s age, school or work schedule and conditions, physical activity, 
eating patterns, social situation, and cultural factors. Treatment of patients with T2DM 
includes education, evaluation for microvascular and macrovascular complications, 
normalization of glycaemia, minimization of cardiovascular and other long-term risk 
factors and avoidance of drugs that can aggravate abnormalities of insulin or lipid 
metabolism. In order to achieve the preconized glycaemic goals, most patients require 
continuous treatment that, according to the severity and characteristics of the disease, 
is focused on increasing insulin secretion and responsiveness, or decreasing the rate of 
carbohydrate absorption (ADA 2013a). 
Improved glycaemic control lowers the risk of microvascular complications in patients 
with T2DM and weight reduction, diet, and exercise can all be used to improve glycaemic 
control. In addition to glycaemic control, vigorous cardiac risk reduction by the mean of 
smoking cessation, blood pressure control and reduction in serum lipids should be a 
priority for all patients. However, in spite of evidence that risk factor reduction lowers 
the risk of both microvascular and macrovascular complications, less than 50% of 
patients do not achieve recommended goals for HbA1C, blood pressure control, and 
management of dyslipidaemia. In the twentieth century, about two-thirds of diabetes 
patients died of premature cardiovascular disease (UKPDS Study Group 1998b). 
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Adherence to prescribed therapies is an important factor in the management of T2DM 
that shows a wide range of results. Inadequate adherence to oral anti-diabetic agents, 
even if it has a greater adherence than lifestyle modifications, is estimated to apply to 
between 36% and 93% of patients (C. J. Bailey and Kodack 2011).  
Several literature reviews suggest that a significant proportion of T2DM patients exhibit 
poor adherence to treatment and poor management of the disease. Some of the 
identified factors that compromise adherence include complex pharmacological 
treatment dosing regimens, clinical inertia, safety concerns, socioeconomic issues, 
ethnicity, poor patient education, beliefs, and social support (Carl Asche et al. 2011b; 
Delamater 2006; 2006). 
Both pharmacological and non-pharmacological approaches to treatment and care in 
T2DM should be considered and discussed with the patient. Lifestyle interventions 
should be the first step in treating recently diagnosed T2DM and, on account of this, 
nutritional management of the disease must play a pivotal role in patient self-care, as 
there is strong evidence of its effectiveness (Wheeler et al. 2012). The UK National 
Institute for Health and Clinical Excellence (NICE) evidence-based guidelines for diabetes 
care (NICE 2009) recommend that metformin, the first ADOA to be used, should only be 
started in a person who is overweight or obese and whose blood glucose is inadequately 
controlled by lifestyle interventions alone, but evidence suggests that the majority of 
patients will require medication over the course of the disease (Nathan et al. 2009). 
Overall, the objective of diabetes treatment and management is to avoid 
hyperglycaemia without exposing patients to unnecessary risk for hypoglycaemia, in 
order to prevent or delay the progression of the chronic complications associated with 
the disease. Other cardiovascular risk factors should be addressed and minimized 
(Ismail-Beigi 2012), and adequate glycaemic control should be achieved as soon as 
possible, as it is believed that the first years of the disease’s clinical stage have a strong 
impact in the late-onset complications of diabetes (Holman et al. 2008). 
The ADA guidelines for glycaemic control (ADA 2013a) propose that patients should 
achieve an HbA1c below 7%, while the IDF and the European Association for the Study 
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of Diabetes (EASD) propose a more strict cut point of 6.5% (Ray and Singhania 2011; 
Secnik et al. 2007). These HbA1c cut points reflect a level of glycaemic control associated 
with a reduction in the risk of microvascular and macrovascular complications (UKPDS 
Study Group 1998b). 
The poor adherence to therapy reflects on the prevalence of glycaemic control.  Bertoni 
and collaborators reported a 45% prevalence of HbA1c below 7% in a sample of 5145 
T2DM patients (Bertoni et al. 2008), and Shi and colleagues, a prevalence of 56% (Shi et 
al. 2011). A ten year follow-up of 1772 patients between 1996 and 2006 revealed a 
prevalence of adequate glycaemic control between 23.4% and 26.9% (Blumenthal et al. 
2010). 
In Portugal, an assessment of 2673 T2DM patients revealed an HbA1c below 7% in 51.7% 
of them. The same study found that 6.7% of the patients had an HbA1c above 10% 
(Cortez-Dias et al. 2010). 
Considering the prevailing adherence to treatment, the prevalence of adequate 
glycaemic control and integrating information on therapy, its outcomes, synergistic 
effects, costs and potential for adverse events,  the ADA and the European Association 
for the Study of Diabetes issued a consensus treatment algorithm for clinical and 
therapeutic management of T2DM (Nathan et al. 2009) that is also reflected in the ADA 
Standards of Medical Care in Diabetes (ADA 2013a). This algorithm serves as a basis for 
the guidelines for the treatment of diabetes proposed by the Portuguese Society of 
Diabetology (Duarte et al. 2007). In these guidelines, a pharmacological therapy with 
metformin is advised at the time of diagnosis, together with the implementation of an 
adequate diet and physical activity programs. Following the diagnosis, periodical 
assessments of the therapeutic objectives should guide the need of adjusting 
pharmacological agents in order to achieve and maintain, for most of the patients, an 
HbA1c below 7%. The guidelines focus on obtaining metabolic control, without 
recommending a strict sequence of pharmacologic agents that should be used. In 2011, 
in Portugal, the DGS issued a code of practice for diabetes pharmacological treatment 
that guides clinicians in the Portuguese National Health Service (DGS 2011a). 
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1.7.1. Pharmacological therapy and management  
Most of T2DM patients will need medication over the course of the disease as lifestyle 
interventions often fail to achieve or maintain the metabolic control goals (Nathan et al. 
2009). As metabolic control usually worsens with age, early treatment that can maintain 
proper HbA1c is associated with improved glycaemic control over time and with 
decreased long-term complications (Stephen Colagiuri et al. 2002), supporting the claim 
for early pharmacological therapy use.  
The majority of treatment guidelines now recommend that oral anti-diabetic agents 
(OADA), be initiated around the time of diagnosis, accompanying diet and physical 
activity interventions (Aguilar 2011). Nevertheless, considering the increasingly complex 
process of pharmacological glycaemic management (due to a widening array of 
pharmacological agents), a position statement for the management of hyperglycaemia 
was issued by the ADA and the EASD, recommending a non-prescriptive, patient-
centered approach to  treatment, encouraging clinicians to integrate the current 
evidence in the context of patient-specific factors, including patient preferences, needs, 
and values (Inzucchi et al. 2012). This position statement advises that patients with 
moderate hyperglycaemia or in whom lifestyle changes are anticipated to be 
unsuccessful, should promptly start an anti-hyperglycaemic agent, which can be 
modified or discontinued if lifestyle changes are successful. At the time of diagnosis, 
highly motivated patients with HbA1c near 7% could be given the opportunity to engage 
in lifestyle change interventions for a period of 3 to 6 months before the use of any 
pharmacotherapy. 
The results from a trial on T2DM cardiovascular outcomes (Turnbull et al. 2009) suggest 
that aggressive therapy for glycaemic control can be unbeneficial in some patients, and 
that long-term, large scale, clinical trials are still needed in order to clarify the benefits 
and risks of using different treatment approaches, with different pharmacological 
agents, each with its specific properties and side effects. 
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OADA are the most common pharmacological therapy in adult patients without 
ketoacidosis, and are grouped in different pharmacological classes, according to their 
mechanisms of action. Table 4 presents the OADA available in Portugal, in 2013. 
  
Table 4. Classes and types of antidiabetic oral agents available in Portugal. Adapted from INFARMED (2012) Prontuário 
Terapêutico 2013. INFARMED, Portugal. 
Classes 
Biguanides Sulfonylureas 
α-glucosidase 
inhibitors 
Thiazolidinediones Meglitinides 
DPP-4 
inhibitors 
Metformin 
Glibenclamide 
Acarbose Pioglitazone Nateglinide 
Sitagliptin 
Glicazide 
Glimepiride 
Vildagliptin 
Glipizide 
 
Metformin is the most well-known biguanide and, in the absence of specific 
contraindications, is recommended as the initial pharmacotherapy agent for its high 
level of acceptance, absence of weight gain or hypoglycaemia, generally low level of side 
effects, and relatively low cost (Nathan et al. 2009). It can reduce HbA1C levels by 1.5%, 
promote weight loss or weight stabilization, prevent cardiovascular complications, and 
lower LDL cholesterol and triglyceride levels (Inzucchi et al. 2012; Moghissi et al. 2009). 
Metformin was also shown to decrease the risk of diabetes-related endpoints and all-
cause mortality (UKPDS Study Group 1998a). Metformin decreases hepatic glucose 
output, and increases insulin-mediated glucose utilization in peripheral tissues, such as 
muscle and liver, particularly after meals. Its action is dependent on the presence of 
insulin, and, besides the effects on glucose, has an anti-lipolytic effect that lowers serum 
free fatty acid concentrations, thereby reducing substrate availability for 
gluconeogenesis (Clifford J Bailey 1992; Stumvoll et al. 1995). 
Metformin is associated with some gastrointestinal side effects, including a metallic 
taste in the mouth, mild anorexia, nausea, abdominal discomfort, and soft bowel 
movements or diarrhoea. These side effects are mild, transient, and reversible after a 
dose reduction or discontinuation of the drug. Due to its effects on glucose utilization, 
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most current guidelines state that metformin should be initiated concurrently with 
lifestyle intervention, at diagnosis (Aguilar 2011). 
The oldest class of oral hypoglycaemic agents are sulfonylurea insulin secretagogues, 
which act by stimulating the beta-cells to produce endogen insulin, regardless of 
glycaemia levels. Sulfonylureas have shown to reduce HbA1C levels by 1-2%, and 
medications in this class include second-generation sulfonylureas such as glipizide, 
glimepiride, and gliclazide (Bolen et al. 2007). They are only effective in patients with 
some pancreatic beta-cell activity, and are contraindicated for type 1 diabetes, 
advanced liver or kidney disease, sulfa drug allergy, or in situations of ketoacidosis 
(Moghissi et al. 2009).  
Sulfonylureas block ATP-dependent potassium channels in pancreatic beta-cells and 
reduce the potassium permeability of these cells. This causes a calcium influx and 
increased insulin secretion, with consequent lowering in plasma glucose (Bolen et al. 
2007). In addition, a number of extra-pancreatic effects, such as increased tissue 
sensitivity to glucose, and reduced hepatic production of glucose, have been described 
as associated with this class of OADA, but they occur at a minimal level (Schmitz et al. 
2002). 
The most common side effect of sulfonylureas is hypoglycaemia, especially in older 
patients, and when using long-acting sulfonylureas. This makes shorter-acting 
sulfonylureas, such as glipizide, a preferred course of treatment. Risk factors for 
sulfonylurea use include physical effort, alcohol abuse, stress, poor nutrition, kidney 
disease, and concurrent therapy with salicylates, allopurinol, sulphonamides, and 
fibrates. Further adverse effects of this pharmacotherapy include weight gain, hunger, 
gastrointestinal upset, light sensitivity, and liver abnormalities (Nathan et al. 2009). 
Acarbose is an OADA that slows the digestion of complex carbohydrates by inhibiting 
the upper gastrointestinal enzymes alpha glucosidases, which results in a delayed 
glucose absorption and decreased postprandial hyperglycaemia. In addition, acarbose 
reduces the insulinotropic and weight-increasing consequences of sulfonylureas, and is 
expected to reduce HbA1C levels by 0.5-0.8% (Inzucchi et al. 2012; Rodbard et al. 2009).  
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Acarbose may be used alone or in combination with other OADA. When used in 
monotherapy, it has proven to improve the metabolic control of patients (Inzucchi et al. 
2012). However, due to its specific mechanism of action, its administration is especially 
recommended in combination with other agents; for instance, in patients with 
postprandial hyperglycaemia and increased HbA1C, it may be used as an additive to 
metformin (Aguilar 2011)  
Acarbose administration is contraindicated in patients with diabetic ketoacidosis, 
cirrhosis, and intestine/bowel problems (e.g., inflammatory bowel disease, intestinal 
obstruction, colon ulceration, and digestion or absorption disorders). As acarbose slows 
the digestion of complex carbohydrates, the most common side effects are flatulence, 
diarrhoea, aerophagia, stomach pain, and bloating. It can also cause higher liver 
transaminase levels and hypoglycaemia when in combination with sulfonylureas, and 
increase insulin sensitivity in older patients (ADA 2013a; Rodbard et al. 2009). 
Thiazolidinediones are a recent class of OADA, represented currently by pioglitazone for 
the treatment of T2DM. It acts by reducing insulin resistance and improving glycaemic 
control, alone or in combination with other OADA, such as sulfonylureas or metformin. 
Pioglitazone activates a specific nuclear receptor to enhance insulin sensitivity, causing 
an improved insulin-dependent glucose disposal, and a decreased hepatic 
gluconeogenesis (Kaku 2009; Schernthaner et al. 2004). As monotherapy, 
thiazolidinediones are considerably more expensive than generic sulfonylureas and 
metformin, and seem less effective in lowering glycaemia than metformin: 
thiazolidinediones lower HbA1C by 0.5 to 1.4%. They are also associated with more 
weight gain and fluid retention than metformin (Schernthaner et al. 2004). The reported 
weight gains varies between 3 to 6kg in the first year, and there is also evidence that 
pioglitazone may lead to peripheral fat mass, fluid retention (which may cause 
peripheral oedema, particularly in combination with insulin therapy, and induce cardiac 
failure), muscle pain, sore throat and headaches (Bolen et al. 2007).. 
The use of pioglitazone in T2DM must be considered carefully, and it is usually not 
chosen for initial therapy, being reserved for second-line treatment in combination with 
other OADA, where synergistic effects can lower HbA1c (Aguilar 2011; Bolen et al. 2007). 
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Meglitinides are non-sulfonylurea insulin secretagogues that decrease blood glucose 
levels by stimulating pancreatic insulin secretion. This group includes repaglinide, (not 
available in Portugal), and nateglinide, which are associated with the same increased 
risk of weight gain that sulfonylureas. Meglitinides use is more expensive than the use 
of sulfonylureas, but as the two classes of OADA are pharmacologically distinct, 
meglitinides may be used in patients who have an allergy to sulfonylureas. Meglitinides 
use may also imply less risk of hypoglycaemia, making them useful for the treatment of 
T2DM in elderly individuals when the goal of avoiding hypoglycaemia is very important. 
Apart from this, there are no further advantages of meglitinides use over sulfonylureas 
(Nathan et al. 2009).  
Nateglinide showed a similar ability to metformin to reduce HbA1c and both OADA can 
be used simultaneous for and improved effect, especially in postprandial 
hyperglycaemia. Nateglinide is not recommended for patients with diabetic ketoacidosis 
and severe hepatic insufficiency. Other side effects of nateglinide include headache, 
nasal congestion, runny nose, diarrhoea, cough, flu-like symptoms, nausea, back pain, 
joint pain, and dizziness (Inzucchi et al. 2012; Moghissi et al. 2009). 
DDP-4 inhibitors are a class of oral hypoglycaemic agents that block dipeptidyl-
peptidase-4, a ubiquitous enzyme that deactivates other bioactive peptides, including 
glucagon-like peptide-1 and gastric inhibitory peptide, and therefore potentially affect 
glucose regulation through multiple effects. Sitagliptin and vildagliptin are the only DPP-
4 inhibitors available in Portugal (INFARMED 2012).  
As DPP-4 inhibitors are more expensive, less effective in lowering glucose levels, and 
have limited clinical experience, they are mostly administered in combination with other 
agents, especially in patients who do not react to other monotherapies or when 
adequate glycaemic control is not provided by combining metformin and sulfonylureas. 
DPP-4 inhibitors are not associated with weight gain or increased risk of hypoglycaemia, 
and when used as monotherapy, HbA1C levels decrease by 0.6%-0.9% (Raz et al. 2006). 
In sitagliptin-treated patients, reported side effects comprise severe hypersensitivity 
reactions, pancreatitis, nasopharyngitis, upper respiratory tract infection, and 
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headache. In patients treated with vildagliptin, clinical trials describe rare cases of 
hepatic dysfunction, including hepatitis, that is usually asymptomatic (White 2008). 
Patients with T2DM can also be treated with insulin, but both patients and providers are 
often reluctant to initiate insulin therapy, despite its proven efficacy and cost advantage 
compared with many newer agents; this may be due to concerns about life-restriction, 
weight gain, hypoglycaemia, and also with the patient's perception that insulin therapy 
is associated with a worsening of the disease (Peyrot et al. 2005b). 
Despite the weight gain and hypoglycaemia risk, data support using insulin earlier and 
more aggressively in T2DM. After achieving normoglycaemia with intensive insulin 
therapy, both endogenous insulin secretion and insulin sensitivity improve, and this 
glycaemic control can be maintained with diet, exercise, and OADA (UKPDS Study Group 
1998b). 
Most clinicians consider insulin a reasonable choice for initial therapy in patients who 
present symptomatic or poorly controlled diabetes, and is the preferred second-line 
medication for patients with HbA1C >8.5% or with symptoms of hyperglycaemia, despite 
initial therapy with metformin and lifestyle intervention (Inzucchi et al. 2012). In patients 
with poor glycaemic control on two OADA, switching to insulin is usually preferable than 
adding a third oral agent. A clinical trial with 188 subjects with T2DM showed that 
patients on three oral agents (a sulfonylurea, metformin and a thiazolidinedione) had 
similar glycaemic control, but more side effects, a more atherogenic profile, and 
substantially higher costs than patients on twice daily insulin along with metformin 
(Schwartz et al. 2003). 
All these multiple approaches to pharmacotherapy will require a thoughtful role for 
clinicians, who should consider all scientific evidence, all patient-specific factors, and all 
non-pharmacological treatment options, in order to achieve the therapeutic goals. 
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1.7.2. Evidence for nutritional therapy in T2DM 
The link between nutrition and maintaining adequate blood glucose levels, a lipid profile 
that reduces the risk for cardiovascular disease, blood pressure in an ideal range, and 
improved quality of life, has been addressed in several randomized controlled trials and 
observational studies. Franz et al. (2010), in a comprehensive literature review, 
expanding on a practice guideline from the Academy of Nutrition and Dietetics (ACD), 
conclude that there is strong evidence that nutritional therapy provided by registered 
dietitians is an effective and essential therapy in the management of diabetes (ACD 
2008; Marion J. Franz et al. 2010). These authors also report clear improvements in 
metabolic outcomes, such as glycaemia and HbA1C, in diabetes patients included in 
nutrition intervention studies, both when interventions have independent nutritional 
therapy, or when nutrition therapy is provided as part of an overall program for diabetes 
patient self-management. Other literature reviews of clinical trials and analytical studies 
concluded that, depending on the duration of the disease, nutritional therapy for T2DM 
decreases HbA1c between 1% and 2% (Pastors et al. 2002; Pastors et al. 2003).  
Data from the UKPDS, with 3044 adults with T2DM, showed that three nutritional 
interventions in one-month intervals, consisting in the proper adjustment of the 
macronutrient (carbohydrates, proteins and lipids) and energy contents of the diet, 
were significantly associated (p<0.001) with a reduction of 1.9% in HbA1c, of 4.5kg in 
weight, of 7.8 mg/dL in LDL cholesterol, and of 28.4 mg/dL in triglycerides (UKPDS Study 
Group 2000). Ziemer and colleagues, in a randomized controlled trial with 648 T2DM 
adults, report that four nutrition education counselling sessions, focused on healthy 
food choices,  during a six-month period, were responsible for a reduction of 1.9% in 
HbA1c and of 35.5 mg/dL  in total cholesterol (Ziemer et al. 2003). Different randomized 
controlled trials recorded mean reductions in HbA1c ranging from 0.3% to 0.7% (M.-C. 
Huang et al. 2010) and mean weight reductions of 4.8kg (Andrews et al. 2011), and 2.1kg 
(Coppell et al. 2010a) as a result of six-month nutrition interventions. 
The existing evidence supports the claim that lifestyle interventions to improve glucose 
levels, blood pressure, and lipid levels, and to promote weight loss or at least avoid 
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weight gain, should be considered throughout the management of T2DM, 
independently of the use of pharmacological therapy (Nathan et al. 2009). The 
Standards of Medical Care for Diabetes proposed by the ADA (2013a) further express 
the importance of nutritional therapy for diabetes, recommending that all individuals 
with pre-diabetes or diabetes should receive individualized nutritional therapy, 
preferably provided by a registered dietitian familiar with the process of care and, due 
to the evidence that nutrition therapy can result in improved outcomes and in treatment 
cost-savings, that this non-pharmacological treatment should be adequately covered by 
insurance and other payers. 
According to the ADA, the main goals of nutrition therapy for individuals with diabetes 
are (ADA 2008): 
I. To achieve and maintain 
 Blood glucose levels in the normal range or as close to normal as is safely 
possible 
 A lipid and lipoprotein profile that reduces the risk for vascular disease 
 Blood pressure levels in the normal range or as close to normal as is 
safely possible 
II. To prevent, or at least slow, the rate of development of the chronic 
complications of diabetes by modifying nutrient intake and lifestyle 
III. To address individual nutrition needs, taking into account personal and cultural 
preferences and willingness to change 
IV. To maintain the pleasure of eating by only limiting food choices when indicated 
by scientific evidence 
Nutrition therapy contributes to important and essential outcomes in the management 
of diabetes, but the relative importance of each nutritional goal varies with individual 
patient characteristics. Just as several approaches exist for pharmacotherapy, there is 
no uniform dietary intervention that is appropriate for all diabetes patients. What is 
essential is that professionals select nutritional therapy interventions that are 
appropriate to the patient they are counselling and that will lead to positive outcomes. 
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Randomized controlled trials and observational outcome studies have reported 
decreases in HbA1C similar to those from OADA, achieved by different types of nutrition 
interventions, which include reduced energy/fat intake, carbohydrate counting, 
simplified meal plans, individualized meal-planning strategies, exchange choices, use of 
insulin-to-carbohydrate ratios, physical activity, and behavioural strategies. The 
evidence reviews seem consistent in the conclusions that reducing the energy content 
of usual food intake is paramount to achieve successful outcomes, and that nutritional 
interventions should have multiple encounters between patient and health 
professional, in order for education and counselling to be provided on a continued basis 
(Marion J. Franz et al. 2008). 
 
1.7.3. Nutritional recommendations in T2DM 
There is no individual strategy for completely and unequivocally achieving the 
nutritional goals in T2DM, but there are several evidence-based recommendations for 
nutritional therapy. The Evidence-Based Practice Committee for the ACD, proposes a set 
of evidence-based nutrition practice guidelines for adults with type 1 and type 2 
diabetes (Franz et al. 2010) that complement previous literature reviews from the ACD. 
The ADA has also published a set of evidence-based nutrition guidelines (ADA 2008) that 
have been updated and included in the diabetes standards of medical care and reviewed 
annually, as new evidence becomes available (ADA 2013a). In the United Kingdom, a 
group of experts in diet and diabetes in the Diabetes UK Nutrition Working Group 
proposed evidence-based nutrition guidelines for the prevention and management of 
diabetes and the implementation of nutrition advice (Dyson et al. 2011), drawn jointly 
from the ADA recommendations and a literature review of published evidence from 
2008 to 2010. These nutrition guidelines were further completed with specific position 
statements regarding low-carbohydrate diets for people with T2DM (Diabetes UK 2011), 
and regarding the consumption of carbohydrates in people with diabetes (Diabetes UK 
2012). Other widely known evidence-based references include the American Association 
of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management 
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of Diabetes mellitus (Rodbard et al. 2007), and the Evidence-based Nutritional 
Approaches to the Treatment and Prevention of Diabetes mellitus, from the European 
Association for the Study of Diabetes (EASD) Diabetes Nutrition Study Group (Mann et 
al. 2004). Despite some differences in these reviews and position statements, the 
general agreement suggests that nutrition therapy must be aimed at weight 
loss/maintenance interventions, at adequate distribution of macronutrients and eating 
patterns and, also, to coadunate with other interventional strategies, like promoting 
physical activity.  
Specifically, nutrition intervention should consider the caloric intake, the consistency in 
day-to-day carbohydrate intake in all meals, as well as the timing for the meals and the 
nutritional content of foods. Weight loss and management interventions must be 
combined with increased physical activity, appropriate to the characteristics of the 
patient (e.g., age, mobility, diabetes complications). 
The nutritional treatment and management of T2DM is a complex process that should 
be started at diagnosis and maintained throughout all activities of patient care. The ACD 
recommends the process to be started by an initial series of three to four sessions or 
consultations with a dietitian, each lasting from 45 to 90 minutes, during the first three 
to six months after diagnosis. After this period, at least one yearly follow-up encounter 
is recommended, to reinforce lifestyle changes and to evaluate and monitor outcomes. 
As the patient progresses towards desired outcomes, additional sessions should be held 
if the health professional considers appropriate (ACD 2008). 
The Diabetes UK recommendations propose that every patient and/or their carer should 
receive diabetes education at the time of diagnosis, with an annual follow-up, and that 
nutritional advice from a registered dietitian should be constant during patient 
education (Dyson et al. 2011). 
The nutrition intervention during initial patient evaluations must include the assessment 
of food intake, use of OADA, and levels of metabolic control, as inferred by glycaemia, 
lipids, and blood pressure. Physical activity habits and anthropometric measurements, 
such as weight, waist circumference or percent of fat mass, should also be recorded, in 
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order to serve as the basis for implementation of the nutrition prescription and to 
establish the goals and type of intervention (ACD 2008; ADA 2008; Dyson et al. 2011; 
Mann et al. 2004). The goal set for glycaemic control should be the lowering of HbA1c 
to around 7%. This goal may be set lower than 7%, and as close to normal as possible 
(below 6%), if this can be achieved without significant hypoglycaemia. Patients who have 
adequate pre-prandial glycaemia values but have HbA1C values above target, should be 
monitored regarding PPG, in order to reduce PPG between one to two hours after the 
start of a meal to levels below 180 mg/dl (ADA 2013a). 
 
1.7.3.1. Weight management  
Weight control plays a pivotal role in the treatment and management of T2DM, and, 
during patient assessment, the relative importance of weight control for the overweight 
or obese patient should be analysed. Modest weight loss has been shown to improve 
insulin resistance, but sustained interventions lasting one year or longer reported 
inconsistent effects on glycaemic control (Wing et al. 2011). 
Data from the Look AHEAD (Action for Health in Diabetes) study, a randomized trial in 
5145 overweight or obese T2DM patients with the aim of assessing if weight reduction 
and physical activity can reduce cardiovascular disease morbidity and mortality, suggest 
that at one-year follow-up, weight reduction was associated with the frequency of 
education interventions. This study randomized patients in either intensive lifestyle 
intervention (ILI) or diabetes support and education (DSE). After one year, ILI subjects 
had a higher reduction in average body weight and improvements in cardiovascular 
fitness and HbA1c when compared to DSE subjects (Look AHEAD 2007). Patients in the 
ILI group had weekly individual or group education interventions for the first six months, 
and three times per month from the seventh month up to the end of the first year of 
follow-up. Weight reduction at one year was associated with improvements in 
triglycerides and HDL cholesterol, greater in individuals who lost 10% to 15% of their 
initial body weight (Look AHEAD 2007). The weight-loss strategies associated with a 
lower BMI were regular self-weighing, eating breakfast, and infrequent consumption of 
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fast food (Raynor et al. 2008). Better attendance levels in education sessions, and 
exercising a mean of 137 minutes/week, were indicators of success after one year. 
Greater self-reported physical activity presented the strongest correlation with weight 
loss (Thomas A. Wadden et al. 2009). 
In this study, from the second through the fourth year of follow-up, the ILI subjects were 
accompanied in a monthly, individual or group-based, educational session, while the 
DSE group patients were invited to three group sessions each year. The results from the 
follow up show a maximal weight lost by the end of the first year, with slow weight 
regain in the ensuing years (Thomas A. Wadden et al. 2011). This provides an important 
insight on the determinants of maintaining weight loss, even when patients are provided 
with frequent education opportunities and support at no cost. 
As weight reduction is effective in improving glycaemic control and cardiovascular risk 
factors, this should be the primary nutritional strategy in managing glycaemic control 
for T2DM patients who are overweight or obese. Dietary, physical activity, surgical, and 
pharmaceutical approaches that are currently recommended for individuals without 
diabetes can be adopted by diabetes patients with the guidance of a health professional 
(Dyson et al. 2011).  
The main strategy in a dietary approach for weight reduction is to balance energy intake 
in a way that it becomes less than energy expenditure. This can be achieved by first 
obtaining the individual estimated energy requirement by predictive equations, like the 
Harris-Benedict equation, one of the more commonly used predictive equations to 
estimate basal energy expenditure used in clinical settings (Rippe and Angelopoulos 
2012), or by the set of equations from the report on dietary reference intakes from the 
Institute of Medicine (IOM) in the USA (IOM 2005) 
The equation set from the IOM allows the determination of estimated energy 
expenditure according to factors that that account for energy expenditure, age, sex, 
weight, height, and physical activity level, based on the energy intake needed to 
maintain energy balance in individuals with healthy weights, as measured by doubly-
labelled-water (IOM 2005). 
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In order to promote weight loss, a trained health professional can encourage an energy 
reduction of 500 kcal/day, or obtain the energy requirements for a safe weight goal 
below the current weight, and prescribe a meal plan accordingly. Weight loss is then 
monitored and assessed in order to assure a correct decrease in fat body mass (Rippe 
and Angelopoulos 2012). 
 
1.7.3.2. Macronutrient composition of the diet  
Although the focus in nutritional therapy for glycaemic control should be total energy 
intake, the macronutrient composition is also important, as the total amount of 
carbohydrate consumed is a strong predictor of glycaemic response (Dyson et al. 2011). 
Nevertheless, it is unlikely that an ideal macronutrient intake exists for all T2DM adult 
patients (ACD 2008; ADA 2008; Marion J. Franz et al. 2010; Wheeler et al. 2012).  
Different macronutrient distributions have shown different results in weight 
management, lipid profile and metabolic control in T2DM patients. 
Results from a randomized controlled trial show that a high carbohydrate diet, 
compared with a diet high in monounsaturated fat, is associated with a modest rise in 
blood pressure. Nevertheless, high total fat intake might increase the risk of 
atherosclerosis, and excess protein could promote the development of diabetic 
nephropathy (M. Shah et al. 2005). 
Wheeler et al., in a systematic review analysing research on macronutrients, food 
groups, and eating patterns in the management of diabetes, concluded that several 
different macronutrient distributions may lead to improvement in glycaemic and/or 
cardiovascular disease risk factors, but the results were inconclusive regarding an ideal 
macronutrient balance. This study analysed very-low-carbohydrate diets (with 21 to 70 
g/day of carbohydrate), moderately low–carbohydrate diets (30 to 40% of daily energy 
intake as carbohydrate), moderate-carbohydrate diets (40 to 65% of daily energy intake 
as carbohydrate), and high-carbohydrate diets (65% of daily energy intake as 
carbohydrate). The authors reported that when total carbohydrate intake was low, 
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markers of glycaemic control and insulin sensitivity improved, but the short duration of 
the low-carbohydrate diet, the lack of randomization, and the high dropout rates in 
some studies, do not allow to recommend a specific low-carbohydrate distribution. 
Serum lipoproteins typically improved with reduction of total carbohydrate intake but, 
with the exception of HDL cholesterol, were not statistically better than those of the 
comparison diet (Wheeler et al. 2012).  
Based on similar results, the ADA suggests that either low-carbohydrate or low-fat 
calorie-restricted diets may be effective to reduce weight and to improve glycaemic 
control, up to one year. During the course of the diet, hypoglycaemia should be 
prevented and also for patients on low-carbohydrate diets, lipid profiles, renal function, 
and protein intake must be monitored and adjusted as needed, especially if OADA are 
used (ADA 2013a).  
Overall, research does not support an ideal percentage of energy from macronutrients 
in the daily meal plan for patients with diabetes, and the macronutrient distribution 
should be adjusted to meet individual metabolic goals (ACD 2008; ADA 2008, 2013a; 
Dyson et al. 2011; Nield et al. 2007; Wheeler et al. 2012). According to this evidence, it 
is recommended that the macronutrient intake in T2DM patients should follow the 
patterns associated with a healthy, balanced diet (ACD 2008; Dyson et al. 2011). 
The macronutrient content of a healthy daily diet can be prescribed based on the dietary 
reference intakes reported by the IOM (2005), presented in table 5. 
 
Table 5. Acceptable distribution ranges for macronutrients. Adapted from Institute of Medicine (2005) Dietary Reference 
Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients), 
National Academies Press. 
Macronutrient Acceptable distribution ranges of total energy intake (%) 
Carbohydrate 45–65 
Fat 20–35 
Protein 10–35 
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Regardless of the macronutrient distribution, total energy intake must be appropriate 
for weight management and there should be an encouragement for food choices that 
the patient is able and willing to follow in the long term (ADA 2008). A diet that a patient 
enjoys and finds acceptable is more likely to succeed and to lead to improved outcomes, 
as it seems that diet outcomes are predicted by the degree of diet adherence rather 
than by the type of dietary intervention (Nield et al. 2007). 
Individualization of the macronutrient composition of the diet can be considered, 
depending on the metabolic status of the patient, which may present a lipid profile that 
can benefit from specific interventions. There is evidence that nutritional therapy 
provided by a dietitian to individuals with dyslipidaemia can reduce patients’ daily 
dietary fat by 5% to 8%, with a decrease in 2% to 4% in saturated fat. This can result in 
a reduction in serum total cholesterol between 7% and 21%, in LDL cholesterol reduction 
between 7% and 22%, and in triglycerides reduction between 11% and 31% (ACD 2011). 
Patients with diabetes have an increased risk of cardiovascular disease (CVD), estimated 
to be about the same as in individuals without diabetes but with pre-existing CVD. This 
is partly due to abnormalities in plasma lipids and lipoprotein concentrations that are 
common in T2DM (Buse et al. 2007). Due to this similarity in CVD risk, an ACD review of 
43 studies related to the prevention and treatment of CVD in diabetes, recommends 
that the dietary goals for patients with diabetes should be the same as for individuals 
with pre-existing CVD. It is also suggested that a cardio-protective nutrition intervention 
should be implemented in the initial series of nutrition therapy sessions (ADA 2008; 
Marion J. Franz et al. 2010). 
A cardio-protective nutrition intervention should provide 20% to 35% of calories from 
fat, with less than 7% of calories from saturated (SFA) and trans fatty-acids (TFA). The 
association between TFA and elevated levels of total and LDL cholesterol leads to believe 
that TFA intake should be as low as possible. Furthermore, cholesterol intake should be 
below 200 mg/day, and the majority of total fat intake should be derived from 
unsaturated fat sources (ACD 2011). The ADA recommends that HDL cholesterol should 
be above 40 mg/dL in men and above 50 mg/dL in women, and that the desirable goal 
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for triglyceride levels is below 150 mg/dL (ADA 2013a). In individuals without overt CVD 
the goal should be to achieve a LDL cholesterol below 100 mg/dL, and in individuals with 
overt CVD, a lower LDL cholesterol goal below 70 mg/dL. 
Overall, regarding lipid profile in T2DM, the main position papers are in agreement that 
the goals are to limit SFA below 7% of total energy, a minimal intake of TFA, and 
cholesterol intake below 200 mg/day, so as to reduce risk for CVD (ACD 2008; ADA 
2013a; Dyson et al. 2011). Further recommendations include a daily consumption of 
foods fortified with plant sterols or stanols (2g to 3 g⁄day), which significantly improve 
total and LDL cholesterol in diabetes patients, irrespective of statin treatment (Dyson et 
al. 2011). The consumption of oily fish, rich in ω-3-unsaturated fats, is recommended at 
least twice per week (ADA 2008; Dyson et al. 2011). 
Weight loss can also benefit lipid profile, as it has been shown that it can decrease 
triglycerides and raise HDL cholesterol (Look AHEAD 2007). Nutrition interventions like 
the DASH diet (Azadbakht et al. 2011), Mediterranean-style eating patterns, and high-
protein diets also seem effective in improving various markers of cardiovascular risk in 
patients with diabetes, and should be considered in the overall strategy for the 
management of the disease (Ajala et al. 2013). 
Although there is evidence that high-protein diets promote significant decreases in 
serum total cholesterol, LDL cholesterol, triglyceride levels, and blood pressure, these 
results are only reported in studies with a short-term follow-up (Ajala et al. 2013; 
Wheeler et al. 2012). Considering the available evidence from systematic reviews and 
randomized controlled trials in diabetes patients with normal renal function, neither the 
ACD (ACD 2008; Marion J. Franz et al. 2010), the ADA (2008) or the Diabetes UK 
organization (Dyson et al. 2011) support recommending a change in the usual protein 
intake of 15% to 20% of total daily energy intake. This includes the use of high-protein 
diets as method for long-time weight loss, as the long-term effects of protein above 20% 
of total caloric intake are still unclear (ACD 2008). Exceptions for suggesting different 
changes in protein intake are in individuals with an excessive intake of protein-rich foods 
that are high in SFA, in people who have a protein intake of less than 0.8g good-quality 
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protein/kg body weight/day, or in patients with diabetic nephropathy (Wheeler et al. 
2012). 
The role of carbohydrates in glycaemic control, and in insulin secretion and action led to 
believe that managing carbohydrate intake is a primary strategy for achieving glycaemic 
control. But although the total amount of carbohydrate ingested is the main 
determinant of postprandial blood glucose response, there is little evidence to support 
specific recommendations for carbohydrate intake in T2DM (Dyson et al. 2011). In type 
1 diabetes or in T2DM patients treated with insulin, additional monitoring is needed to 
achieve an adequate balance between carbohydrate intake and insulin units 
administered, but, overall, the total amount of recommended carbohydrates is in 
accordance with the guidelines for carbohydrates in a healthy diet. 
The acceptable macronutrient distribution ranges from the IOM predict 40% to 60% of 
total daily intake in the form of carbohydrates, and set a recommended dietary 
allowance (RDA) for carbohydrates of at least 130 g/day for adults and children. This 
RDA is based on the estimated average requirement for carbohydrate ingestion that will 
provide the brain with adequate glucose, and a coefficient of variation of 15% based on 
the variation in brain glucose utilization. The RDA is equal to the estimated average 
requirement plus twice the coefficient of variation, to cover the needs of 97–98% of 
individuals (IOM 2002). 
Evidence suggests that most patients with diabetes do not eat a low- or high-
carbohydrate diet, but rather have a moderate intake of this macronutrient. Data from 
the USA general population suggest that individuals have an intake of carbohydrates 
corresponding to approximately 50% of the total daily caloric intake (Marriott et al. 
2010; Moshfegh et al. 2005), which does not differ significantly from reported intakes in 
patients with diabetes. A sample of 2757 food frequency questionnaires completed by 
T2DM patients in the Look AHEAD trial showed an average carbohydrate intake of 44% 
(Vitolins et al. 2009). Other results included the findings that more than 10% of total 
calories were from saturated fat, and that 20% of participants met the proposed fibre 
goal, while less than 50% met the minimum recommendation for servings of fruits, 
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vegetables, dairy foods, and whole grains. Although the proportion of total 
carbohydrates is adequate in this study, the qualitative analysis conducted suggests that 
the reported proportion is achieved with a dietary pattern than can be improved. Other 
studies reported an intake of carbohydrates of approximately 46% in individuals with 
type 1 diabetes (Delahanty et al. 2009) and approximately 44% in patients with T2DM 
(Esposito et al. 2009). Data from the UKPDS also suggest that despite receiving individual 
education from dietitians that was designed to promote a carbohydrate intake of 50–
55%, patients with T2DM report a carbohydrate intake of 43%, similar to the intake of 
the general population. 
When comparing higher-carbohydrate diets to low-carbohydrate diets, data from 
clinical trials report similar improvements in HbA1c, and it appears likely that the total 
energy intake of the eating pattern outweighs the distribution of carbohydrates. High-
carbohydrate diets are generally low in fat, and tend to have beneficial effects on total 
cholesterol and LDL cholesterol, whereas low-carbohydrate diets tend to have beneficial 
effects on triglycerides and HDL cholesterol (Wheeler et al. 2012). On account of the 
relative similarities in outcomes, it seems prudent to recommend an eating pattern with 
moderate amounts of carbohydrate, which includes carbohydrates sources like fruits, 
vegetables, and whole grains, in appropriate amounts and portion sizes (ACD 2008).  
As day-to-day consistency in the amount and source of carbohydrate intake is associated 
with improved glycaemic control in type 1 diabetes (Wolever et al. 1999) and in T2DM 
(Boden et al. 2005), the ACD recommends, in its practice guidelines, that patients with 
diabetes receiving either medical nutrition therapy alone, glucose-lowering 
medications, or fixed insulin doses, should consistently distribute carbohydrate in meals 
throughout the day, on a daily basis (ACD 2008). The same guidelines add that patients 
that administer insulin should adjust insulin doses to match carbohydrate intake, which 
can be adequately achieved by collaboration with the health care team  and by 
comprehensive nutrition education on interpretation of blood glucose patterns and 
nutrition-related medication adjustment (ACD 2008; Marion J. Franz et al. 2010). 
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Overall, the different position statements agree that the adequate carbohydrate intake 
for the treatment and management of T2DM should be similar to the one in the 
acceptable ranges in the general population. If weight loss is to be encouraged, either 
low-carbohydrate or low-fat calorie-restricted diets may be effective up to one year 
(ACD 2008; ADA 2008; Marion J. Franz et al. 2010).  
Regarding the type of carbohydrates that should exist in patients’ daily meal plan, it is 
recommended that sucrose-containing foods can be substituted for other 
carbohydrates, in order to avoid excess intake in energy, and excess intake of simple, 
fast-absorbing carbohydrates. Intake of dietary fibre, a group of no digestible 
polysaccharides, is encouraged in the same amount as for the general population. There 
is not enough evidence to recommend a higher fibre intake for diabetes patients (ADA 
2008). 
Diets containing a daily fibre intake between 44g to 50 g seem associated to an improved 
glycaemic control, while more usual intakes (up to 24 g/day) have not shown beneficial 
effects on glycaemia (Marion J. Franz et al. 2010). Nevertheless, the evidence sustaining 
high-fibre diets is reported in a controlled, experimental setting, with a short follow-up 
period. The meal plan needed to achieve a daily intake of 50g of dietary fibre cannot be 
easily sustained in a free-living environment. The current agreement is that fibre intake 
for patients with diabetes should be similar to the recommendations for the general 
population, which state that daily diet should include foods containing 25–30g of fibre, 
with special emphasis on soluble fibre sources (between 7g and 13 g), on account of 
their beneficial effect on lipid profile (ADA 2008). A prospective study with a 26-year 
follow-up of 7822 women with T2DM showed that intakes of whole grain, cereal fibre 
and bran were inversely associated with all-cause and CVD mortality (He et al. 2010), 
contributing to the evidence that fibre-containing foods such as legumes, fibre-rich 
cereals, fruits, vegetables, and whole-grain products should be privileged (ADA 2008). 
Regarding fibre intake, the ACD notes that it may be difficult to meet dietary fibre 
recommendations with a low carbohydrate intake, so weight-loss diets with low 
carbohydrate content must be adequately planned (ACD 2008, 2011). 
Chapter 1: Literature review 
62 
 
 
1.7.3.3. Glycaemic index of carbohydrates  
When considering carbohydrate intake in patients with diabetes, some evidence has 
suggested that the use of glycaemic index (GI) for meal planning can provide a modest 
additional benefit over the one observed when total carbohydrate is considered alone 
(ADA 2008).  
The glycaemic index measures the relative area under the glucose curve of 50 g 
digestible carbohydrate, compared with 50 g of a standard food, either glucose or bread 
(although glucose is the usual reference). This allows to rank foods according to their 
blood glucose response and to infer that foods with a lower GI are associated with a less 
pronounced response, producing gradual rises in blood sugar and insulin levels (Wolever 
2013).  
Research that suggests advantages of the GI is controversial. A one year controlled trial 
with T2DM patients has shown no evidence of benefit of low glycaemic index over other 
nutritional strategies (Wolever et al. 2008), but a review of randomised controlled trials 
with follow-up of four weeks or longer reports a decrease of 0.5% in HbA1c in low GI 
diets (Thomas and Elliott 2009). Recent evidence considers that the GI has limitations as 
an indicator of carbohydrate quality compared with other measures such as dietary fibre 
or whole grains (Wolever 2013), and the practice guidelines of the ACD for nutritional 
therapy in diabetes suggest that if the GI is proposed as a method of meal planning, the 
patient should be advised on the conflicting evidence of effectiveness of this strategy 
(ACD 2008; Wheeler et al. 2012). The ADA notes that most individuals already consume 
a moderate-GI diet, but states that, however, for individuals consuming a high-GI diet, 
consuming a low-GI diet may result in a modest benefit in postprandial hyperglycaemia 
(ADA 2008). 
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1.7.3.4. Micronutrient contents of usual diet  
Other agreements on nutritional therapy for diabetes focus on micronutrients and 
alcohol consumption.  
Micronutrients are vitamins and minerals, which are required in small quantities for 
specific physiological functions. Micronutrients often function as coenzymes or 
cofactors for metabolic processes and, as such, are involved in the metabolism of 
carbohydrates and other nutrients, and with the body’s use of glucose and insulin. 
Healthy adults can receive all the necessary nutrients from foods, but specific 
populational groups, such as growing and developing children and youths, pregnant and 
lactating women, individuals with a low energy intake (less than 1,200 kcal/day), elderly 
individuals, patients in intensive care units or long-term nursing facilities and 
vegetarians, have an higher risk of micronutrient deficiency (Marion J. Franz et al. 2010).  
Patients with diabetes that exhibit poor glycaemic control also seem more likely to have 
deficiencies in magnesium, zinc, vitamin D, and water-soluble vitamins (Marion J. Franz 
et al. 2010; Pastors et al. 2002), but the current evidence does not justifies for routine 
supplementation of vitamins and minerals in patients with diabetes (ACD 2008; ADA 
2013a).  
Systematic reviews on micronutrient intake and diabetes report that findings from small 
clinical and animal studies, where diets can be manipulated easily in comparison to the 
diet of human free-living subjects, are frequently extrapolated to clinical practice, and 
that human studies with diabetes patients often do not take into account that urinary 
losses are increased if uncontrolled hyperglycaemia with glycosuria is present. This leads 
to biases in the recorded effect of the response to micronutrients (Marion J. Franz et al. 
2010; Wheeler et al. 2012) 
The nutritional therapy guidelines for diabetes state that, presently, there is no evidence 
of benefit from vitamin or mineral supplementation in diabetes patients without 
underlying evidence of a deficiency, but it is recommended that meal planning includes 
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optimization of food choices to meet the daily recommended intake (DRI) for all 
micronutrients (ACD 2008; ADA 2013a).  
 
1.7.3.4. Alcohol intake  
Recommendations on alcohol intake in diabetes follow the same trend as other 
recommendations, as there is no data to support alcohol use to people with or without 
diabetes who do not currently drink. Abstinence is recommended for individuals with 
risks related to alcohol consumption but, for patients who consume alcohol in 
moderation, alcohol consumption does not need to be discouraged if limited to one 
drink per day or less for adult women, and two drinks per day or less for adult men (ACD 
2008; ADA 2013a). This allowed intake is based on the protective effect of alcohol 
against coronary heart disease, reported in the general population. Several systematic 
reviews and meta-analysis (Corrao et al. 2004; Rimm et al. 1999; Xin et al. 2001) 
document a 10 to 40% reduction in risk associated with one to three drinks per day. This 
is attributed to the association of alcohol with increased HDL cholesterol, decreased 
platelet aggregation, decreased clotting factors such as fibrinogen, improvement in 
markers of inflammation and endothelial dysfunction, and enhanced insulin sensitivity. 
This association seems consistent, backed by the existence of plausible biological 
mechanisms, but the true magnitude of the effect of alcohol may be lower than 
suggested, due to difficulties in removing confounding factors from comparisons, as well 
as the problems caused by the use of non-drinkers as the reference group (Corrao et al. 
2004). 
In T2DM, moderate alcohol consumption is associated with decreased CHD and 
mortality risks, and decreased total mortality. The type of alcoholic beverage does not 
influence beneficial effects, and the most consistent mechanism reported for the 
beneficial effects is an increase in insulin sensitivity. Improvements in markers of 
inflammation and endothelial dysfunction are also reported (Koppes et al. 2006; I. Shai 
et al. 2004).  
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Moderate consumption of one to two alcoholic drinks (15g to 30g/day) has minimal 
effects on the glycaemia of patients with, and a U- or J-shaped association is reported 
between these variables, supporting the benefits from moderate alcohol consumption 
(Iris Shai et al. 2007). 
A systematic review of the effect of alcohol concludes that moderate consumption does 
not acutely impair glycaemic control in T2DM patient, and may actually result in a small 
decrease in glycaemia concentrations. On the other hand, chronic ingestion (above 45 
g/day) is associated with deterioration in glucose control (Howard et al. 2004).  
 
1.7.4. Physical activity and nutritional therapy efficacy  
The success of nutritional therapy is also determined by other interventions and care 
strategies, such as physical activity. In T2DM, physical activity paired with nutrition 
interventions for weight loss has shown to be helpful in achieving weight control, and 
improve glycaemia, blood pressure, and lipid profile (Marion J. Franz et al. 2010). A joint 
position statement of the ADA and the American College of Sports Medicine on exercise 
and T2DM, which also includes an evidence-based literature review, reports that regular 
exercise improves blood glucose control, reduces cardiovascular risk factors, contributes 
to weight loss, and improves well-being. Both aerobic and resistance training improve 
insulin action, glucose control, and fat oxidation in muscle tissue (Colberg et al. 2010).  
The Pre-diabetes Risk Education and Physical Activity Recommendation and 
Encouragement (PREPARE) study suggests that the benefits of moderate physical 
activity are sustained after 24 months (Yates et al. 2011), with subjects who underwent 
a 3h structured education session with personalized pedometer use showing a 
significant reduction in 2h post exercise plasma glucose, when compared with a control 
group. 
Physical activity is also important for maintenance of weight loss, as suggested by the 
results of the Look AHEAD trial, in which 4-year data indicated that greater physical 
activity is a factor for success in minimizing weight regain (Wadden et al. 2011). 
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The evidence on the benefits of physical activity is reflected on the standards for 
diabetes care, which state that exercise is an important part of the diabetes 
management, and that adults with diabetes should perform at least 150 minutes every 
week of moderate-intensity aerobic physical activity (50–70% of maximum heart rate), 
spread over at least three days, with no more than two consecutive days without 
exercise. Furthermore, in the absence of contraindications, adults with T2DM should be 
encouraged to perform resistance training at least twice per week (ADA 2013a). 
Individuals who already exercise at moderate intensity may be encouraged to consider 
increasing the intensity of their exercise to obtain additional benefits in both aerobic 
fitness and glycaemic control (Franz et al. 2010) 
 
1.7.5. Adherence to treatment and management of T2DM  
The pathophysiology of diabetes and its complications entail that the treatment and 
management of diabetes require a long-term, multifaceted and comprehensive 
approach that includes nutritional therapy, physical activity combining aerobic and 
resistance training, and behavioural modification strategies. As the disease progresses, 
most patients require an increasing care in order to be able to achieve glucose, lipid, and 
blood pressure targets. This increase in care implies an additional effort from health care 
providers and also an increased patient commitment to adhere to the behaviours 
associated with an adequate treatment and management of the disease (ADA 2013a). 
The majority of daily care in diabetes is handled by patients or families (Asche et al. 
2011a), making evident the importance of patient self-care. Nevertheless, being 
compliant to self-care activities will not lead to good metabolic control. Metabolic 
control is a combination of many variables, not just patient compliance (Sabatâe 2003; 
Schechter and Walker 2002; Seidu and Khunti 2012). A literature review highlights 
adherence, attitude, beliefs, knowledge about diabetes, culture and language 
capabilities, health literacy, financial resources, co-morbidities, and social support, as 
patient-related determinants of glycaemic control (Nam et al. 2011). The same study 
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identified effective communication, and the attitude, beliefs and knowledge about 
diabetes, as clinician-related determinants. 
According to the American Association of Diabetes Educators (AADE), self-care activities 
are behaviours undertaken by people with or at risk of diabetes in order to successfully 
manage the disease on their own. The AADE identified seven essential self-care 
behaviours for diabetes patients, positively correlated with good glycaemic control, with 
the reduction of complications, and with improvement in quality of life. These essential 
behaviours are healthy eating, being physically active, monitoring of blood sugar, 
compliant with medications, good problem-solving skills, healthy coping skills and risk-
reduction behaviours (AADE 2008). A recent literature review states that self-care 
encompasses not only performing these essential activities, but also the 
interrelationships between them, as diabetes self-care requires the patient to make 
dietary and lifestyle modifications with the supportive role of healthcare providers in 
order to maintain a high level of self-confidence. Adherence to these activities has been 
found to be low, especially when looking at long-term changes, as diabetes patients are 
expected to follow a complex set of actions on a daily basis, further complicated by the 
need to integrate and sequence these actions into daily routine (Shrivastava et al. 2013). 
Adherence to treatment is defined as the active, voluntary involvement of the patient 
in the management of his or her disease, by following a mutually agreed course of 
treatment and sharing responsibility between the patient and health care providers 
(Barofsky 1978). In health studies, non-adherence to treatment regimens has been 
described and measured as complying in less than 80% of the prescribed treatment 
(Delamater 2006), and it is believed that, as a group, diabetes patients are especially 
prone to substantial adherence problems (Day 2000; Kurtz 1990; Shrivastava et al. 
2013). A 2003 report from the WHO states that non-adherence rates for chronic illness 
treatment regimens and for lifestyle changes are approximately 50% (Sabatâe 2003) 
and, in the case of diabetes, literature reviews report general adherence to treatment 
ranging from 23% to 77% (Cramer 2004; Delamater 2006; Walker and Usher 2003). 
Adherence to one component of the treatment also seems independent of the 
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adherence to other components (Walker and Usher 2003), as research suggests that 
adherence to pharmacotherapy is higher than adherence to nutritional therapy or 
lifestyle change behaviours (Asche et al. 2011a; Cramer 2004; Sabatâe 2003). A 
Portuguese study on adherence to therapy in T2DM patients also reflects these results, 
recording an adherence to pharmacotherapy that is higher than to nutritional therapy 
and physical activity (do Ó and Loureiro 2007). However, it is believed that the methods 
for measuring adherence can be biased, and that there are serious methodological 
problems in the treatment of diabetes adherence estimates (Schechter and Walker 
2002). This can account, in part, for the wide range of results in the published estimates 
of adherence. 
Adherence to pharmacotherapy seems to be the behaviour with the highest prevalence, 
with reports of adherence to therapeutic regimens of OADA ranging from 70% to 80% 
(Ahmad et al. 2013; Asche et al. 2011a; Cramer 2004). Glucose monitoring, even with 
the availability of technologies that allow patients to conveniently measure glycaemia 
at home, is infrequent in T2DM patients, with several studies reporting approximately 
one third of participants as non-adherent to regular glycaemia monitoring (Adams et al. 
2003; Karter et al. 2000; Vincze et al. 2004). Regular physical activity also presents a low 
prevalence in diabetes patients, with a literature review reporting an adherence to a 
physical activity plan of 26%, and stating individuals with diabetes are considered among 
the least likely to engage in regular physical activity (Qiu et al. 2012). This review also 
suggests that only 25% of older adults with diabetes meet the recommendations for 
physical activity proposed by the ADA (2013a). 
Adherence to proper dietary habits can also be improved. An USA cross-sectional study 
suggests that approximately half of diabetes patients follow a meal plan (Jill Armstrong 
Shultz 2001). An Italian sample of 540 patients with T2DM showed that 43% of patients 
had an intake of more than 10% of saturated fat, and only 6% of patients had an 
adequate intake of fibre. Caloric intake exceeded the individual estimated daily 
requirements in about 300 kcal in men and in about 200 kcal in women (Rivellese et al. 
2008). A cross-sectional study in 1895 patients with T2DM from six countries in the 
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Mediterranean Basin (Greece, Italy, Algeria, Bulgaria, Egypt and Yugoslavia) reports that 
dietary habits vary greatly among countries, showing a clear trend for low carbohydrate 
intake and high fat and protein intakes, resulting in a poor compliance with nutritional 
recommendation (Mann et al. 2004). In this study, dietary habits were compared with 
the nutritional recommendations of the Diabetes Nutrition Study Group of the EASD, 
and compliance after age-standardisation ranged from 3.5% in Bulgaria to 56.4% in 
Egypt for carbohydrates, and from 5.7% in Bulgaria to 67.3% in Yugoslavia for fat.  
It is suggested that low adherence to dietary recommendations can be improved by 
nutritional education by a trained professional. Norris et al. (2002), in a meta-analysis of 
31 studies, report that contact time with a diabetes educator was the best predictor of 
improvements in glycaemic control. A cohort study with 18404 diabetes patients 
followed between 1993 and 2001 revealed that educational consultations, especially by 
a trained nutrition professional, were associated with fewer hospitalizations and 
reductions in total hospital charges (Robbins et al. 2008). Despite these data, the 
literature suggests that not all patients receive nutrition education. Results from the 
Diabetes Prevention and Control Programs in the USA from 2000 to 2010 indicate an 
yearly mean of 45.1% of patients with diabetes who report that they did not attend any 
type of diabetes self-management class (CDC 2011). Robins and colleagues (Robbins et 
al. 2008) also report that only 9.1% of patients had at least one nutrition consultation 
with a dietitian within a 9-year period. 
A report from the Portuguese Health Regulation Authority (Entidade Reguladora da 
Saúde – ERS), the independent public body responsible for regulating the activity of 
health care providers in Portugal, states that the National Health System coverage for 
dietitian consultations for diabetes patient is far from adequate. There are several 
Health Centres without a dietitian and the report concludes that, considering the impact 
that nutrition has on diabetes patients, the lack of appropriate response is reason for 
great concern. The ERS recommends that a multidisciplinary consultation is needed, 
with support by a dietitian, in order to implement Nutrition Therapy and Education 
Programs for diabetes patients (Entidade Reguladora da Saúde 2011). 
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The literature on the determinants of food choice has reported the complexity of the 
process of selecting food, indicating that what we choose to eat is not only determined 
by physiological factors, but also by major biological, economic, physical, social and 
psychological factors (Nestle et al. 1998; Sobal and Bisogni 2009). The predominance of 
the different determinants of food choice varies according to the stage of life and health 
status, thus implying that an intervention to modify food behaviour will not suit all 
population groups. This constitutes a challenge for health and nutrition professionals, 
who need to adequately tailor their health promotion messages to their specific target 
population. As food intake is of paramount importance in the control of T2DM and in 
the prevention of its associated comorbidities, the identification of factors influencing 
patients’ decisions on food choice can prove to be extremely useful in the quality of care 
that is to be provided. 
Health psychology research has helped to enlighten the understanding of the way 
people make decisions about their health and has been the source of health behaviour 
models which have been used to predict the likelihood that dietary behaviour change 
will occur (Spahn et al. 2010).  
It is known that changing food behaviour is not an easy task because it requires 
alterations in habits that have been built up over the course of an extended period of 
time, but targeted interventions that include behaviour and nutrition counselling have 
proven to be successful in primary care and community settings, including in T2DM 
patients (Spahn et al. 2010).  
As previously stated, a proper food intake in patients with T2DM is associated with 
improvements in metabolic outcomes and with the delay of health complications, 
contributing to the conclusion that nutritional therapy is an effective and essential 
therapy in the management of diabetes (ACD 2008). Nevertheless, adherence to the 
behaviours needed to achieve and maintain a healthy diet has been reported as being 
low, especially in diabetes patients (Shrivastava et al. 2013). 
Reports from focus group studies state that the diagnosis of T2DM seems to inflict an 
emotional toll on the patients, who identify stress, frustration, depression, and denial, 
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as factors inhibiting adherence to a healthy mode of living. Patients also frequently 
mention the failure to recognize the risks and consequences of diabetes as a promoter 
of low adherence to therapy, while suggesting that they feel the need for additional 
counselling, like follow-up consultations and refresher courses, support group 
discussions, nutrition and medication education, availability of different education 
modalities, and expanded clinic hours (Gazmararian et al. 2009; Jerant et al. 2005; 
Toobert et al. 2000; UKPDS Study Group 1995b; Vijan et al. 2005). 
Besides the lack of awareness of the disease and of educational programs for its control, 
patients also report dissatisfaction with the nutritional advice given, namely the 
perceived low applicability of the nutritional advice to patients’ daily routine (Jerant et 
al., 2005).  
Other factors for low adherence to nutrition and lifestyle changes include social and 
family pressures for maintaining eating habits, due to the social gathering nature of 
meals, comorbidities like osteoarthritis, which make patients feel that they cannot 
participate in regular exercise, and financial issues, with patients stating that they 
believe that a healthy diet is more expensive (Gazmararian et al. 2009; Jerant et al. 2005; 
Toobert et al. 2000; UKPDS Study Group 1995b; Vijan et al. 2005). Some patients also 
consider a burden to change their diet, comparing the troubles of a diet aimed at weight 
loss to the burden they associate with daily insulin injections, and perceiving the food 
portion sizes in a recommended diet as small for their nutritional needs (Gazmararian 
et al. 2009; Jerant et al. 2005; Toobert et al. 2000; UKPDS Study Group 1995b; Vijan et 
al. 2005). 
The determinants of food choice are influenced by health status, thus making an analysis 
on the role of glycaemic control in the adherence to a proper diet and in the perception 
of barriers to adequate food behaviour in T2DM, a direction in research that can 
contribute to improve the care provided to diabetes patients. 
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1.7.6. Novel therapies and monitoring systems  
The burden that diabetes and its complications pose for patients and for health systems, 
together with the still unclear pathogenesis of this disease and the high worldwide 
prevalence, have established the importance for continuous research and development 
of diabetes preventions strategies, therapies, and disease monitoring systems. 
Improvements in technology and care efficiency have played a role in controlling both 
type 1 diabetes and T2DM, and there are, currently, several branches of research that 
may lead to promising results in this field. 
Recently, a novel class of pharmacological agents called sodium- glucose cotransporter 
2 (SGLT2) inhibitors has been studied and suggests good results in T2DM control (Kim 
and Chung 2014; Riser Taylor and Harris 2013). SGLT2 inhibitors contribute to reduce 
the reabsorption of filtered glucose in the kidney and lowering the blood glucose 
concentration at which glucose is no longer reabsorbed from the proximal tubule but is 
instead excreted (L. H. Chen and Leung 2013). 
The current approved drugs in this class are dapagliflozin, canagliflozin and 
empagliflozin, with others undergoing phase II or phase III clinical trials (Kim and Chung 
2014; Riser Taylor and Harris 2013). SGLT2 inhibitors could be a promising therapeutic 
agent that acts independent of insulin secretion, and can also provide useful to treat co-
morbidities of diabetes such as hypertension, obesity, and dyslipidaemia. 
Epidemiological surveillance will ultimately assess the safety and efficacy of SGLT2 and 
further studies are needed for assessing their long-term benefits and risks in larger 
populations, but the inhibition of SGLT2 represents a highly promising therapeutic 
approach for T2DM treatment (Haas et al. 2014; Kim and Chung 2014). 
Improvements in glucose monitoring also have been important for diabetes managing, 
hoping to address one of the most inconvenient components of insulin therapy, which 
is the need for patients being treated with multi-dose insulin to monitor their glycaemia, 
usually by puncturing the fingertips, several times in a single day. These glucose 
measurements are painful to the patients and the strips used in the glucometers are 
expensive, which means that replacing this method would represent a significant 
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improvement in patients’ quality of life and reduction in the disease’s economic burden 
(Ratheau et al. 2011). 
Research suggests that patients with diabetes, especially those with T2DM, avoid self-
monitoring of blood glucose due to their unwillingness to think about blood glucose 
values and, more broadly, diabetes itself, to the belief that self-monitoring is unlikely to 
be of value, and to the sense of self-monitoring as an unpleasant, costly task (Polonsky 
et al. 2014). Although healthcare professionals need to assess and improve the way they 
present, make use of and discuss self-monitoring of blood glucose with patients with 
diabetes (Polonsky et al. 2011), technology improvements during the last few decades 
have allowed for the glucose measurements to be performed in a more patient-friendly 
way. For example, there has been an increasingly reduced requirement for blood in the 
sample tested and additional approaches using subcutaneous sensors to determine 
glucose concentration in interstitial fluid have also been developed. Several 
manufacturers have produced accurate, reliable, and portable continuous glucose 
sensors that can be used for up to seven consecutive days, and which appear to be 
associated with HbA1c reduction (Langendam et al. 2012; Vashist et al. 2011). Despite 
their accuracy, they still imply discomfort to patients and require continuous calibration 
(Vashist et al. 2011). 
The development of non-invasive glucose measuring systems using thermal, raman 
impedence, and infrared spectroscopy, optical coherence tomography, temperature-
modulated localized reflectance, ultrasound, and electromagnetic sensing have all 
shown promising accuracy and reliability (Ciudin et al. 2012; Langendam et al. 2012; 
Vashist et al. 2011), and encouraging  evidence exists for the development and use of 
methods using infrared laser light applied on top of the skin, (Pleitez et al. 2013) or 
exhaled breath analysers (Prathibha et al. 2013; Schivo et al. 2013). Nevertheless, the 
manufacturing costs and portability of these devices have yet to be improved to the 
point where they can be widespread. 
Subcutaneous glucose sensors gave rise to continuous subcutaneous insulin infusion 
systems, which appear to be linked to a lower incidence of severe hypoglycaemia and 
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provide patients with a flexible and convenient way of controlling glycaemia (Hanaire-
Broutin et al. 2000; Joubert and Reznik 2012). Yet, although these insulin delivery 
systems offer a way of fine-tuning metabolic control and thus allowing for a better 
glucose control in everyday planned and unplanned activities, patients who are 
candidates for these devices should be carefully selected, educated and motivated, as it 
is desirable that patients be aware of the intricacies of insulin therapy to adequately 
self-monitor and to know the relationship between the insulin dosage needed for the 
meals they consume (Didangelos and Iliadis 2011). Despite this link in monitoring and 
infusion systems, a truly automated closed loop device has yet to be achieved, partly 
due to the fact that the systems do not work directly in the blood stream. Monitoring is 
made interstitially and the delivery is subcutaneous, which makes inevitable for a lag 
both in sensing glycaemia changes and in the insulin response. Research efforts 
sponsored by industry are underway, and it is to be believed that advances in the next 
few years are very likely (Vashist et al. 2011).  
The ultimate goal of continuous insulin infusion is to create an artificial pancreas, where 
glucose levels trigger appropriate insulin release from an insulin reservoir. Although the 
lag between insulin sensing and releasing is, until now, impossible to avoid, predictive 
algorithms for determining insulin need are in development, together with techniques 
and devices that can mean that future insulin pumps may be internally implanted. 
Current challenges with these devices include insulin precipitation, short battery life, 
pocket infections, and catheter obstructions (Joubert and Reznik 2012; Siegmund et al. 
2013). Nevertheless, emerging technology on electronics and biomedicine, seems to 
make the realization of a continuous insulin infusion system that can be used to prevent 
hypoglycaemia and maintain stable glycaemic control with less variability of blood 
glucose concentration, a possibility in the near future (Bakhtiani et al. 2013; Gifford 
2013; Hanazaki et al. 2013). 
Other methods for insulin administration have also been proposed, like inhalation, 
which has by now largely ceased development due to reports of increased risk for 
pulmonary function complications (Hegewald et al. 2007). Nasal, oral and buccal insulin 
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administrations continue to show some promise, although with mixed results (Guevara-
Aguirre et al. 2007; Heinemann 2014). 
On par with novel administration methods, insulin pen devices have become more 
convenient, discrete, attractive, and portable. Insulin pens for long-term use now have 
software memory functions and insulin dose calculators, and their combination with 
microfine needles makes insulin delivery almost painless. This is still the most used 
insulin delivery method and it is important to note the role that doctors and other 
diabetes educators play in providing appropriate training in their use, as the outcomes 
of this treatment and correct use are closely related (Heinemann 2014). 
Surgical treatments for diabetes, with whole or segmental pancreas transplantation 
which aims to restore endogenous insulin secretion, have also been evolving. Patient 
survival seems better with simultaneous pancreas-kidney grafts than with a pancreas 
transplant alone, but even so, the procedure is associated with significant mortality and 
morbidity in the early period following transplant, with survival being around 80% at 3 
years and less than 25% at 10 years (Tavakoli and Liong 2012). Ongoing research will 
continue to refine the surgical techniques and immunosuppressive regimens to further 
improve outcomes, but it is unlikely that this diabetes treatment will significantly evolve, 
due to the limitations on the supply organs for transplant and the specific indications for 
the procedure (de Kort et al. 2013; Tavakoli and Liong 2012). 
Surgical procedures can benefit from advances in other forms of treatment, like gene 
therapy, which is still much in its infancy, or stem cell therapy, which aims to provide a 
source of cells nearly identical to the pancreatic β cell for treatment of diabetes by 
transplantation. Both embryonic and adult stem cells have been studied and 
manipulated to produce insulin and some trials have shown positive results in reducing 
blood glucose in animals, but although tremendous progress has been made in recent 
years, the challenge of reconstructing an  in vitro β-cell,  whether through stem cell 
differentiation or reprogramming, remains open (Pagliuca and Melton 2013). Serious 
side effects in stem cell therapy, mostly related to immunosuppression, need to be 
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resolved in future trials in order to establish the long-term safety and cost benefit of this 
treatment (Ashcroft and Rorsman 2012).  
Despite the novel therapies involving advanced medical procedures, and also the new 
knowledge and products resulting from a vast body of research in pharmacology and 
OADA therapy (Grunberger 2013b, 2013a; Ludvigsson 2012; Munro and Levy 2007), the 
future of diabetes therapy must also be supported on studies aimed at improving the 
diabetes care process (Burke et al. 2014; Leroy 2011; Paschou and Leslie 2013). 
Diabetes patients show low adherence to therapy, and complex strategies, which may 
include combinations of more thorough counselling, close follow-up, supervised self-
monitoring, and family therapy, have been demonstrated to improve adherence and 
treatment outcomes and improvements in diabetes control are associated with a more 
frequent interaction between health professionals and patients, which seems an 
important determinant in adherence (Tahmasebi et al. 2013). Nevertheless, frequent 
contacts with patients require a substantial amount of effort and Health Service’s 
resources. This has been a reason for the development of simple and technological 
strategies for improving patient monitoring and treatment adherence. These strategies 
range from electronic monitoring devices to increase medication adherence, like 
electronic caps for insulin injection systems or other pharmacological therapies which 
use visual and acoustic reminder signals (De Bleser et al. 2010), to recent smartphone 
software that doctors may find useful to recommend (Demidowich et al. 2012). 
At the time of the writing of this document, an internet search using “diabetes” as a 
keyword in the two main application stores for smartphones and tablet personal 
computers with iOS and Android operating systems, results in more than 800 
applications ready to download. Approximately half of these applications are provided 
at no cost, while others have prices ranging between €0.89 and €12.50. The applications 
have different natures, offering food pyramid guides, calorie and carbohydrates 
counters, physical activity trackers, recipes repositories, recipes ingredients converters, 
access to specific diabetes forum, glycaemia, blood pressure and other health variables 
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tracker, medication reminders, information booklets and various types of multimedia 
educational material on the disease.  
Research on the usability, features and characteristics of diabetes applications for 
Android smartphones has proposed that few provide a comprehensive method 
of diabetes management, and attributed a mean usability score of 3.0 out of a possible 
5.0 to the applications reviewed (Demidowich et al. 2012). Despite the recent 
proliferation in this type of software, it seems that the potential to deliver real-time 
feedback, dynamic diabetes education, and secure data sharing remains largely 
underexplored (Goyal and Cafazzo 2013). Nevertheless, as patients become more 
technologically aware, an increasing demand for applications that provide a response to 
consumer needs may contribute to the improvement of the applications that are 
currently offered, and this form of disease monitoring and prevention can be a 
significant determinant of care in the future (Goyal and Cafazzo 2013) and contribute to 
reduce health disparities (Silow-Carroll and Smith 2013). 
In order to fulfil their potential for contributing to patient care, mobile health 
applications for diabetes control should focus on automatic data transfer between 
patients and health professionals, motivational and visual user interfaces, and on 
including context sensitivity. This can empower patients to take a more active role in 
managing their own health (Arsand et al. 2012). Overall, the widespread access to 
wireless communication indicates that future care models incorporating home 
monitoring and tailored feedback have the potential for a broad adoption by T2DM 
patients, if the systems and software can be intuitive and clear enough for patient use.   
Self-monitoring of blood glucose in patients with T2DM that are not using insulin seems 
to present advantages for the overall care process mainly in patients that are included 
in a programmatic, structured intervention (Polonsky et al. 2011) with a structured 
feedback management (Garg and Hirsch 2014; Heller 2014; Welschen et al. 2005). For 
patients with T2DM, engaging in routinely scheduled appointments with healthcare 
professionals who make appropriate use of data from blood glucose monitoring at home 
can be clinically meaningful and contributes to significant improvement in glycaemic 
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control (Polonsky et al. 2011). This provides insight on the importance and potential of 
information technologies aimed at improving home glucose monitoring. As the use of 
electronic medical records advances, it is likely that it may be possible to provide 
patients with the ability to upload home glucometer readings, which can then be 
interpreted by a clinician.  
Apart from research into technological advances for diabetes care, studies aimed at 
improving the system of patient care and the approaches for therapy and prevention 
interventions have also led to promising results. Strategies for tailoring care to specific 
patients or groups of patients, combining patient education with arrangements for 
follow-up by multiple professionals, have resulted in positive improvements in HbA1c, 
glycaemic control, and other health outcomes (Loewenberg 2011; Mudd-Martin et al. 
2013; Tricco et al. 2012; Umar-Kamara and Adams Tufts 2013; Weymann et al. 2013). 
As strategies to improve the care for diabetes patients, it is recommended that care 
systems support team-based care, community involvement, patient registries, and 
embedded decision support tools to meet patient needs, while also being tailored to 
individual patient preferences, prognoses, and comorbidities (ADA 2013a). 
 
1.8. Diabetes complications risk perception 
Beliefs and perceptions are considered determinants of health behaviours, but research 
has poorly addressed, so far, patients’ perception and emotional responses to the risk 
of developing diabetes complications. A thorough understanding of perceived risk of 
diabetes complications can provide insight on the actions taken by patients to achieve 
adequate self-care and good glycaemic control, as well as contribute to the study of 
adherence to diabetes therapy and management. Although health educators are 
generally aware that knowledge of risk is important to adopt and sustain behaviour 
change, the degree of perceived risk and the type of risk perceptions are not fully 
understood (Fisher et al. 2002), and the nature of the relationship between risk 
Chapter 1: Literature review 
79 
 
perceptions for chronic disease and health behaviours to reduce risk of disease is 
unclear (Weinstein 2003). 
Risk perception can be defined as the subjective assessment of the probability of a 
specified type of event happening and how concerned we are with the consequences. 
Risk perception includes evaluations of the probability as well as the consequences of a 
negative outcome (Weinstein 1980).  
Risk perception is related to risk knowledge. Individuals may have, or believe they have, 
sufficient information for adequate decision making, but knowledge does not always 
translates into desirable behaviour. An example of this is the reported knowledge and 
perceptions regarding food and nutrition, and their assessment considering indicators 
of adequate intake. Buttriss (1997), in a representative sample of adult UK residents, 
concludes that although most respondents believe that they are informed about 
nutrition and can correctly identify proper nutrition-related health behaviours, they do 
not choose nutritionally adequate foods in their usual daily meals. Bowen and Beresford 
(2002) have concluded that individuals choose and adequate food intake and incur in 
health promotion behaviours if they believe and perceive that those behaviours will be 
useful to them.  
It is believed that the perception of the consequences associated with certain health 
behaviours is an important factor for the decision to act, at an individual and 
populational level, and that health promotion policies should be created taking this into 
account (Krewski et al. 2012). The WHO, in its 2002 World Health Report, states that in 
order to identify proper strategies and interventions for health promotion, it is 
necessary to assess health risks, considering the social, cultural and economic contexts 
(WHO 2002). This report describes that, overall, individuals perceive new or unknown 
risks with a higher degree of fear. A risk factor is also considered more important if it 
affects us personally, instead of affecting the general population. Furthermore, we 
assess in a more negative way risk factors that are imposed on us, while we fear less a 
risk factor in which we believe we can exert some degree of control. Slovic, in a pioneer 
work in risk perception (Slovic 1987), proposed that the assessment of probabilities 
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associated with risk factors are not independent from the possible losses or damages 
they incur. We tend to assess in a more optimistically way risks that have desirable 
consequences while overestimating the risk associated with particularly damaging 
consequences. Slovic also identifies anchoring behaviours, in regard to risk assessment 
and perception, as it is believed that initial assessments and perceptions are resistant to 
change, and that additional information will only be correctly considered if it is 
consistent with initial beliefs. 
Weinstein and colleagues (Weinstein et al. 2007) suggest that there is a discrepancy 
between perceived and desired risks, as some individuals tolerate higher risks to gain 
greater benefits. These authors also agree that perceived risk predict health behaviour 
better than a purely cognitive probability judgment. 
The discrepancy in risk perception is also evident when comparing perceptions between 
the general population and experts, and this has supported the existence of an 
unrealistic optimism, translated in a general optimism about the outcome of an event 
(Weinstein 1980). Individuals seem to have a strong but unjustified sense of subjective 
immunity, and the tendency to believe that one's own risk is less than that of others may 
reduce interest in health-protective behaviours.  According to Weinstein, this optimistic 
perception can partly explain why health education messages often fail, as there is 
evidence that health education can even exacerbate unrealistic optimism (Weinstein 
and Klein 1995). 
Unrealistic optimism, or optimistic bias, is determined by several factors, but it is still 
unclear how it is triggered. A literature review on optimistic bias and food (Miles and 
Scaife 2003), concludes that unrealistic optimism is not found in all risk factors nor in 
the same degree, making it hard to predict its existence. Nevertheless, optimistic bias is 
lower in risks that are perceived as less probable, and in risks which individuals have 
some previous experience. Risk factors believed as more controllable are associated 
with a higher degree of optimistic bias.  
The existence of an optimistic bias, and the relationship between risk perception for 
diabetes complications and diabetes self-management behaviours, has not been 
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thoroughly studied, even if risk perception for developing diabetes complications is 
believed to raise patients' awareness of diabetes care. Searle and collaborators (Searle 
et al. 2008) reported that diabetes patients were concerned and aware of their risk of 
developing diabetic foot ulceration and retinopathy, but their perceived risk was biased, 
as patients with foot ulcers held a greater belief in personal control of diabetes, 
compared to that of diabetic controls without serious complications. A prospective 
study with 139 diabetic patients (Meltzer and Egleston 2000) with the objective of 
comparing patients’ risk perceptions for major complications of diabetes (blindness, 
end-stage renal disease, and lower-leg amputation) with the actual risk for these 
complications, showed that patients significantly underestimate their risk for diabetes-
related complications. These results are consistent with the reports that suggest that 
individuals have a poor ability to predict their risk for developing disease (Weinstein 
1980; 2003), but are not consistent with the nature of the prediction. In this case, there 
was no evidence of an optimistic bias. 
Walker et al. (2007b) conducted the first report of comparative risk perceptions and risk 
knowledge in a mainly low-income, urban, minority sample of persons with diabetes. 
Results suggest that knowledge about the factors that increase or decrease the risk of 
diabetes complications was fairly high, and there were no significant differences in risk 
perceptions between different demographic characteristics, except age and household 
income. Lower income was associated with less risk knowledge and older subjects (aged 
64-85 years) had less risk knowledge than younger subjects (aged 20-52 years). Risk 
knowledge did not differ between genders or with ethnicity. 
Calvin et al. (2011), in an African-American sample of diabetes patients diagnosed for an 
average of approximately two years, found a low perception of risk for complications, 
which was incongruent with risk estimates according to HbA1c and blood pressure.  Less 
than 33% of participants saw themselves as being at high risk for developing any 
complications of diabetes but the mean HbA1c in the sample was 8.7%, and 61.3% of 
the patients were hypertensive. These results suggest that this population’s perception 
of risk for diabetes complications needs to be addressed, especially if we take into 
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account the implication that disease perception shapes the procedures for coping with 
or controlling the disease (Leventhal et al. 1992). Moreover, a patient’s perception of a 
health problem is frequently not in agreement with the clinical assessment, and it is 
usually the patient’s illness perception that influences adherence to treatment regimens 
(Harrison et al. 2003). 
It is proposed that perhaps the perception of being at low risk for diabetes complications 
may be attributed to the lack of visible symptoms, and to the fact that most patients are 
engaged in a  treatment regimen, even if it may not definitively reduce the risk of 
complications (Frijling et al. 2004). Symptoms are considered motivators of protective 
behaviour, and the way people view their symptoms is an important factor in how health 
is perceived, and whether health care should be sought (Stover et al. 2001). 
Risk perception may play an important role in the adherence to diabetes treatment and 
management, on account that, theoretically, one is more likely to participate in self-care 
if the perceived risk of developing complications is high (van der Pligt 1998; Walker et 
al. 2007b). Unrealistic optimism for developing diabetes complications might be a major 
barrier to behaviour change, particularly in patients who have uncontrolled blood 
glucose and low education (Hevey et al. 2009). 
On the other hand, patients with T2DM have also shown over-pessimistic views about 
their risk of developing coronary heart disease and stroke, which the researchers 
suggest to be associated with the reinforcement of the relationship between diabetes 
cardiovascular complications and mortality by doctors, in regular diabetes consultations, 
or to the fact that cardiovascular disease may well be a very dreaded and particularly 
feared outcome of diabetes (Asimakopoulou et al. 2008). 
Nevertheless, these authors also mention previous evidence suggesting that 
perceptions of a threat as likely and severe can result in low motivation to deal with that 
same threat (Weinstein 2000), which can have an important impact in diabetes self-care, 
as unduly pessimistic patients may be reluctant to self-care, seeing little point in 
managing an illness seen as overly risky (Asimakopoulou et al. 2008). 
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Further studies are needed to clarify the unrealistic risk perceptions for diabetes 
outcomes but the conclusions from the research on risk perception in T2DM agree that 
the study of risk perception in diabetes can have implications for clinicians, researchers 
and diabetes educators, as communication with the patient can be achieved in a more 
holistic way if a comparative risk perception indicator is available. Health education 
interventions can be integrated in the context of other health risks the patient is 
experiencing, like environmental safety concerns or health behaviours like smoking, for 
example. Overall, risk perception research can provide further insight on why a patient 
acts or does not act on risk perceptions related to diabetes 
 
1.9. Aims, research questions and hypotheses  
The complexity of diabetes determinants, and of its therapeutic regimens and 
outcomes, denotes that the management and control of the disease cannot obey to a 
universal approach. In order to provide patient-centred care, and to effectively target 
interventions, adherence to treatment and its barriers should be assessed. 
Scientific research has proven the efficacy of nutritional therapy in the management of 
T2DM and its role in controlling and preventing complications associated with the 
disease. On account of the available evidence, nutritional therapy must be adequately 
implemented in all patients. Available data also suggests that individuals believe 
nutrition is important in daily life and that they can identify behaviours related with 
desirable nutritional health; nonetheless, adherence to proper eating patterns is 
reported as low, even when nutrition education and consultations are provided.  
Among the determinants of adherence to a proper diet, the perceived risk of diabetes 
complications has not been thoroughly studied, and its assessment can contribute to 
the development of future nutrition education interventions. Furthermore, patient-
centred approaches to treatment can benefit from the knowledge of how optimistic bias 
and patients’ expectations shape self-care behaviours. 
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In a clinical setting, management of T2DM is evaluated by metabolic control, as inferred 
by HbA1c. Patients who achieve a low value of HbA1c believe that their treatment is 
successful, and place higher value on pharmacotherapy, in detriment of nutrition and 
lifestyle interventions. Recently, the association of PPHG with CVD has brought into 
attention that postprandial glucose imbalance is common in patients with T2DM, even 
in those with adequate HbA1c. These findings can imply that additional evaluations 
should be undertaken in patients with T2DM, so as to fully evaluate metabolic control. 
As PPG is a state that is highly prevalent throughout the day in most patients, self-
monitoring of blood glucose can be a very important behaviour in diabetes self-care.  
The main predictor of PPG is the nutritional content of the meal, especially in 
carbohydrates, which signifies that the best option for regulating PPHG can be 
nutritional therapy, as it can bring several added benefits to the management of 
diabetes and its complications (e.g., weight reduction, improvement in lipid profile), 
without the side effects and costs of pharmacotherapy. This poses a challenge for 
dietetic and nutrition professionals, as meal plans for patients with diabetes should take 
into account the need to regulate PPG and, at the same time, the daily routine,  
preferences, and beliefs of each patient. The construction of effective nutritional 
guidelines can only be achieved if research addresses the adherence to a proper diet, 
and the influences of HbA1c on glycaemic response. The comparative analysis of the 
glucose curve in response to a common meal in patients with different metabolic control 
may be a useful study design to clarify this issue. 
Most study designs on adherence to diet in patients with T2DM are cross-sectional, or 
based in samples from prospective studies, which are generally undertaken to study the 
role of a particular set of risk factors and its association with designated health 
outcomes. The study constructed for the present work starts with patients at the 
endpoint (adequate or inadequate glycaemic control), and comparatively assesses 
adherence with nutritional recommendations, while further exploring the perceived risk 
of diabetes complications, and analysing the similarities between glycaemic responses 
by exposing patients to a nutritionally controlled meal. 
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The aim of the present study was to use a case-control design to undertake a 
comparative analysis regarding PPG, nutritional therapy adherence, and risk perceptions 
of diabetes complications. Subjects are patients with T2DM which differ in their 
glycaemic control, based on HbA1c results. This study can contribute to the 
identification of differences and similarities between patients with different glycaemic 
control, and provide information for the development of treatment and monitoring 
guidelines. 
The specific research questions in this research are: 
 Does adherence to nutrition recommendations differ between patients with 
adequate glycaemic control and those with poor glycaemic control? 
 What barriers patients identify in the adherence to nutrition recommendations? 
 What is the association between PPG levels and HbA1c? 
 How do patients with T2DM with different glycaemic control perceive their risk 
of diabetes complications? 
Based on the research questions and on the literature review, the hypotheses of this 
study are: 
1. There is no significant difference in PPG between patients with adequate 
glycaemic control and those with poor glycaemic control; 
2. Patients with adequate glycaemic control have a better compliance of nutrition 
recommendations; 
3. Patients with poor glycaemic control identify barriers to nutrition 
recommendation compliance different from those identified by patients with 
adequate glycaemic control; 
4. Patients underestimate their risk for health complications of diabetes associated 
with food behaviour; 
5. There is a significant difference in risk perception for diabetes complications 
between patients with adequate glycaemic control and those with poor 
glycaemic control. 
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2.1. Study design 
This study followed an analytic, case-control design. Analytic studies allow to examine 
associations and causal relations as they concern with identifying, measuring and 
interpreting the effects of risk factors or of specific exposures. In an analytical study, 
individuals may be classified according to the absence or presence of a known attribute 
(Ahrens and Pigeot 2007). 
The research questions for the current study can be defined as having an analytic nature, 
due to the intention to measure and describe possible causal relationships between the 
presence of glycaemic control and several outcome variables. Additionally, the analytic 
nature is also reflected in the assessment of past exposures and their association with 
current glycaemic control. 
Each subject was classified as “case” if he/she had been recorded as having an HbA1c of 
7.0% or above in the 60 days prior to data collection. Alternatively, subjects with a 
recorded HbA1c below 7.0% were considered “controls”. 
Additional information pertaining to the inclusion of subjects in an analytic, case-control 
study are considered and detailed in sections 2.2. 
I used a mixture of prospectively and retrospectively measured variables, which could 
account on the present study being described as either prospective or retrospective. 
Several definitions have been used for the terms “prospective” and “retrospective” and 
a central feature of case-control studies has been the assessment of exposure by recall, 
after the disease or outcome being analysed has occurred, which has led to case-control 
studies being generally classified as retrospective (Porta 2008). Nevertheless, not all 
case-control studies involve recall, as there are case-control studies that evaluate 
exposures by having the information on the exposures and risk factors taken from 
records or registries that predate development of the outcomes. These case-control 
studies may described as prospective, at least with respect to the measurement of 
exposure (Rothman et al. 2008). 
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The study design for the present work was, thus, a case-control that included a 
retrospective measurement of exposures and risk factors, and also a prospective 
measurement that allowed group comparisons of outcomes associated with the 
characteristic that defines the study groups. 
The retrospective assessment was aimed at addressing the hypotheses regarding better 
compliance of nutrition recommendations, identification of barriers to nutrition 
recommendation compliance, optimistic bias in the risk perceptions for diabetes 
complications, and the existence of group differences in the risk perception for diabetes 
complications. 
The prospective measurement was conducted to address the hypothesis regarding the 
smilaritues in PPG between patients with adequate glycaemic control (HbA1c of 7% or 
below) and those with poor glycaemic control (HbA1c above 7%). The prospective 
assessment involved the exposure of both cases and controls to a nutritionally 
controlled meal, in order to assess glucose responses and its similarities between 
patients. This feature of the research design allows this branch of the study to be 
classified, according to some authors, as quasi-experimental, due to the fact that 
conditions during the period of study were changed (Ahrens and Pigeot 2007). As the 
exposure (controlled meal) was not different for cases or controls and there was no 
random allocation of subjects for each group, this cannot be classified as an 
epidemiological or clinical trial (Porta 2008). 
 
2.2. Population and sample 
2.2.1. Population 
The study population was composed by patients with T2DM receiving health care in a 
Diabetes Clinic in the municipality of Faro, in the Portuguese region of the Algarve. The 
clinic is integrated in a regional association of diabetes patients (AEDMADA). The 
AEDMADA Diabetes Clinic is an outpatient clinic based in Faro which offers consultations 
with highly experienced and qualified diabetologists, and other consultations aimed at 
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increasing the quality of life in patients with diabetes and at providing care across all of 
the complications and impairments associated with diabetes (e.g., foot care, 
psychology, dietetics and nutrition, pharmacotherapy adjustments, orthotics and 
prosthetics) (AEDMADA 2013). 
 
2.2.2. Sampling and sample size   
The sampling procedure was non-randomized. Patients were invited to be a part of this 
study during their Diabetology consultations in the AEDMADA Diabetes Clinic and 
afterwards were contacted by the researcher to proceed with the data collection. 
Recruitment for the study started on June 3rd 2012 and lasted up to the end of November 
2012. All patients who met the inclusion criteria were invited to be a part of the research 
and the final sample was composed of 32 controls and 34 cases. 
A minimum sample size was estimated through the formula proposed by Fleiss and 
collaborators (Fleiss et al. 2004) for testing differences between two proportions, solved 
for n, the number of subjects. 
In order to estimate a proportion for use in the sample size formula, I used the results 
from the Guideline Adherence to Enhance Care (GUIDANCE) study, suggesting more 
than two thirds of patients with elevated HbA1c do not satisfactorily comply with T2DM 
treatment while patients with a good glycaemic control appear more compliant, even if 
at least one third of them also show poor treatment adherence (Stone et al. 2013). Thus, 
I assumed a hypothetical proportion of non-adherence of 35% in patients with HbA1c 
below 7% (controls) and a hypothetical proportion of non-adherence of 75% in patients 
with HbA1c of 7% or above (cases). According to the calculations, a minimum of 25 case 
subjects would be required in order to detect a real odds ratio with 80% power and two 
sided type I error probability of 5%. This sample size was then continuity-corrected for 
use with corrected chi-square and Fisher's exact tests, resulting in a minimum sample 
size of 28 cases. 
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For a fixed number of subjects, statistical power for testing the null hypothesis is 
optimized by having equal numbers of cases and controls (Ahrens and Pigeot 2007), so 
the minimum sample size was set at 56 patients with T2DM, half of them cases and half 
of them controls. 
 
2.2.3. Inclusion and exclusion criteria 
The inclusion criterion for this study were: 
 Male or female patients with medical diagnosis of T2DM for at least 12 complete 
weeks, obtained by  previous assessment and identification of one or more of 
the following: HbA1c ≥ 6.5%, FPG ≥ 126 mg/dl (7.0 mmol/l), 2h plasma glucose 
≥ 200 mg/dl (11.1 mmol/l) during a OGTT, or presence of classic hyperglycaemia 
symptoms and a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l); 
 Age below 85 years 
The exclusion criteria were: 
 Undergoing a pharmacotherapy regimen with insulin or any ADOA other than 
metformin; 
 Diagnosis of degenerative disorder of the central nervous system; 
 Following a lactose-free or gluten-free diet; 
 
2.2.4. Sample construction procedures and final sampled subjects  
The subjects in the study population were invited to be a part of this study in the 
Diabetology consultations in the AEDMADA Diabetes Clinic. Patients who conformed to 
the inclusion criteria were approached with a brief explanation of the study by the 
clinician responsible for the consultations and were asked permission for a later contact 
by the researcher. Up to five days after the consultation the researcher contacted the 
patients by telephone, explained the study, and set up an individual appointment with 
each patient. In this initial contact, the patients were informed that they should attend 
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the appointment before any intake of food and that a breakfast would be provided, free 
of charge, as a part of the study. If patients choose to decline participation in the study, 
they still would be offered breakfast. Furthermore, it was clearly stated at this time that 
participants would not be compensated monetarily for their collaboration or 
reimbursed for their expenses with any trips to attend the appointment. 
The individual appointments were held in the School of Health of the University of 
Algarve. At the start of each appointment, the study’s protocol was thoroughly 
explained to the patients and the researcher discussed the important role patients can 
play in the scientific advances on diabetes research. Patients’ comfort and anonymity 
were assured at all times and all ethical considerations were followed, as detailed in 
section 2.4. 
Two of the patients that were contacted by telephone refused to participate in the study 
citing their unwillingness to carry out the data collection procedures and a third patient 
was excluded in his individual appointment. This patient did not comply with the 
preparatory procedures for data collection, which required the assessment to take place 
before any intake of food. In order to preserve patient’s comfort, the interview was not 
conducted and was replaced by a nutrition education session. 
The final sample was composed of 66 patients with T2DM, divided into 32 cases and 34 
controls. As previously stated, the classification of the study’s subjects as “case” was 
done based on an HbA1c value of 7.0% or above in the 60 days prior to data collection.  
The HbA1c assay for classification of each patient was conducted at the time of the last 
consultation which took place up to four weeks before data collection.  
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2.3. Variables, data collection tools and procedures 
The data for this study were collected during an individual interview with each of the 
patients and by recording information present in the patients’ clinical records. After 
their agreement in be a part of the research, patients were scheduled for a single data 
collection interview which included all the tools needed for the inquiry. The interview 
lasted between 150 minutes and 180 minutes and was held in the morning. According 
to patients’ availability and convenience, data collection started between 8:00h A.M. 
and 9:00h A.M. Subjects were asked to skip their breakfast at home in the day of data 
collection, in order for some procedures to be performed in the fasting state. 
The inquiry was divided into five sections, corresponding to: 
I. Clinical data 
II. Anthropometric assessment; 
III. Glucose response to a meal; 
IV. Lifestyle and care assessment; 
V. Risk perception of diabetes complications.  
 
2.3.1. Clinical data 
Important patient information was collected from the clinical file, as well as data for 
HbA1c levels which were obtained from a blood sample collected in the AEDMADA 
Diabetes Clinic in the day the physician informed the patients about this research. 
Demographic information was also obtained from the patient file. This information was 
confirmed and completed during the course of the interview. 
Table 6 presents the variables for this study that were constructed with the first stage 
of the interview and with data from the patients’ files. 
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Table 6. Variables and operational definition for the information obtained from the patients’ clinical files. 
Variable Definition 
Age Age stated by the patient in complete years at the time of the data collection 
Gender Gender, as recorded in the patients’ files, classified as “male” or “female” 
Marital status 
Marital status stated by the patient, classified into “married”, “widower”, 
“never married” or “divorced/separated” 
Persons in the 
household 
Number of persons living in the patient household at the time of data 
collection 
Occupation Patient occupation, classified as “employed” and “unemployed/ retired” 
Years of 
schooling 
Number of years of formal schooling completed 
Age at diabetes 
onset 
Age of the patient when diabetes was diagnosed 
Previous 
diagnosis of 
diabetes related 
illness 
Previous diagnosis of excess weight, renal disease, cardiovascular disease, 
retinopathy, and hypertension, mentioned in the patient clinical file  
HbA1c 
HbA1c value as reported in a laboratory analysis by a certified method based 
on the blood sample collected during eight weeks previous to data 
collection 
Lipid profile 
Latest values of total cholesterol, HDL cholesterol, LDL cholesterol, and 
triglycerides, reported in the patient clinical file 
 
2.3.2. Anthropometry and blood pressure assessment  
The second section of data collection consisted of measuring height to the nearest 
centimetre and weight to the nearest 0.1kg, using a stadiometer (Seca, Model 217, Seca, 
United Kingdom) and a scale (Seca, Model 899, Seca, United Kingdom), appropriated for 
medical use and calibrated according to the manufacturer’s instructions. Waist 
circumference was measured with an extensible measuring tape (Seca, Model 218, Seca, 
United Kingdom). 
All the measurements followed the International Standards for Anthropometric 
Assessment procedures (Marfell-Jones and Stewart 2006) and were collected in a 
consultation office, respecting patients’ intimacy and comfort. 
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Blood pressure was also collected during this stage, using a sphygmomanometer 
(OMRON, M6 Confort, OMRON Healthcare Co., Ltd., Japan) for upper-arm 
measurements, validated for clinical use in adults through the European Society of 
Hypertension International Protocol (Altunkan et al. 2007). Patients were seated and 
the left arm was used for blood pressure measurement. Three blood pressure 
measurements were conducted and the data used in this study corresponds to the mean 
value of the three measurements.  
Table 7 shows the variables resulting from this section of data collection: 
 
Table 7. Variables and operational definition for the anthropometric and blood pressure assessment. 
Variable Definition 
Height 
Patient standing height without shoes measured to the nearest 0.1 cm, with 
his head, shoulder blades, buttocks, and heels touching the back of a 
stadiometer, and with his head aligned in the Frankfort horizontal plane. 
Weight 
Patient weight while wearing only light clothing, measured to the nearest 
0.1 kg by standing in the centre of a scale platform with his hands at his 
sides, and looking straight ahead. 
Waist 
circumference 
Patient’s waist girth measured to the nearest 0.1 cm at the level of the 
narrowest point between the lower costal border and the iliac crest, while 
he is standing erect and has relaxed the abdominal muscles. 
Blood pressure 
Systolic and diastolic blood pressure measured with a certified oscillatory 
sphygmomanometer on the patient’s left arm, bared and unrestricted by 
clothing, and positioned so that the midpoint of the upper arm is at the level 
of the heart.  
 
The anthropometric variables were used to assess metabolic and cardiovascular risk 
associated with excess body fat. Using the cut-off points for Europeans proposed by the 
WHO (2000, 2011), men with a WC above 94 cm are considered as having an increased 
metabolic and cardiovascular risk. If WC is above 102 cm men are considered as having 
a substantially increased metabolic and cardiovascular risk. In women, the cut-off points 
in WC for increased risk and substantially increased risk are, respectively, 80 cm and 88 
cm. 
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The BMI was computed by the ratio between weight and squared height, rounded to 
the nearest 0.1 kg, and participants were categorized according to the cut-off points 
proposed by the WHO (2000), which state that a BMI in the range of 25–29.9 kg/m2 
represents overweight and is associated with an increased risk of comorbidities related 
to excess fat. A BMI of 30 kg/m2 or above represents a high risk of comorbidities related 
to excess fat and participants in this category are classified as obese. 
 
2.3.3. Glucose response 
In order to assess glucose response, all patients were offered a controlled breakfast, 
constructed according to the dietetic recommendations for patients with T2DM (ADA 
2008; M.J. Franz and Bantle 2012), and composed of foods traditionally consumed in a 
Mediterranean culture and obeying to usual eating habits in the region.  
The experimental meal had the following composition (table 8): 
 
Table 8. Foods and nutritional values for the experimental breakfast 
Food 
Amount 
(g) 
Energy 
(Kcal) 
Protein 
(g) 
Fat 
(g) 
Carbohydrates 
(g) 
Sugars 
(g) 
Wheat bread 80 231.13 6.72 1.76 45.84 1.68 
Ham 30 90.98 5.40 7.65 0.15 0.15 
Milk 200 93.68 6.60 3.20 9.80 9.80 
Apple 135 76.78 0.27 0.68 18.09 18.09 
 Total 492.6 19.0 13.3 73.9 29.7 
 
The experimental breakfast corresponded to 24.6% of a daily caloric intake of 2000Kcal. 
Additionally, this meal was designed to provide 75g of carbohydrate which allowed to 
establish comparisons with reference values in the literature, due to this being the same 
amount of carbohydrate ingested in an OGTT. 
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In the day scheduled for data collection, patients were asked to follow their usual 
pharmacologic therapy and were offered the experimental breakfast between 8:00h 
A.M. and 9:00h A.M., according to individual preferences and usual breakfast intake 
hour. Subjects were asked to completely eat the all food items it contained, while 
seated, and without significant interruptions. 
Glucose response to the experimental breakfast was assessed by the measurement of 
capillary blood glucose while the patients were in fasting, and in 30 minute intervals 
after the start of breakfast, up to 120 minutes after the meal. Five glucose 
measurements were collected for all patients with a portable blood glucose monitoring 
system (Freestyle Lite, MK-23, Abbot, USA). This particular handheld device has showed 
good analytical performance and clinical accuracy, with a precision standard deviation 
(SD) of 2.8–3.9 mg/dl (0.16–0.22 mmol/liter) at glucose concentrations below 100 mg/dl 
(<5.56 mmol/liter) and a variation coefficient of 3.9–5.0% at glucose concentrations 
above 99 mg/dl (≥5.56 mmol/liter) (Alva 2008). Approximately 97% of the 
measurements in the validity study for the device were within the International 
Organization for Standardization accuracy limits, which specifies an accuracy interval 
limit of 95% (Alva 2008). 
The same device was used for all patients to minimize variability and test strips came 
from the same batch. Before the data collection with each patient, a test measurement 
with the Freestyle Control Solution was conducted, in order to guarantee compatibility 
and precision with the discardable test strips. The blood samples for testing were 
obtained by puncture in the fingers of the left hand. During all of the measurements, 
the strictest safety and hygiene procedures were obeyed. 
Patients were asked to remain seated during the course of the measurements in order 
to minimize physical activity, which could influence glucose response during the 
postprandial period. 
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2.3.4. Lifestyle and care assessment  
The lifestyle and diabetes care assessment variables were obtained by direct interview 
with the researcher. The interview was conducted between patients’ glucose 
measurements, following a semi-structured interview script (Annex 1). The interview 
was previously practiced by the researcher with two healthy volunteers, in order to 
evaluate any shortcomings or interviewer biases. Precautions with language, posture, 
tone of voice and interviewer appearance were taken, according to specific 
recommendations for clinical interviews and patient counselling (Gable 2008; Holli et al. 
2003; Pope and Mays 2008; Sommers-Flanagan and Sommers-Flanagan 2012). 
The interview included dietary and physical activity habits, and assessment of tobacco 
and alcohol use.  
Physical activity was assessed with the short-form version of the International Physical 
Activity Questionnaire (IPAQ). This tool can be used to obtain comparable estimates of 
moderate-intensity activities, vigorous-intensity activities, and walking, based on 
metabolic equivalents (MET) of energy expenditure associated with these specific type 
of activities (Hagströmer et al. 2007). The metabolic equivalents attributed to each 
activity are based on their estimated energy expenditure as compared with energy 
expenditure while resting. Vigorous activities were estimated as requiring eight times 
the energy expenditure while resting, moderate activities as requiring four times the 
energy expenditure while resting, and walking as requiring approximately 3.3 times the 
energy expenditure while resting. 
The IPAQ scoring protocol allows for the results to be expressed in MET-min per week 
(MET level x minutes of activity x events per week) or by classifying individuals into three 
physical activity categories. Individuals with a high level of physical activity engage in 
vigorous-intensity activities on at least three days a week, accumulating at least 1500 
MET-minutes/week, or, alternatively, engage in a daily combination of walking, 
moderate-intensity or vigorous intensity activities achieving a minimum of at least 3000 
MET-minutes/week. Individuals with a moderate level of physical activity engage, 
weekly, in at least 20 minutes of vigorous activity during three days, or moderate-
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intensity activity or walking of at least 30 minutes during five days, or any combination 
of walking, moderate-intensity or vigorous intensity activities achieving a minimum of 
at least 600 MET-min/week, during five days. Individuals who do not meet criteria for 
the high or moderate physical activity categories are considered as having low physical 
activity. 
The IPAQ is considered internationally valid and reliable in adolescents and adults in 
diverse settings (Craig et al. 2003). A Portuguese translation of the IPAQ has shown to 
be valid in men above 60 years old (Benedetti et al. 2007) and the short-form was 
successfully used in a Portuguese nationally representative sample for assessment of 
physical activity prevalence (Bauman et al. 2009). 
This assessment of food intake was achieved by the recall of all the food items ingested 
by the patient in the previous day, plus questions regarding usual eating habits, both 
aided by the use of images representing usual food items and different portions 
(Cheyette 2011), which were presented to the patients for clarification of their 
description.  
During the course of the interview, the language and communication strategies used 
allowed to put patients at ease and facilitated their ability to recall food intake. A short 
history of the previous day’s activities was also put together during the interview, in 
order to help establishing the different meals and snacks of the day. Information like the 
time of waking up, the time of leaving the house, and any trips to shops or other venues 
was recorded.  
This study intended to estimate usual intake and it is considered that a single recall is 
insufficient to achieve this goal, as within-individual variability in daily intake is 
considerable, due to variation in the diet and other random sources of measurement 
error (Willett 1998).  
Several statistical modelling methods have been developed for estimating the 
distribution of usual intake of nutrients using data from at least two 24h recalls (Dodd 
et al. 2006). The National Cancer Institute (NCI) method has shown to provide reliable 
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estimates (Tooze et al. 2006) and is considered an improvement over existing methods 
(Tooze et al. 2006). One of the advantages of the NCI method is its ability to provide 
estimates through the incorporation of covariates into the model  (Tooze et al. 2010). 
The characteristics of this method and the fact that it is a non-commercial product used 
in nutritional epidemiology research prompted its use in this study. Thus, in order to use 
the NCI method, a second 24h recall was recorded between eight to ten weeks after the 
data collection interview. This second recall was held by phone interview, as this mode 
of administration is considered equally valid than a direct face-to-face interview (Willett 
1998). The second 24h recall was obtained from a random subset of 10 cases and 10 
controls from the initial sample, as statistical significance can be achieved with a subset 
of the initial group (Tooze et al. 2010).  
The nutritional composition of the food items in all 24h recalls was estimated using a 
food composition table for Portuguese food items (INSA 2010). Some food items 
reported by the subjects were not present in the Portuguese food composition table 
and, in other instances, nutrient information was not provided. In these cases, 
information from the “McCance and Widdowson's The Composition of Foods” food 
composition reference was used to complete the data set (McCance et al. 2002). 
The variables resulting from the data collected in this section were are presented and 
defined in table 9. 
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Table 9. Variables and operational definition from the data collected on lifestyle and diabetes care 
Variable Operational definition 
Visits to health 
professional 
Number of times patient visited a doctor, dietitian, or nurse, on account of 
his diabetes, during the last 12 months. 
Time of last visit 
Time since the patient’s last visit to a doctor, dietitian, or nurse, on account 
of his diabetes 
Referencing for 
consultation 
Classification of patient’s last visit to a doctor, dietitian, or nurse as being 
“self-initiated” or “referred” by other health professional. 
Measurement of 
glycaemia 
Number of times patient states self-measuring glycaemia each day, week, 
month, or year. 
Smoking habits 
Patient statement on whether or not he currently smokes or has smoked in 
the past. 
Number of 
cigarettes 
Number of cigarettes patient states smoking each day, week, or month. 
Food shopping 
Patient self-classification of his role in food shopping for the household, 
choosing between “don’t engage in food shopping”, “share food shopping 
duty”, and “are the main food shopper” categories. 
Meal preparing 
Patient self-classification of his role in planning and preparing meals for the 
household, choosing between “don’t engage in meal planning/ preparing”, 
“share meal planning/ preparing duty”, and “are the main meal planner/ 
preparer” categories. 
Perception of 
diet advice 
Patient perception on whether he was previously told by a health care 
provider to follow an exercise program, follow a diet or meal plan, weigh or 
measure food, keep a record of his meals, and use food list to plan meals 
Perception of 
food behaviour 
Patient self-rating, in a five point Likert scale ranging from 1 (“never”) to 5 
(“always”), of the frequency he follows a regular schedule for meals and 
snacks, weighs or measures food, keeps a record of his meals, and use food 
lists to plan meals. 
Physical activity 
Time spent doing vigorous physical activities, moderate physical activities, 
and walking, as defined in the IPAQ (Hagströmer et al. 2007), in each of the 
last seven days. 
Time sitting 
down 
Mean time spent seated on weekdays, during the last seven days  
Special diet Patient statement on whether he/she currently follows a special diet 
Nutritional 
intake 
Intake of macronutrients and micronutrients in the last 24h 
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The interview also included a section with an open-ended nature, which provided 
evidence on the views of this specific population on the barriers to a proper diet and on 
the reasons behind the adherence to nutrition therapy. 
In addition to the aforementioned variables, I also calculated the individual estimated 
energy requirements, using the formulas proposed by the IOM (2005) and taking into 
account subjects’ age, height, sex, and physical activity levels. The physical activity levels 
used for the calculation were the ones contained in the IPAQ, which was also a part of 
the data collection tools, as stated before. 
The Devine formula was used to calculate the ideal body weight in men:   
 
𝐼𝑑𝑒𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔) = 50 + 2.3 𝑘𝑔 𝑝𝑒𝑟 𝑖𝑛𝑐ℎ 𝑜𝑣𝑒𝑟 5 𝑓𝑒𝑒𝑡 
Figure 1. Devine formula for ideal body weight in men (B. Shah et al. 2006). 
 
The Robinson formula was used to calculate the Ideal Body Weight in women:   
 
𝐼𝑑𝑒𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔) = 53.07 + 1.36 𝑘𝑔 𝑝𝑒𝑟 𝑖𝑛𝑐ℎ 𝑜𝑣𝑒𝑟 5 𝑓𝑒𝑒𝑡 
Figure 2. Robinson formula for ideal body weight in women (Robinson et al. 1983) 
 
2.3.5. Risk perception of diabetes complication and optimistic bias 
In order to study risk perception and optimistic bias, the last stage of the interview 
included items adapted from the Risk Perception Survey for Diabetes Mellitus (RPS-DM) 
questionnaire (Walker et al. 2007a). This tool was developed by the Albert Einstein 
College of Medicine of Yeshiva University to assess comparative risk perceptions related 
to diabetes and its complications. The RPS-DM is composed by seven subscales totalling 
31 items and was constructed based on factors identified in risk perception research 
that were specifically applied to diabetes. It is available in English and Spanish, for data 
collection by telephone interview, in-person completion, or by self-administration as a 
self-fulfilment questionnaire. 
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For the purpose of the present study, I created specific items, adapted and translated 
into Portuguese from the interview form of the RPS-DM. The items were translated by 
the researcher and, independently, by a qualified translator without knowledge of the 
purpose of the study or the questionnaire. All the items had a straightforward 
translation, due to the fact that literal equivalents exist in Portuguese. Both translations 
were reviewed and used to construct the final version of the risk perception items. 
This adaptation and translation resulted in 20 items, grouped into an Optimistic Bias 
subscale, a Personal Disease Risk subscale, and an Environmental Risk subscale. In both 
the items from the Personal Disease (PD) and the Environmental Risk (ER) subscales, 
patients were asked to rate their risk of selected diabetes complications and their risk 
of hazards or dangerous conditions. In the Optimistic Bias (OB) subscale, patients were 
asked to compare their likelihood of diabetes complications and serious health 
problems, with the likelihood for the same complications and health problems of other 
individuals with diabetes. 
The subscales and items used are presented in table 10. 
 
Table 10. Subscales and items of the data collection section regarding the risk perception of diabetes complications 
Subscale Items 
Optimistic Bias 
Rating, in an agreement scale ranging from 1 (“strongly agree”) to 4 
(“strongly disagree”) of two sentences: 
“Compared to other people with diabetes of the same age and sex, I am less 
likely than they are to get diabetes complications” and “Compared to other 
people with diabetes of the same age and sex, I am less likely to have serious 
health problems”.  
Personal Disease 
Risk 
Selection between “almost no risk”, “slight risk”, “moderate risk”, and “high 
risk” for heart attack, foot amputation, cancer, vision problems, high blood 
pressure, numb feet, stroke, blindness, and kidney failure 
Nutritional 
intake 
Selection between “almost no risk”, “slight risk”, “moderate risk”, and “high 
risk” for experiencing health problems from medical tests, violent crime, 
extreme weather, driving or riding an automobile, illegal drugs, air 
pollution, pesticides, household chemicals, and cigarette smoke from other 
people 
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Face validity of the subscales was ensured by translating the original English version into 
European Portuguese according to recommendations for cross-cultural research 
(Grigorenko 2009). The scales were translated and then back-translated by two 
independent translators, without access to the original version. These versions were 
evaluated by a Psychology and Linguistics expert with English skills, in order to ensure 
the accuracy of the final version.   
A pre-test interview was held for the final item list in a convenience sample of eight 
patients with diabetes, four males and four females, all with age above 50 years old. This 
pre-test intended to assess if the items and the classification scale were easily 
understood. After the pre-test interview, patients were debriefed and questioned on 
their opinion on the items, and asked to repeat them in their own words. All the subjects 
in this sample stated that the items were understood and showed no difficulty with the 
classification scale. 
A week after the pre-test, the original subjects were retested with the same version of 
the scales to assess test-retest reliability. 
 
2.3.6. Perceived barriers to adequate food intake  
Determinants of food intake have been studied in healthy and diabetic populations and 
several barriers for following an adequate diet are identified in the literature 
(Gazmararian et al. 2009; Jerant et al. 2005; Toobert et al. 2000; UKPDS Study Group 
1995b; Vijan et al. 2005). In order to analyse this topic, I created a set of sentences 
reflecting the barriers previously identified in the literature and asked the subjects to 
rate their agreement with these sentences in a five point Likert scale, ranging from 
“strongly disagree” to “strongly agree”. 
The sentences used in the interview are presented in table 11. 
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Table 11. Sentences related to barriers to nutrition therapy adherence 
Sentences 
1. My diet is balanced and adequate to my needs. 
2. In general, population in my age group has a balanced diet. 
3. A balanced and proper diet takes too much effort. 
4. Whatever I eat, my diabetes doesn’t seems to be affected by my diet.  
5. The amount of food in a balanced diet is less than enough for me. 
6. The type of food items in a balanced diet is not to my liking. 
7. I do not have enough time to prepare meals. 
8. I do not have enough time to eat all the meals in a proper diet. 
9. A proper diet implies different meals from the rest of the family. 
10. I often eat out or attend to social gatherings and there are no adequate meal options. 
11. A proper diet is more expensive. 
12. I feel I don’t know enough about nutrition in diabetes. 
13. I am confused with the nutrition information I received. 
14. I feel I need more advice on what is a proper diet. 
  
Both the scale for classification of agreement and the sentences were read to the 
patients during the course of the interview, with the scale being repeated often between 
sentences, as to facilitate proper response. For a thorough assessment of the barriers 
for a proper diet, an additional open-ended question was placed in the end of the 
interview which encouraged patients to express their opinions on this topic and to 
identify any barriers not previously referred. 
 
2.4. Ethics considerations 
All stages of this study obeyed the ethical rules for health sciences research as stated in 
the sixth revision of the Declaration of Helsinki, including an informed consent form 
which was signed by every patient during the briefing and recruitment (Annex 2). 
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A Cranfield University Health Research Ethics Committee approval was sought (Annex 
3), as well as approval from the Ethics Committee of the Algarve Regional Health 
Directorate, the Administração Regional de Saúde Algarve (Annex 4). 
Approval was based on this study’s protocol (Annex 5). 
All questions regarding the participation were answered before written consent was 
given and subjects did not incur in any costs. 
The data resulting from the inquiry were only accessed by the researcher. The 
information was directly inputted into a password protected electronic spreadsheet, 
and all patient identification was numerically coded in order to protect the identity of 
the subjects. 
 
2.5. Data analysis 
Data were analysed with IBM-SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA). 
Patient description and characterization were presented as mean values, median values 
(Mdn), and standard deviations. The prevalence of several variables and characteristics 
was calculated as the percent of the total number of valid observations in each 
calculation. 
The Kolmogorov-Smirnov test was used to assess adherence to the Normal distribution 
and, accordingly, parametric or non-parametric statistical procedures were used to 
compare groups. For comparisons between two groups, Student’s t-test or Mann-
Whitney test were computed, while a one-way analysis of variance (ANOVA) with 
Bonferroni post-hoc correction was used for multiple group comparisons. 
The main statistical procedure for analysing the differences between cases and controls 
in qualitative variables was the chi-square test, or Fisher’s exact test, were applicable. 
OR estimates and their 95% CI were also computed. 
To analyse the predictive effect of age, education, BMI, nutritional intake, and psycho-
behavioural characteristics, on glycaemic control, a binary logistic regression model was 
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constructed, using a backward stepwise covariate selection, based on the probability of 
the likelihood-ratio statistic, as proposed by Hosmer et al. (2013). 
Statistical significance in all procedures was determined by two-tailed analysis and set 
at 0.05. 
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3.1. Clinical, anthropometric and demographic analysis 
The distribution of gender, schooling, and occupation is presented in table 11. 
 
Table 12. Demographic characteristics of the sample. 
Variable 
Cases (N=32) Controls (N=34) 
N (%) N (%) 
Gender   
Male 20 (62.5%) 17 (50%) 
Female 12 (37.5%) 17 (50%) 
Schooling*   
Primary school (1 – 4 years) 9 (28.1%) 21 (61.8%) 
Middle school (5 – 6 years) 6 (18.8%) 3 (8.8%) 
Upper school (7 – 9 years) 7 (21.9%) 4 (11.8%) 
Secondary school (10 – 12 years) 5 (15.6%) 5 (14.7%) 
Tertiary education (above 12 years) 5 (15.6%) 1 (2.9%) 
Occupation**   
Employed 24 (75%) 13 (38.2%) 
Retired 8 (25%) 21 (61.8%) 
* Statistical significant differences at the 0.05 probability level, according to 2 test; P=0.048. 
** Statistical significant differences at the 0.01 probability level, according to 2 test; P=0.003. 
 
 
Cases and controls had a statistically similar distribution in gender (2(1)=1.046, 
P=0.307) but controls have less formal schooling than cases (X2(4)= 9.1, P=0.048), with 
62% of controls having completed only primary education. In regard to occupation, 
controls have a higher prevalence of retired participants (2(1)=9.046, P=0.003). 
These results suggest that, in this study, low education seems associated with better 
glucose control. Nevertheless, I found no association between education and 
occupation (X2(1)=1.9, P=0.215). 
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Apart from the expected differences in HbA1c, there are also significant differences 
between cases and controls regarding age, age at diagnosis, BMI, total cholesterol, and 
LDL cholesterol, as shown on table 12. 
 
Table 13. Mean differences between cases and controls in selected clinical, anthropometric, and demographic variables 
Variable 
Cases (N=32) Controls (N=34) P-value of 
Student’s t-
test Median Mean (SD) Median Mean (SD) 
HbA1c (%) 7.9 8.6 (1.40) 6.1 6.1 (0.51) < 0.001* 
Age (years) 58 57.8 (7.08) 67 63.7 (7.79) 0.002* 
Age when diagnosed 
(years) 
52 51.8 (6.45) 58 57.0 (7.87) 0.005* 
Disease duration 5 6.0 (3.65) 5 6.4 (5.18) 0.730 
BMI (kg/m2) 31.7 31.3 (4.44) 29.4 28.9 (3.85) 0.024** 
Waist circumference (cm) 106.4 105.7 (10.16) 102.8 103.4 (10.36) 0.366 
Waist-to-height ratio 0.64 0.64 (0.07) 0.65 0.65 (0.06) 0.668 
Systolic blood pressure 127 127.7 (16.10) 128 127.7 (17.14) 0.986 
Diastolic blood pressure 71 71.8 (11.10) 68 68.4 (9.71) 0.202 
HDL cholesterol (mg/dl) 43 48 (16.84) 47 49.3 (13.76) 0.735 
Total cholesterol (mg/dl) 183 182.9 (33.17) 162 163.4 (35.01) 0.026** 
LDL cholesterol (mg/dl) 103 113.2 (30.47) 78.5 88.2 (27.75) 0.014** 
Triglycerides (mg/dl) 121 151.3 (85.74) 106 113.9 (45.94) 0.108 
SD – Standard deviation 
* Significant differences between groups at the 0.01 probability level 
** Significant differences between groups at the 0.05 probability level 
 
 
Cases seem to have been diagnosed at an earlier age than controls (P=0.005) and were 
significantly younger than controls at the time of data collection (P=0.002), although I 
did not find significant association between HbA1c and years of T2DM duration 
(P=0.730).  
The associations between glucose control, age, and age at diagnosis, are also apparent 
in the significant correlations found between HbA1c and age at the time of diagnosis 
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(r(66)= -0.367, P=0.002) and at the time of data collection (r(66)= -0.368, P=0.002), and 
also by the non-significant correlation between HbA1c and years of disease duration 
(r(66)= -0.022, P=0.863). The significant negative correlations suggests that glycaemic 
control is poorer in younger patients, but age seems a better predictor of glycaemic 
control, as evidenced by the fact that when controlling for years of disease progression, 
the correlation between HbA1c and age at the time of diagnosis is still significant (r(63)= 
-0.384, P=0.002). I also found a significant negative correlation between BMI at the time 
of data collection and age at diagnosis (r(66)= -0.312, P=0.011), but not between BMI 
and years of diabetes duration (r(66)= -0.071, P=0.570), as shown on table 13. 
 
Table 14. Correlations between waist circumference, waist-to-height ratio, age at diagnosis, and disease duration 
Variable 
Pearson’s correlation coefficient (P-value) 
Age at diagnosis Disease duration 
Waist circumference -0.111 (0.376) -0.085 (0.498) 
Waist-to-height ratio -0.078 (0.534) -0.030 (0.810) 
BMI -0.312 (0.011)* -0.071 (0.570) 
* Significant correlation at the 0.05 probability level 
 
The correlation between BMI and age at diagnosis is also present when adjusting for 
years of diabetes duration (r(63)= -0.341, P=0.005). Although non-significant, the 
adjusted correlation is also visible when analysing only cases (r(29)= -0.231, P=0.211)  or 
controls (r(31)= -0.305, P=0.084). 
I did not found significant differences in mean waist circumference between cases and 
controls (t(64)=-0.91, P=0.366), as shown on table 12, but both groups of T2DM patients 
have a high prevalence of cardiometabolic risk, according to the classification of waist 
circumference. Only 3% of cases and 6% of controls (figure 3) show a waist 
circumference below the WHO proposed cut-point for increased cardiometabolic risk 
(WHO 2000, 2011). 
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Figure 3. Increase in metabolic risk according to waist circumference (WC), interpreted according to WHO (2011) Waist 
Circumference and Waist-hip Ratio: Report of a WHO Expert Consultation, Geneva, 8-11 December 2008, World Health 
Organization. No increase in risk corresponds to WC ≤94cm (men) or WC ≤80cm (women), increased risk corresponds to 
WC>94cm (men) or WC>80cm (women), and substantially increased risk corresponds to WC>102cm (men) or WC>88cm 
(women). Differences between cases and controls are statistically non-significant (2 (2)=0.293, P=0.864). 
 
The results of WtH ratio also suggest abdominal obesity and a high cardiometabolic risk, 
for both cases and controls (figure 4). According to Ashwell et al. (2012), a WtH ratio 
above 0.5 is an indicator of cardiometabolic risk. 
 
Figure 4. Waist-to-height (WtH)ratio classification, interpreted according to Ashwell et al. (2012;  Obesity Reviews 13(3): 
275-286). Ratio above 0.5 is considered a good predictor of cardiometabolic risk. Differences between cases and controls are 
statistically non-significant (2 (2)=0.523, P=0.770). 
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The BMI for cases and controls also reflects poor nutritional status and high 
cardiometabolic risk for both groups of patients. Although cases have a higher mean 
BMI (M= 31.2 kg/m2, SD= 4.44 kg/m2) than controls (M = 28.9 kg/m2, SD= 3.85 kg/m2) in 
a statistically significant way (t(64)=2.308, P=0.024), the prevalence of overweight and 
obesity is statistically similar (2 (42)=9.34, P=0.063). The distribution of BMI categories 
is presented in figure 5. 
 
 
Figure 5. BMI classification, according to WHO (2000) Obesity: preventing and managing the global epidemic, World 
Health Organization. No underweight participants were present in the study. Differences between cases and controls are 
statistically non-significant (2 42)=9.34, P=0.063). 
 
In the present study, as reported in table 12, cases have significantly higher mean values 
for total cholesterol and LDL cholesterol. When comparing the mean values for different 
components of lipid profile in cases and in controls with the recommended values 
proposed by the ADA (2013), LDL cholesterol was the only component which presented 
significant differences. Both cases (t(18)=6.2, P<0.001) and controls (t(17)=2.8, P=0.013) 
have significantly higher LDL cholesterol than the ADA recommended level, set as LDL 
cholesterol below 70 mg/dl. The recommendations for lipid profiles and recorded mean 
values in this study are presented in table 14. 
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Table 15. Lipid profile results in cases and controls, compared with American Diabetes Association recommendations (2013, 
Diabetes Care 36(Supplement 1): S11-S66). 
Lipid profile 
Cases (N=32) Controls (N=34) American Diabetes 
Association 
recommendations Mean (SD) Mean (SD) 
Total cholesterol (mg/dl) 182.9 (33.17) 163.4 (35.01) <200 
LDL cholesterol (mg/dl) 113.2 (30.47)* 88.2 (27.75)** <70 
HDL cholesterol (mg/dl) 48 (16.84) 49.3 (13.76) >40 (men)/ >50 (women) 
Triglycerides (mg/dl) 151.3 (85.74) 113.9 (45.94) <150 
SD – Standard deviation 
* Significant differences between recorded values and recommendations at the 0.01 probability level 
** Significant differences between recorded values and recommendations at the 0.05 probability level 
 
When analysing the proportion of patients with a recorded value of lipid profile 
component above the ADA recommendations, it is possible to report that 95% of cases 
and 72% of controls have a LDL cholesterol level of 70 mg/dl or above. The proportions 
of patients with lipid profile components above the ADA recommendations are 
presented in figure 6. 
  
Figure 6. Proportion of patients with lipid profile components above the recommended level proposed by the American 
Diabetes Association (2013, Diabetes Care 36(Supplement 1): S11-S66). Differences in lipid profile between groups are 
statistically non-significant in all types of lipids (P>0.05) 
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According to Pearson’s chi-square, none of the differences recorded in the prevalence 
of lipid levels above ADA recommendations are statistically significant (P>0.05).  
The prevalence of pharmacological therapy for hyperlipidaemia (X2(1)=2.4, P=0.122) 
and hypertension (X2(1)=0.655, P=0.418) are also similar in cases and controls. Data 
regarding hyperlipidaemia and hypertension pharmacotherapy are presented in table 
15. 
 
Table 16. Pharmacotherapy for hypertension and hyperlipidaemia in cases and controls. 
Lipid profile Cases (N=32) Controls (N=34) 
P-value for group 
differences 
Hyperlipidaemia 
pharmacotherapy (%) 
31% 51% 0.122* 
Years on hyperlipidaemia 
pharmacotherapy (Mean, SD) 
3.5 years SD= 3.45 
years 
4.6 years SD= 3.50 
years 
0.433** 
Hypertension 
pharmacotherapy (%) 
34% 44% 0.418* 
Years on hypertension 
pharmacotherapy (Mean, SD) 
5.1 years SD=5.43 
years 
5.5 years SD=5.57 
years 
0.815** 
SD – Standard deviation 
* P-value computed with the X2 test 
** P-value computed with Mann-Whitney’s test 
 
In both forms of pharmacotherapy, the duration of the treatment is also similar between 
groups (hyperlipidaemia, U=69.5, P=0.433; hypertension, U=78, P=0.815). 
The present study also analysed some self-care behaviours, among them the number of 
doctor visits during the last year on account of diabetes, physical activity habits and 
frequency of glucose measurement.  
The number of doctor visits is similar (U=503.5, P=0.597) between cases (Mdn=3) and 
controls (Mdn=3), as is the frequency of glucose measurement (X2(3)=2.81, P=0.454), 
shown on table 16. 
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Table 17. Frequency of glucose measurement in cases and controls.  
Measurement frequency 
Cases (N=32) Controls (N=34) P-value for the X2 
test N (%) N (%) 
Daily 8 (30.8%) 15 (50%) 
0.454 
Weekly 15 (57.7%) 11 (36.75%) 
Monthly 2 (7.7%) 2 (6.7%) 
Yearly 1 (3.8%) 2 (6.7%) 
 
When analysing physical activity levels, classified according with the IPAQ 
recommendations (Hagströmer et al. 2007) into “low”, “moderate” and “high” levels of 
physical activity, we did not find any participant in the “high” physical activity category. 
Most participants (81% in cases and 94% of controls) are classified as having low physical 
activity and the differences between groups are non-significant (P=0.143, Fisher's exact 
test). The distribution of physical activity categories is presented in figure 7. 
 
Figure 7. Classification of physical activity according to the International Physical Activity Questionnaire, by Hagströmer et 
al. (2007; Public Health Nutrition 9(06)). No participants presented high activity level. Differences between cases and controls 
are statistically non-significant (Fisher's exact test, P=0.143). 
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I found no statistical association between education and physical activity (X2(4)=0.08, 
P=0.078), number of doctor visits during the previous year (r(66)=0.02, P=0.851), or 
frequency of glucose measurement (r(66)=0.10, P=0.483). 
Education showed negative correlations with age (r(66)=-0.44, P<0.001) and with years 
of diabetes duration (r(66)=0-.29, P=0.019) but it must be noted that only 6 subjects 
were younger than 50 years old, with the youngest being 47 years old. In fact, when the 
comparisons between HbA1c and education are age-adjusted, both show a non-
significant correlation (r(63)=0.07, P=0.572). 
 
3.2. Diet and adherence to nutrition recommendations  
The dietary assessment showed significant differences between cases and controls. 
Cases report a significantly lower (U=239.5, P<0.001, r= 0.52) number of meals (Mdn=3) 
than controls (Mdn=4), and the number of daily meals also has a significant negative 
correlation with HbA1c (r(66)=-0.401, P=0.001).  
Subjects with inadequate glycaemic control showed significantly higher intakes of 
energy (P=0.030) and sugars (P=0.012). I also found a significant correlation between 
energy intake and HbA1c (r(66)=0.282, P=0.022).  
The results of the dietary assessment are presented in table 17. 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
117 
 
Table 18. Dietary assessment in cases and controls 
Variable 
Cases (N=32) Controls (N=34) P-value of 
Student’s t-
test Mean (SD) Mean (SD) 
Energy (kcal) 2449 (781) 2079 (536) 0.030* 
Protein (g) 91.2 (29.81) 85.6 (25.78) 0.419 
Total carbohydrates (g) 292.5 (124.12) 243.9 (75.62) 0.062 
Sugars (g) 128.9 (77.92) 87.2 (51.14) 0.012* 
Fibre (g) 18.3 (8.73) 17.7 (8.13) 0.783 
Lipids (g) 94.4 (36.95) 84.9 (31.03) 0.263 
Total saturated fatty acids (g) 31.0 (14.61) 27.9 (14.53) 0.389 
Total monounsaturated fatty acids (g) 35.4 (16.95) 29.5 (12.32) 0.110 
Total polyunsaturated fatty acids (g) 19.6 (10.22) 19.7 (7.49) 0.989 
Cholesterol (mg) 365 (231) 378 (251) 0.828 
Sodium (mg) 4277.7 (2057.04) 3921 (1530.06) 0.425 
Potassium (mg) 3083.8 (1375.35) 2601.9 (806.19) 0.085 
Water (g) 1247 (1042.31) 943.9 (1205.85) 0.280 
SD – Standard deviation 
* Significant differences between groups at the 0.05 probability level 
 
When considering individual estimated energy requirements, calculated for each 
subject’s estimated ideal body weight using the IOM equations (2002), a Mann-Whitney 
test indicated a statistically significant (U= 198, P= 0.034) excess energy intake that is 
higher in cases (Mdn=299 Kcal) than in controls (Mdn=172 Kcal). This suggests that 
patients with T2DM, independently of their level of glucose control, show an excess 
energy intake when compared to their individual estimated energy requirements. In 
fact, more than two thirds of both cases and controls present an energy intake above 
their estimated energy requirements, as shown in figure 8. 
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Figure 8. Percentage of cases and controls with an energy intake exceeding estimated individual requirements, computed 
through the Institute of Medicine energy requirements equations (2005; Dietary Reference Intakes for Energy, Carbohydrate, 
Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients), National Academies Press) 
 
The distribution of the percentage of daily total caloric intake (TCI) for each 
macronutrient suggests that all subjects follow a diet with adequate protein intake, high 
lipid intake, and a moderate carbohydrate intake. When comparing the participants’ 
percentages of TCI for each macronutrient with the IOM recommendations proposing  
acceptable macronutrient distribution ranges for carbohydrate, fat, and protein of 45–
65%, 20–35%, and 10–35% of total energy, respectively (IOM 2005), I found significant 
differences in carbohydrates and fat, as shown on table 18. 
 
Table 19. Macronutrient distribution of the total caloric intake and comparison with the Institute of Medicine macronutrient 
distribution range (2005; Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, 
and Amino Acids (Macronutrients), National Academies Press) 
Percentage of TCI 
Mean (SD) IOM 
Acceptable 
macronutrient 
distribution 
range 
P-value for the 
comparison of all 
subjects with 
IOM nutrient 
recommendation 
All  
(N=66) 
Cases 
(N=32) 
Controls 
(N=34) 
Carbohydrates (%) 47 (11) 47 (11) 47 (10) 45%-65% 0.039* 
Protein (%) 16 (4) 15 (4) 17 (4) 10%-35% 0.069 
Lipid (%) 36 (10) 35 (10) 36 (9) 20%-35% 0.015* 
SD – Standard deviation 
IOM – Institute of Medicine 
* Significant differences between groups at the 0.05 probability level 
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Cases in this study present a mean of 20.9% (SD=9.56%) for the sugars distribution in 
TCI, whereas controls show a mean of 16.7% (SD=9.08%), with the statistically significant 
differences in the amount of sugars in the usual diet (t(64)=2.59, P=0.012) evidencing 
and association with glycaemic control, further supported by the positive correlation 
between sugars and HbA1c (r(66)=0.345, P=0.005). The correlation between sugars and 
HbA1c is also stronger and more significant than the correlation between HbA1c and 
total carbohydrates (r(66)=0.245, P=0.047). In fact, when controlling for the sugars 
content in the diet, the association between total carbohydrates and HbA1c is non-
significant (r(63)=-0.059, P=0.641). 
Approximately 35% (n=23) of the patients in this study reported following a specific diet 
(n=10 in cases and n=13 in controls), but no statistical difference was found between 
groups (X2(1)=0.354, P=0.552). The specific diets mentioned by the subjects are 
presented in figure 9.  
 
 
Figure 9. Distribution (n) of specific diets mentioned by the subjects. No statistical differences were found in cases and 
control for any of the specific diets mentioned (P>0.05).  
 
The diet most frequently mentioned by the patients was a “diabetic diet”. All 
participants that mentioned this diet described it as having low “bread, potatoes, pasta 
and rice” and two of the cases also stated that it excluded fruit. All 12 patients that 
mentioned the “diabetic diet” denoted that it was recommended by a doctor and in 8 
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of them this recommendation was made over 2 years before data collection. None of 
the 12 patients had ever been in a consultation with a dietitian or other nutrition health 
professional. All other specific diets mentioned by the patients were recommended by 
a registered dietitian and the 11 patients were still being monitored by that same 
dietitian. 
When considering different health professionals (table 19), subjects did not differ in any 
aspect of their consultations with a nurse (P>0.05), during the last year. The difference 
in number of doctor consultations is non-significant (t(64)=0.37, P=0.71), contrarily to 
the time since the last consultation with this health professional, which is longer in cases 
(t(64)=3.3, P=0.002). Cases also report a lower prevalence of dietitian consultations 
(2(1)= 4.67, P= 0.031), a lower mean number of consultations with a dietitian in the last 
year (t(64)=-1.9, P=0.029), and a longer period of time since the last consultation with a 
dietitian (t(28)=2.3, P=0.028). 
 
Table 20. Consultations with doctor, nurse, or dietitian on account of diabetes 
Health 
professional 
Cases Controls 
Consulted 
during the 
last year 
(%) 
Consultations 
during the last 
year 
M (SD) 
Months since 
last 
consultation 
M (SD) 
Consulted 
during the 
last year (%) 
Consultatio
ns during 
the last year 
M (SD) 
Months since 
last 
consultation 
M (SD) 
Doctor 100% 4.3 (2.06) 4.3 (2.06)* 97,1% 3.3 (2.69) 2.4 (0.53) 
Nurse 37.5% 1.3 (0.5) 4 (2.45) 58.8% 1.3 (0.5) 4 (2.83) 
Dietitian 12.5%** 0.3 (0.5)+ 22.5 (12.37)++ 35.3% 1.2 (0.97) 6 (5.79) 
SD – Standard deviation 
* Higher mean value for cases, when compared with controls using Student’s t-test; P=0.002 
** Lower prevalence in cases, when compared with controls using 2 test; P=0.031 
+ Lower mean value in cases, when compared with controls using Student’s t-test; P=0.029 
++ Higher mean value in cases, when compared with controls using Student’s t-test; P= 0.028 
 
The total number of patients in this study with at least one dietitian consultation in the 
last year is low (4 cases and 12 controls), which can compromise statistical significance, 
but, nevertheless, I recorded higher mean values in HbA1c (t(64)=2.1, P=0.038), total 
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carbohydrates (t(64)=2.2, P=0.031), and sugars intake (t(64)=2.4, P=0.021) in subjects 
without dietitian consultations. 
Only 30 subjects (12 cases and 18 controls) stated ever having a consultation with a 
dietitian. Among these, none of the cases and only 3 of the controls had a consultation 
by their own initiative. All other subjects were referred to the consultation by a doctor. 
These differences are non-significant (P=0.255, Fisher’s exact test), but reflect a very low 
prevalence of dietitian consultations by own initiative in both cases and controls.  
Previous recommendations from health professionals for engaging in physical activity 
and proper nutrition were reported by both cases and controls. All subjects were 
previously recommended by a professional to follow an exercise plan and a meal plan, 
as shown in table 20.  
 
Table 21. Previous physical activity and nutrition recommendations 
 
Cases 
(N=32) 
Controls 
(N=34) 
P-value 
for X2 test 
Follow a physical activity program 100% 100% - 
Follow a diet or meal plan 100% 100% - 
Weigh or measure your food 28.1% 44.1% 0.177 
Keep a record of your meals 9.4% 11.8% 0.753 
Use food lists to plan your meals 6.3% 11.8% 0.207 
 
Regarding the barriers to nutrition therapy adherence analysed in this study, cases and 
controls show significant differences in their reported agreement. Table 21 shows the 
median and mean agreement for the barriers to adherence to nutrition therapy, ordered 
by statistical significance of the difference between cases and controls. The only 
statements that did not differed between cases and controls were the ones regarding 
the type of foods in a balanced diet not being to the respondents’ liking, the need for 
more advice on what is a proper diet, and the lack of time to prepare meals. 
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Although the cost of consultations was not mentioned as a deterrent for seeking 
therapeutic and educational guidance, the perceived expenses with nutrition were 
considered a limitation to nutrition therapy adherence. When analysing the barriers to 
adherence that were identified by the literature research and included in patient 
interviews, cases reported a higher mean and median agreement with the statement 
indicating a proper diet as more expensive (P=0.013). 
 
Table 22. Mean and median agreement scores with nutrition therapy adherence sentences, assessed in a 5-point Likert scale, 
ranging from 1 (“Strongly disagree”) to 5 (“Strongly agree”) 
Statement 
Cases (N=32) Controls (N=34) Mann 
Whitney’s 
test P-
value 
Mdn M (SD) Mdn M (SD) 
A balanced and proper diet takes 
too much effort. 
4.00 4.16 (0.51) 3.00 3.56 (0.70) <0.001* 
A proper diet implies different 
meals from the rest of the family. 
3.00 2.66 (1.04) 1.00 1.41 (0 .50) <0.001* 
The amount of food in a balanced 
diet is less than enough for me. 
4.00 3.41 (0.98) 2.00 2.38 (1.21) <0.001* 
Whatever I eat, my diabetes doesn’t 
seems to be affected by my diet. 
3.00 2.75 (1.16) 2.00 1.74 (0.71) <0.001* 
I am confused with the nutrition 
information I received. 
2.00 2.44 (0.98) 2.00 1.65 0.001* 
I do not have enough time to eat all 
the meals in a proper diet. 
1.00 1.25 (0.44) 1.00 1.00 (0.00) 0.002* 
I often eat out or attend to social 
gatherings and there are no 
adequate meal options. 
3.00 2.69 (0.97) 2.00 2.03 (0.90) 0.005* 
A proper diet is more expensive. 3.00 3.09 (0.73) 2.00 2.50 0.013** 
I feel I don’t know enough about 
nutrition in diabetes. 
3.00 2.53 (0.72) 3.00 3.00 0.013** 
The type of food items in a 
balanced diet is not to my liking. 
3.00 3.25 (0.88) 3.00 3.59 (0.92) 0.180 
I feel I need more advice on what is 
a proper diet. 
3.00 2.84 (0.77) 3.00 3.00 0.627 
I do not have enough time to 
prepare meals. 
2.00 1.94 (0.67) 2.00 1.97 (0.94) 0.790 
Mdn – Median; M – Mean; SD – Standard deviation 
* Statistical difference between cases and controls, at the 0.01 probability level 
** Statistical difference between cases and controls, at the 0.05 probability level 
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On the overall, subjects with poor glycaemic control believe that a balanced and proper 
diet takes too much effort (P<0.001), is more expensive than other diets (P=0.013), 
implies different meals from the rest of the family (P<0.001), and is composed by less 
than enough food (P<0.001). Additionally, cases also had an increased agreement with 
the statements indicating that diet doesn’t seems to affect glucose control (P<0.001), 
confusion with nutrition information (P=0.001), and insufficient knowledge about 
nutrition in diabetes (P=0.013). Furthermore, the number of daily meals recommended 
in a proper diet also seems to be a barrier to adherence to nutrition recommendation 
(P=0.002), together with the attendance of social gatherings (P=0.005), were subjects 
believe that there aren’t adequate meal options.  
When asked to identify additional barriers to the ones described in the interview, all but 
one of the subjects referred any such barrier, considering that the interview focused on 
the beliefs, behaviours, and situations that they already associate with adherence to 
nutritional recommendations and with a proper diet. The only additional barrier 
mentioned by a single subject was “lack of willpower”, who further denoted that this 
was the reflex of a proper diet being composed by food items that were not completely 
to his liking and of his preference for high energy, sugars-rich foods. 
The agreement with the proposed barriers shows no association (P>0.05) with previous 
consultation with a dietitian, except in the statement regarding the belief of not knowing 
enough about nutrition in diabetes. Subjects which attended at least a dietitian 
consultation agree less with this statement (U=430, P=0.019). 
Regarding the perceptions on diet adequacy, cases and controls rated in a statistically 
similar way  the agreement with the adequacy of their own diet (P=0.099) and the 
adequacy of the diet of the general population their age (P=0.682), as shown in table 22. 
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Table 23. Classifications of agreement with statements related to diet perception, assessed in a 5-point Likert scale, ranging 
from 1 (“Strongly disagree”) to 5 (“Strongly agree”) 
Statement 
Cases Controls Mann 
Whitney’s 
test P-
value 
Mdn M (SD) Mdn M (SD) 
My diet is balanced and 
adequate to my needs. 
4.0 4.0 (0.69) 3.0 3.7 (0.86) 0.099 
In general, population in my 
age group has a balanced diet. 
2.50 2.44 (0.72) 3.00 2.53 (0.93) 0.682 
Mdn – Median; M – Mean; SD – Standard deviation 
 
These results on diet adequacy reflect the existence of an optimistic bias. Only one 
subject scored their diet as more inadequate than the diet of the general population, 
and according statistical procedures for paired-samples, both cases (W=-5.0, P<0.001) 
and controls (W=-4.3, P<0.001) score their own diet as significantly more adequate than 
the diet of the general population. 
The mean difference in the classification of diet adequacy on the Likert response scale 
is not correlated with previous consultations with a dietitian (rSpearman=0.023, P=0.854), 
HbA1c (rSpearman=0.162, P=0.193), BMI (rSpearman=0.166, P=0.184), WC (rSpearman=0.05, 
P=0.690), energy intake (rSpearman=0.172, P=0.072), carbohydrate intake (rSpearman=0.112, 
P=0.369), duration of diabetes (rSpearman=0.190, P=0.127), and age at the time of 
diagnosis (rSpearman=-0.107, P=0.391).  
Regarding usual food behaviour, subjects report that they usually follow a regular 
schedule for their meals (table 23).  
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Table 24. Patient classification of selected components of diabetes nutrition counselling 
How often do you… 
Cases Controls Mann 
Whitney’s 
test P-
value 
Mdn M (SD) Mdn M (SD) 
Follow a regular schedule for 
meals and snacks? 
4.0 3.7 (0.97) 4.0 4.2 (0.64) 0.016* 
Weight or measure the food 
for your meals? 
1.0 1.0 (0.0) 1.0 1.0 (0.0) - 
Keep a record of your meals? 1.0 1.0 (0.0) 1.0 1.0 (0.0) - 
Use food list to plan your 
meals? 
1.0 1.0 (0.0) 1.0 1.0 (0.0) - 
* Statistical difference between cases and controls, at the 0.05 probability level 
 
These results are not associated with the number of consultations with a doctor 
(rSpearman=0.188, P=0.194), nurse (rSpearman=0.106, P=0.144), or dietitian (rSpearman=0.201, 
P=0.055), age (rSpearman=-0.06, P=0.863), disease duration (rSpearman=0.262, P=0.062), BMI 
(rSpearman=-0.089, P=0.479), energy intake (rSpearman=-0.241, P=0.055), or carbohydrate 
intake (rSpearman=-0.257, P=0.061). Nevertheless, cases score significantly lower (U=368, 
P=0.016), which indicates that better glycaemic control seems statistically associated 
with a regular meals schedule. Both cases and controls reported that they never weigh 
or measure foods, keep a record of meals, and use food lists to plan meals. 
Food shopping appears to be different for cases and controls but not meal planning and 
preparing, as shown in table 24. A significantly higher number of controls shares food 
shopping duty or is the main food shopper (X2(2)=6.8, P=0.033).  
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Table 25. Subject’s engagement in food shopping and meal planning and preparation 
 
Cases 
(N=32) 
Controls 
(N=34) 
P-value of 
X2 test 
Doesn’t engage in food shopping 43.8% 14.7%  
  Shares food shopping duty 50% 73.5% 0.033* 
Is the main food shopper 6.3% 11.8%  
    
Doesn’t engage in meal planning/ preparing 53.1% 73.5%  
  Shares meal planning/ preparing 40.6% 20.6% 0.195 
Is the main meal planner/ preparer 6.3% 5.9%  
* Statistical difference between cases and controls, at the 0.05 probability level 
 
3.3. Diabetes complications perception and glycaemic control  
As previously stated, the perceptions on the risk of diabetes complications was assessed 
by a scale develop for this study, based on the items of the RPS-DM questionnaire (E. A. 
Walker et al. 2007a). The items, similarly to the original RPS-DM questionnaire, are 
grouped in three subscales – Optimistic bias, personal disease risk, and environmental 
risk. Before the data collection phase, the scale underwent a test-retest procedure using 
8 patients with T2DM that were not a part of the final sample. Table 25 shows the mean, 
standard deviation, and Cronbach’s alpha for the scale’s internal consistency in first 
phase of the test-retest procedure. 
 
Table 26. Descriptive statistics and internal consistency of the risk perception subscales in 8 patients 
Scale 
Number of 
items 
Cronbach’s 
alpha 
Test-retest 
difference 
M (SD) 
Wilcoxon’s 
test P-value 
Optimistic bias 2 0.797 0.3 (0.70) 0.823 
Personal disease risk 9 0.729 0.2(0.34) 0.900 
Environmental risk 9 0.707 0.3(0.57) 0.716 
M – Mean; SD – Standard deviation 
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A week after the pre-test, the original subjects were retested with the same version of 
the scales and, according to the Wilcoxon signed ranks test for paired samples, the  
scores in each subscale did not significantly differ between test and retest moments 
(P>0.05), allowing for the use of the scale in its current version. 
The optimistic bias subscale included two statements regarding the likelihood of 
diabetes complications and serious health problems. When subjects were asked to rate 
their agreement with the statement “Compared to people with diabetes of the same age 
and gender than mine, I am less likely to get diabetes complications”, the results showed 
that both cases and controls seem to have a biased diabetes complication perception, 
favouring less individual likelihood of diabetes complications. The results are statistically 
significant (X2(2)= 5.4, P=0.04), with cases having an overall higher agreement with less 
likelihood of complications (figure 10). 
 
 
Figure 10. Agreement with a lower likelihood of diabetes complications than the one of other individuals with diabetes 
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When analysing the agreement with a lower likelihood of serious health problems, and 
not only diabetes complications, cases show a significantly higher prevalence in the 
“strongly agree” category (X2(2)=7.6, P=0.014), even if controls show a higher 
prevalence of answering “agree”, as presented in figure 11.  
 
Figure 11. Agreement with a lower likelihood of serious health problems than the one of other individuals 
with diabetes 
 
The subscale of personal disease risk included nine items for which participants had to 
rate their risk of experiencing them. Both cases and controls predominantly answered 
that they have “almost no risk” or “slight risk” for the different health outcomes, as 
shown in table 26. 
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Table 27. Individual health risks perception 
Item 
Almost no risk 
(%) 
 
Slight risk 
(%) 
 
Moderate 
risk 
(%) 
 
High risk 
(%) 
P-value 
of  X2 
test 
CAS CTRL  CAS CTRL  CA CTRL  CA CTRL 
Heart attack 31.3  38.2  50.0  44.1  15.6  11.8  3.1  5.9 0.855 
Foot 
amputation 
53.1  38.2 
 
46.9  47.1 
 
      -  14.7 
 
-   - 0.076 
Cancer 18.8  2.9  46.9  55.9  31.3  38.2  3.1  2.9 0.224 
Vision 
problems 
28.1  8.8 
 
46.9  73.5 
 
25.0  14.7 
 
-  2.9 0.068 
High blood 
pressure 
28.1  20.6 
 
53.1  58.8 
 
18.8  20.6 
 
-   - 0.775 
Numb feet 25.0  26.5  62.5  52.9  9.4  17.6  3.1  2.9 0.776 
Stroke 28.1  5.9  34.4  55.9  34.4  38.2  3.1   - 0.037* 
Blindness 37.5  14.7  28.1  50.0  34.4  29.4  -  5.9 0.062 
Kidney failure 43.8  32.4  50.0  58,8  6.3  8.8  -   - 0.624 
CAS – cases; CTRL – controls 
* Statistical difference between cases and controls, at the 0.05 probability level 
 
The perception of the risk of stroke was the only item that showed significant differences 
between cases and controls, with the latter group assessing their risk lower than cases 
(P=0.037), even though, as previously reported, their lipid profile, lipid intake, and 
physical activity levels all are less than adequate. 
The replies in the environmental risk subscale, for perceived risk from items 
representing different events or situations, is shown in table 27. 
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Table 28. Environmental risks perception classification in cases (N=32) and controls (N=34). 
Item 
Almost no risk 
(%) 
 
Slight risk 
(%) 
 
Moderate 
risk 
(%) 
 
High risk 
(%) 
P-value 
of X2 
test 
CAS CTRL  CAS CTRL  CA CTRL  CA CTRL 
Medical tests 37.5  55.9  25.0  17.6  25.0  17.6  12.5  8.8 0.525 
Violent crime 21.9  23.5  40.6  41.2  25.0  20.6  12.5  14.7 0.974 
Extreme 
weather 
12.5  20.6 
 
25.0  29.4 
 
46.9  38.2 
 
15.6  11.8 0.745 
Driving/ riding 
in an 
automobile 
3.1.  8.8 
 
15.6  26.5 
 
46.9  50.0 
 
34.4  14.7 0.216 
Illegal drugs 96.9  88.2  3.1  11.8        -      -        -      - 0.185 
Air pollution 50.0  35.3  25.0  20.6  15.6  35.3  9.4  8.8 0.326 
Pesticides 21.9  20.6  37.5  29.4  31.3  29.4  9.4  20.6 0.632 
Household 
chemicals 
18.8  14.7 
 
46.9  29.4 
 
31.3  52.9 
 
3.1  2.9 0.345 
Cigarette 
smoke from 
people around 
you 
25.0  17.6 
 
40.6  32.4 
 
25.0  38.2 
 
9.4  11.8 0.631 
CAS – cases; CTRL - controls 
 
When analysing the individual disease risks and environmental risks using the numerical 
score attributed to each category, which ranged from 1 (“almost no risk”) to 4 (“high 
risk”) the perceived risk of cancer and stroke are the ones that subjects score with a 
higher mean, or greater likelihood of happening, even if both mean values are only 
slightly above the scale’s mean point (table 28). Heart attack, kidney failure, and foot 
amputation were the disease outcomes that were considered less likely and mean 
values for perceived risk are, on the overall, higher in environmental risk. Subjects seem 
to believe that their risk for health problems is higher from environmental risk factors, 
like riding an automobile, extreme weather, or pesticides.   
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Table 29. Mean values for individual disease risk and environmental risk in the sample (N=66). 
Individual disease risk 
item 
Mdn M (SD)  
Environmental risk 
item 
Mdn M (SD) 
Cancer 2.0 2.3 (0.70)  
Driving/ riding in an 
automobile 
3.0 2.9 (0.84) 
Stroke 2.0 2.2 (0.74)  Extreme weather 3.0 2.5 (0.93) 
Vision problems 2.0 2.1 (0.67)  Pesticides 2.0 2.4 (0.99) 
Blindness 2.0 2.1 (0.83)  Household chemicals 2.0 2.3 (0.79) 
High blood pressure 2.0 2.0 (0.67)  
Cigarette smoke from 
people around you 
2.0 2.3 (0.93) 
Numb feet 2.0 1.9 (0.72)  Violent crime 2.0 2.3 (0.97) 
Heart attack 2.0 1.9 (0.81)  Air pollution 2.0 2.0 (1.03) 
Kidney failure 2.0 1.7 (0.61)  Medical tests 2.0 2.0 (1.06) 
Foot amputation 2.0 1.6 (0.63)  Illegal drugs 1.0 1.1 (0.27) 
Mdn – Median; M - Mean; SD – Standard deviation 
 
The interpretation of the risk perception results according with the subscales derived 
from the RPS-DM questionnaire is shown in table 29. 
 
Table 30. Results in the classification scales for optimistic bias and perceived risk 
Scale 
Score 
range 
Cases (N=32)  Controls (N=34) Mann-
Whitney’s test 
P-value Mdn M (SD) 
 Mdn M (SD) 
Optimistic bias 1 - 4 3.0 3.4 (0.54)  3.0 3.3 (0.39) 0.158 
Personal disease risk 1 – 4 1.9 1.9 (0.30)  2.0 2.1 (0.29) 0.030* 
Environmental disease risk 1 – 4 2.2 2.2 (0.47)  2.1 2.2 (0.51) 0.918 
Mdn – Median; M - Mean; SD – Standard deviation 
* Statistical difference between cases and controls, at the 0.05 probability level 
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Cases and controls score their personal disease risk and their environmental risk around 
the scale’s midpoint and cases present a significantly lower (P=0.03) risk perception for 
personal disease. When analysing the association between risk perception subscales and 
previous counselling by a health professional, I did not find any significant correlation, 
as shown in table 30. 
 
Table 31. Correlation between previous counselling and risk perception 
Variable 
Pearson’s or Spearman’s correlations 
r or  (P-value) 
Cases (N=32)  Controls (N=34) 
OB PDR EDR  OB PDR EDR 
Doctor consultations in the 
last year 
0.03 
(0.873) 
0.12 
(0.502) 
0.21 
(0.247) 
 
-0.31 
(0.072) 
-0.28 
(0.115) 
0.003 
(0.985) 
Time since last doctor 
consultation 
-.13 
(0.483) 
0.26 
(0.154) 
0.2 
(0.272) 
 
0.08 
(0.674) 
0.03 
(0.851) 
-0.08 
(0.648) 
Nurse consultations in the 
last year 
0.20 
(0.524) 
0.33 
(0.063) 
0.32 
(0.070) 
 
0.32 
(0.064) 
-0.09 
(0.612) 
-0.251 
(0.368) 
Time since last nurse 
consultation 
-0.11 
(0.734) 
-0.04 
(0.899) 
-0.11 
(0.743) 
 
-0.31 
(0.185) 
-0.03 
(0.893) 
-0.22 
(0.348) 
Dietitian consultations in the 
last year 
-0.04 
(0.839) 
-0.21 
(0.240) 
-0.35 
(0.063) 
 
-0.21 
(0.243) 
0.007 
(0.969) 
0.23 
(0.195) 
Time since last dietitian 
consultation 
-0.39 
(0.216) 
0.03 
(0.922) 
0.57 
(0.064) 
 
-0.11 
(0.658) 
-0.10 
(0.698) 
0.09 
(0.735) 
OB – Optimistic bias; PDR – Personal disease risk; EDR – Environmental disease risk 
 
Additionally, I did not find correlations between risk perception and the prevalence of 
previously diagnosed diabetes complications, as shown in table 31. 
 
 
Chapter 3: Results 
133 
 
Table 32. Previously diagnosed complications in cases and controls 
Previously diagnosed 
complication 
Cases (N=32) 
N (%) 
 Controls (N=34) 
N (%) 
P-value of 
X2 test 
Retinopathy 6 (18.8)  7 (20.6) 0.851 
Overweight 19 (59.4)  16 (47.1) 0.316 
Coronary disease 3 (9.4)  6 (17.6) 0.328 
Stroke 1 (3.1)  2 (5.9) 0.512 
 
 
3.4. Odds ratio for inadequate glucose control  
Overall, when considering the similarities and dissimilarities between cases and 
controls, and by computing the odds ratio for inadequate glucose control from clinical, 
socio-demographic, and nutritional characteristics, together with the risk perception 
results, it is possible to infer that being employed, having completed only primary 
education, having a BMI of 30 kg/m2 or above, engaging in meal planning or preparation, 
the lack of a consultation with a dietitian in the last year, and a poor personal disease 
risk perception are statistically associated with glucose control (table 32). These results 
suggest that BMI (OR=4), being employed (OR=4.8), not having had a dietitian 
consultation in the last year (OR=3.8), engaging in meal planning or preparation 
(OR=3.1), and having a low personal disease perception (OR=1.6) increase the odds for 
inadequate glucose control. Low schooling, in this case expressed as having only 
completed primary education, appear to act as protective factor for poor glucose control 
(OR=0.24).  
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Table 33. Odds ratio for inadequate glucose control due to demographic and clinical characteristics (N=66) 
Characteristics OR (95% CI) P-value of X2 test 
Being employed 4.8 (1.68-13.95) 0.003* 
Having only completed primary education 0.24 (0.09-0.60) 0.006* 
BMI of 30 kg/m2 or above 4.0 (1.44-11.26) 0.007* 
High blood pressure 1.3 (0.39-4.00)  0.711 
HDL cholesterol of 40 mg/dl or above (men) or 
50 mg/dl or above (women) 
0.53 (0.19-1.46) 0.220 
LDL cholesterol of 70 mg/dl or above 6.9 (0.72 – 66.51) 0.063 
Total cholesterol of 200 mg/dl or above 2.7 (0.79 – 8.97) 0.106 
Triglycerides above 150 mg/dl 4.7 (0.82 – 26.60) 0.068 
No consultation with dietitian in the last year 3.8 (1.08-13.49) 0.031* 
Engaging in meal planning/ preparing 3.1 (1.12-8.83) 0.027* 
Low personal disease risk perception 1.6 (1.03-3.24) .040* 
Low environmental risk perception 1.0 (.38-2.63) .998 
OR – Odds ratio 
CI – Confidence interval 
* Significant differences between groups at the 0.05 probability level 
 
Nevertheless, these results must be interpreted considering the potential confounding 
effect of age. In this sample, schooling is negatively correlated with age r(66)=-0.444, 
P<0.001), indicating that older participants have significantly less schooling. Age can also 
be confounding the influence of employment status on glucose control, as employed/ 
active participants have significantly lower mean age than retired participants, as 
presented in table 33. 
 
Table 34. Age on data collection and when diagnosed, in active and retired subjects 
Age 
Active (N=37) Retired (N=29) P-value of 
Student’s t-test Mean (SD) Mean (SD) 
Age on data collection 55.2 (5.37) 68.1 (3.8) <0.001* 
Age when diagnosed 50.2 (6.13) 60.0 (5.51) <0.001* 
          SD – Standard deviation 
          * Significant differences between groups at the 0.01 probability level 
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3.5. Postprandial glycaemia 
The analysis of the differences in glucose response to a mixed-meal containing 75 of 
carbohydrates shows that cases and controls do not significantly differ up to 120 
minutes post-meal. According to the Student’s t-test (df=64), statistical significance for 
group differences is achieved in fasting glycaemia. Mean values up to 120 minutes after 
the experimental breakfast were similar in cases and controls (table 34). 
 
Table 35. Fasting glycaemia and glycaemia at 30 minute intervals after breakfast. 
Time (minutes) 
Glycaemia (mg/dl) 
Student’s t-test 
Cases (N=32) Controls (N=34) 
M (SD) M (SD) t P-value 
0 (fasting) 122.3 (7.25) 116.1 (8.00) 3.32 0.001* 
30  181.1 (25.70) 178.9 (28.80) 0.34 0.737 
60  173.1 (26.54) 171.1 (27.22) 0.294 0.770 
90  167.9 (23.21) 166.8 (26.41) 0.186 0.853 
120  179.4 (12.34) 179.1 (20.49) 0.076 0.939 
M – Mean; SD – Standard deviation 
* Significant differences between groups at the 0.01 probability level 
 
All mean values throughout the glucose monitoring were below 200 mg/dl, even at 120 
minutes, which corresponds to the diagnosis cut-off point for T2DM when using an OGTT 
(ADA 2013b). 
No significant differences were found in the proportion of subjects above the 200 mg/dl 
threshold for glycaemia at 120 minutes after breakfast, and all of the subjects presented 
a PPG level above 140 mg/dl (table 35). 
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Table 36. Proportion of cases and controls above selected glycaemia thresholds 
Glycaemia 
Cases 
(N=32) 
Controls 
(N=34) 
X2 test 
 P-value 
Fasting levels ≥ 126 mg/dl  34.4% 11.8% 0.028* 
Levels ≥ 140 mg/dl 120 minutes after breakfast 100% 100% - 
Levels ≥ 200 mg/dl 120 minutes after breakfast 6.3% 11.8% 0.436 
* Significant differences between groups at the 0.05 probability level 
 
All but 4 of the subjects (2 cases and 2 controls) showed a mean difference between pre-
prandial and postprandial glucose above 40 mg/dl. The mean difference was 57.1 mg/dl 
in cases (SD=13.29 mg/dl) and 63.0 mg/dl in controls (SD=19.73 mg/dl), with the 
differences being non-significant (t(64)=-1.4, P=0.159). 
Mean differences between pre-prandial and postprandial glucose were not correlated 
with age at diagnosis (rSpearman=-0.006, P=0.963) or at data collection (rSpearman=0.024, 
P=0.827), diabetes duration (rSpearman=0.108, P=0.387), HbA1c (rSpearman=-0.215, 
P=0.084), energy (rSpearman=0.013, P=0.916) or carbohydrate intake (rSpearman=-0.129, 
P=0.302), BMI(rSpearman=0.017, P=0.892), or frequency of glycaemia self-measurement 
(rSpearman=0.282, P=0.068). 
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4 .1. Study population and sample 
The classification of the study’s subjects as “case” was done based on an HbA1c value of 
7.0% or above in the 60 days prior to data collection. This cut-point was decided after 
the revision of the ADA guidelines for glycaemic control (ADA 2013a) and the EASD 
guidelines (Ray and Singhania 2011; Secnik et al. 2007) that reflect a HbA1c cut-point 
associated with a reduction in the risk of microvascular and macrovascular 
complications. Although the EASD proposed cut-point of 6.5% is associated with a lower 
vascular risk, the ADA therapeutic guidelines state that levels below 7.0% can be too 
strict and requiring a very intensive pharmacological protocol in some patients (ADA 
2013a). It is proposed that 7.0% is a more sensible and feasible goal for glycaemic 
control, which is a recommendation also reflected in the Portuguese Society of 
Diabetology treatment guidelines (Duarte et al. 2007). Thus, according to this rationale, 
although a cut-off point of 6.5% could have been selected as it represents the desired 
goal for glycaemic control, I chose a cut-off point for HbA1c of 7% due to the fact that it 
may represent a more reasonable and achievable target for most patients. 
The data for HbA1c can be biased due to the different procedures that can be used in its 
collection. In this study, blood samples were collected in the AEDMADA Diabetes Clinic 
on the day the physician informed the patients about this research, and were submitted 
to assays completed under the guidelines proposed by the Portuguese Ministry of 
Health for all assays in the National Health System and for all Clinical Laboratories (DGS 
2011c). This guideline indicates that blood samples must be processed by the same 
laboratory, with a method certified by the National Glycohemoglobin Standardization 
Program and calibrated according to the standards of the International Federation of 
Clinical Chemistry and Laboratory Medicine. The international standards are aimed at 
allowing proper diagnosis and data comparisons between populations (Hoelzel et al. 
2004; D. B. Sacks et al. 2011). 
Apart from the validity and reliability of HbA1c measurements, the setting were 
participants were recruited was thoroughly considered in order to predict and detect 
biases. The Diabetes Clinic were participants were recruited offers consultations and 
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care services to all patients with diabetes and/or other conditions that are members of 
the AEDMADA association. Patients must pay for the care received and the cost of care 
is higher than the fees in the National Health System, but significantly lower than the 
cost for care in private health care institutions. This selection criterion contributes to the 
specificity of the sample but, nevertheless, as this study intended to examine only 
patients undergoing metformin pharmacotherapy or patients that do not yet receive 
any OADA, I propose that this limitation on the number of possible participants has not 
resulted in a significant selection bias. Furthermore, analysing a single clinical setting 
allowed to remove biases related to the subjectivity of the treatment, due to the clinical 
decisions of each attending physician. The patients that were a part of this study 
attended consultations from a single clinician, who has his interpretation of the 
pharmacotherapy and treatment guidelines that are recommended for each individual 
case. If the study population had been from a different setting (e.g., a Health Centre), 
there could have been differences in the treatment regimens prescribed by different 
clinicians, due to heterogeneity in patients and in attending physicians. This would have 
been against the guidelines for an adequate case-control study, which requires that 
controls should have an opportunity of exposure similar to the population that is the 
source of the cases (Rothman et al. 2008). A population were there are different 
approaches to diabetes treatment and management would not have thoroughly allowed 
to study the nutritional related outcomes and glycaemia control. 
The need to avoid selection biases and confounding in the results is the rationale behind 
the decision for the study population to be composed by patients in a specific treatment 
approach. As shown by the literature review, diabetes can be treated with several 
pharmacological agents, each with its own mechanisms for action and side-effects, and 
it was considered that the pharmacotherapy regimen could constitute an extraneous 
factor in the comparison of cases and controls.  
Insulin therapy in T2DM is usually one of the last pharmacotherapy options to be 
considered, when β-cell function is severely impaired. The mode of administration of 
this pharmacotherapy and its effects on glycaemia imply that patients administering 
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insulin are fundamentally different than other patients with T2DM. Other 
pharmacologic agents are associated with weight gain or changes in fat mass, and that 
would make the anthropometric and nutritional comparison between cases and 
controls prone to confounding. Additionally, pharmacotherapy is also an indicator of 
disease progress (e.g., in patients under insulin therapy, T2DM has generally progressed 
significantly) furthering the eventual confounding effect in the data, as determinants of 
glycaemic control and diabetes self-care are associated with the duration of the disease 
(ADA 2013a). 
On account of the possible confounding effects of the pharmacotherapy regimens on 
case-control comparisons, I concluded that patients with T2DM in this study should be 
recruited from the population who is only treated with metformin or does not receive 
any OADA. Metformin is the most common OADA and other substances that are used 
as a second-line pharmacotherapy are more commonly associated with hypoglycaemia 
and weight gain (Nathan et al. 2009; Schernthaner et al. 2004).  
The data available for demographic characterization on the study population suggested 
that the sample would be composed by elder participants, mainly with low schooling. 
According to the last population census in Portugal, held in 2011 (INE 2012), the Algarve 
has 451,005 inhabitants, 64,560 of which in the Faro municipality. The age distribution 
of the inhabitants in the Faro municipality is presented in table 36. 
 
Table 37. Population in the Faro municipality, by gender and age group (INE 2012). 
Age 
Population (n) 
Total  Men Women 
0 - 14 years old 9 400 4 834 4 566 
15 - 24 years old 6 400 3 190 3 210 
25 - 64 years old 37 106 17 847 19 259 
65 years old or above 11 654 5 059 6 595 
Total 64 560 30 930 33 630 
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The Faro municipality has 18.1% inhabitants with 65 years or older, which is slightly 
higher than the national average (16.7%), and approximately the same than the 
proportion for all of the Algarve region (17.9%). Between the previous population census 
held in 2001 and the latest, the proportion of inhabitants in the Algarve with 65 years or 
older increased by 19.2%, with the increase in the Faro municipality being 26.2%. 
The population census of 2011 also suggested an illiteracy rate of 5.4% in individuals 15 
years or older, in all of the Algarve. The illiteracy rate represents individuals who state 
that they cannot, with understanding, read and write a short, simple statement on their 
everyday life. 
According to data available from the World Development Indicators of the World Bank 
and the United Nations Educational, Scientific and Cultural Organization (UNESCO) 
Institute for Statistics (World Bank/UNESCO 2012), the illiteracy rate for the Algarve is 
considerably higher than the mean rates for the European Union (0.97%), countries in 
the Euro area (1.1%), and Organisation for Economic Co-operation and Development 
(OECD) members (2.2%). Considering only individuals above 44 years old living in the 
Faro municipality, 7.9% report not having completed any sort of formal education and 
40.4% reports completing only the first stage of formal education, consisting of four 
years of schooling (INE 2012). 
The final sample in this study was composed by 45.5% of participants that completed 
only up to 4 years of schooling, suggesting a low educational level in this group of 
patients, as was to be expected. 
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4 .2. Clinical, anthropometric and demographic analysis  
The results in this study support the evidence that younger adult patients often have 
poorer glycaemic control (Naranjo et al. 2013) and that inadequate control seems 
independent of HbA1c cut points, when comparing younger and older patients (Fox et 
al. 2006). A cross-sectional analysis of the data from the American 2005-2010 National 
Health and Nutrition Examination Survey (NHANES), shows that diagnosis of T2DM 
between the ages of 30 and 65 is significantly associated with worse subsequent 
glycaemic control (Berkowitz et al. 2013). Nevertheless, the literature also suggests that 
glycaemic control worsens with the increase of diabetes duration, in part due to the 
incidence of disease complications (Quah et al. 2013). In longitudinal studies, besides 
age at onset, disease duration is identified as a significant predictor for diabetes 
complications (Juarez et al. 2012), as mean HbA1c values progressively increase with 
disease duration (Benoit et al. 2005) and with early onset subjects appearing more likely 
to have poorer glucose control (Song and Hardisty 2009). Although the literature reports 
that patients with early diabetes onset may have a more severe form of the disease, 
associated with a higher degree of insulin resistance and glycaemic control that is more 
resistant to some pharmacological treatment (D’Adamo and Caprio 2011), the role of 
lifestyle habits before and after the diagnosis should also be considered. 
The literature supports that the association between weight gain and diabetes duration 
is still unclear, and that weight gain, and consequently BMI increase, is a common 
concern in T2DM. Higher BMI, blood pressure, and triglycerides predict diabetes 
development and are associated with a steeper rate of fasting glucose increase (Fonseca 
2009; UKPDS Study Group 1998a). I found a significant negative correlation between 
BMI at the time of data collection and age at diagnosis (r(66)= -0.312, P=0.011), 
supporting the evidence in the literature and suggesting that patients diagnosed at an 
earlier age present a higher increase in their BMI. 
The nutritional status of the participants was also studied through their waist 
circumference and, according to the WHO criteria for interpreting this parameter (WHO, 
2011), only 3% of cases and 6% of controls show a waist circumference indicating normal 
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metabolic risk. All other participants show an increased or substantially increased 
metabolic risk. According to the literature, abdominal obesity is common in T2DM and 
is also increasing in non-diabetic individuals, accompanying the trends in obesity 
prevalence (Hossain et al. 2007). Data from a Portuguese sample of 16,856 adults (Fiuza 
et al. 2008) showed a prevalence of abdominal obesity of 46.4%, similar to the results 
from other studies, like the NHANES, which up to 2010 shows a prevalence of abdominal 
obesity ranging from 42.4% to 61.3% in adults (Li et al. 2007; Ostchega et al. 2012). 
Several studies with T2DM patients (Bari et al. 2006; Davari and Khoshnood 2010) show 
a wide prevalence range for abdominal obesity, from 27.1% to 67%, which is suggested 
as being the result of the role of lifestyle and food behaviour (Fonseca 2009). 
My data reflect the general overweight and obesity trends in T2DM patients. A 
systematic review of observational studies (Colosia et al. 2013) reports that obesity rates 
exceeded 30% in 38 of the 44 studies analysed for this variable and 50% in 14 of the 44 
studies. Additional data from 3637 UK patients in secondary care (Daousi et al. 2006) 
showed that 86% of patients with T2DM were overweight or obese and, in Spain, a 
nationwide population-based cross-sectional survey with 12,077 individuals, reports 
that only 11.4% had BMI below 25 kg/m2 or a recommended waist circumference 
(Navarro-Vidal et al. 2013). 
As obesity is considered an important cardiovascular risk factor by itself, successful 
interventions to control weight gain and to reduce weight would be desirable in T2DM, 
especially when obesity is considered concomitantly with other diabetes complications 
associated with cardiometabolic risk. The present data seem to suggest that all T2DM 
patients could benefit from these interventions. Nevertheless, as poorer glycaemic 
control is associated with higher BMI, patients with either one of these features should 
be prioritized in health promotion interventions. 
Besides BMI, lipid profile also constitutes an important cardiometabolic risk factor in 
T2DM, as patients often exhibit an atherogenic lipid profile, which greatly increases the 
risk of cardiovascular disease when compared with people without diabetes (Chehade 
et al. 2013). One particular lipid profile seems attributable to insulin deficiency and 
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insulin resistance, which apparently lead to a high plasma triglyceride concentration, 
low HDL cholesterol concentration and increased concentration LDL cholesterol 
(Mooradian 2009). 
The literature suggests that dyslipidaemia affects around 50% of T2DM patients 
(Chehade et al. 2013) and that there is evidence from prospective studies that there is 
a low prevalence of recommended levels of total cholesterol, HDL cholesterol, and 
triglycerides in T2DM patients (Jacobs et al. 2005; Study 1997). Reports from the 
NHANES in 1999-2000 state that among T2DM, control of LDL cholesterol was only 
achieved in 29.7% of patients, and optimal levels of LDL cholesterol, HDL cholesterol, 
and triglycerides were only achieved in 3.4% of patients (Jacobs et al. 2005). The ADA 
recommends that cholesterol levels in T2DM should be below 200 mg/dl, HDL 
cholesterol should be above 40 mg/dl in men and above 50 mg/dl in women, LDL 
cholesterol should be below 70 mg/dl, and that the desirable goal for triglyceride levels 
is below 150 mg/dl (ADA 2013a). My data show that the participants are in need of 
interventions to decrease lipid levels, as 95% of cases and 72% of controls have a LDL 
cholesterol level of 70 mg/dl or above.  
Regarding education, cases and controls were dissimilar in a way that is contrary to the 
reported in the literature. In this study, low education is associated with better glucose 
control, due to the fact that controls report less formal schooling than cases (X2(4)= 9.1, 
p=.048). This association and the ones found between education and age (P<0.001) and 
between education and years of diabetes duration (P=0.019) may be due to the non-
random nature of the sample, but can also reflect the socio-demographic characteristics 
of the Algarve. As previously reported, according to the 2011 census, 44.8% of the 
Algarve population over 50 years old has completed only 4 years of schooling and 20.2% 
has completed less than 4 years of schooling (INE 2012). Thus, T2DM patients with 50 
years old and over, are expected to have a high prevalence of low schooling. This 
confounding effect of age may be the reason for the identification of low schooling as a 
protective factor for poor glucose control (OR=0.24, P=0.006). Furthermore, I did not 
find associations between education and occupation (P=0.215), physical activity 
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(P=0.078), number of doctor visits during the previous year (P=0.851), and frequency of 
glucose measurement (P=0.483), which the literature suggest as existing (Benoit et al. 
2005; Buse et al. 2007; Saydah et al. 2004). 
In my study, the correlation that was found between HbA1c and age at the time of data 
collection is not maintained when analysing only active (Pearson’s r(37)=-0.119, 
P=0.483) or retired (Pearson’s r(29)=-0.251, P=0.189) subjects. This can lead to infer that 
there may exist an underlying determinant of glucose control, related to employment 
status, which distinguishes cases from controls. Therefore, the role of employment 
status must be further addressed, as the literature sustains that it can substantially 
influence lifestyle habits, like food behaviour (in timing, number, and composition of 
meals) or physical activity (ADA 2013a; Benoit et al. 2005; Tahmasebi et al. 2013). 
On the overall, cases and controls, as expected, show significant differences in some 
clinical, anthropometric and demographic variables. Nevertheless, the most surprising 
data are the similarities recorded in both groups of patients regarding cardiometabolic 
risk, obesity prevalence, doctor visits, and frequency of glucose self-measurement. As 
presented in the literature review, these variables are important determinants of 
glycaemic control, but in the subjects in this work their prevalence is not related with 
significantly higher odds of being part of the group of patients with HbA1c of 7% or 
above. 
My data suggest that lifestyle habits are associated with glucose control and, as food 
behaviour is associated with BMI, lipid profile, and hypertension, future research 
focusing on the analysis of patients’ eating habits and nutrition therapy can contribute 
to identify more adequate approaches to glucose control. 
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4.3. Diet and adherence to nutrition recommendations  
Dietary intake was assessed by a 24h recall, which is the standard method for assessing 
dietary intake in epidemiological surveillance studies (Margetts and Nelson 1997; Willett 
1998). I intended to accommodate the greatest detail about the food items ingested and 
their amounts and, although this method of food intake assessment depends on the 
short-term memory of the participants, it was considered the most appropriate for this 
study due to the fact that it did not require literacy. Furthermore, as data on food intake 
is recorded after consumption, this method does not alter eating behaviour. 
Cases and controls were found to be significantly different in some components of their 
nutritional intake. The most significant difference in the nutritional composition of the 
diet of cases and controls is the amount of sugars ingested. Cases show a significantly 
higher (P=0.006) intake of sugars (M=128.9g, SD=77.92g) than controls (M=87.2g, 
SD=51.14g), although intake in both groups is considerably above the recommendations 
for T2DM patients. In general, daily consumption of sugars should not exceed 25g in 
women and 37.5g in men (Johnson et al. 2009), and sucrose or other added sugars in 
excess of 10% of TCI should be substituted by isocaloric amounts of starch, obtained 
from foods containing other important essential nutrients (Franz et al. 2010).  
Cases also have a higher energy (P=0.03) intake than controls and these results support 
the evidence that glycaemic control may be more associated with total energy intake 
than with macronutrient distribution (Heilbronn et al. 1999; Kang and Kim 2012; Masuda 
et al. 2013), at least when diet carbohydrate content is moderately low.  
Total energy intake has been linked to glycaemic control (ADA 2013a), with T2DM 
patients who exceed recommended energy intakes being reported as having a higher 
mean HbA1c (Bell et al. 1995; Masuda et al. 2013; Xu et al. 2007). 
Nevertheless, it must be reaffirmed that all subjects presented a high prevalence of 
excess energy intake. Most of the subjects (72% of cases and 68% of controls) have an 
inadequate energy balance, failing to meet the recommended dietary reference intake 
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(DRI), as proposed by the literature in order to prevent or reduce overweight and 
obesity, and consequently, several associated complications (ADA 2013a). 
The distribution of the percentage of daily TCI for each macronutrient suggests that all 
subjects follow a diet with adequate protein intake, high lipid intake, and a moderate 
carbohydrate intake.  
A 2012 systematic review of the literature regarding macronutrients, food groups, and 
eating patterns in the management of diabetes reports a wide variability in the 
macronutrient distribution in the diet diabetes patients, and states that a high-
carbohydrate intake is often described as a carbohydrate intake of at least 55% of total 
energy, whereas a low-carbohydrate intake may be described as being below 25% of 
total energy (Wheeler et al. 2012). The standards of care for diabetes regarding nutrition 
propose that  the mix of macronutrients should be adjusted to meet metabolic goals of 
the person with diabetes (ADA 2013a), but carbohydrate distributions between 50-55% 
have been recommended by dietitians in order to include in patients’ diet foods that are 
important sources of fibre, vitamins, and minerals, while maintaining dietary palatability 
and attending to individual preferences (Wheeler et al. 2012). Despite these 
recommendations, dietary intake of carbohydrates in T2DM patients is around 45%, as 
demonstrated by meta-analysis (Kirk et al. 2008), randomized trials (Esposito et al. 2009; 
Vitolins et al. 2009), and prospective (e.g. (Eeley et al. 1996)) and populational studies 
(Nelson et al. 2002), which report usual carbohydrate intakes ranging from 40% to 46% 
of TCI, even when dietary recommendations aim at higher intakes. 
In my study, both cases and controls have a lipid distribution of at least 35% of TCI, 
which, when analysed taking into account the overall macronutrient distribution, seems 
to be an important determinant of excess energy, similarly to the results proposed by 
Nelson and colleagues (Nelson et al. 2002). 
Considering the intake of different lipids, subjects showed a high intake of total 
cholesterol and saturated fatty acids (table 22). The ADA recommends limiting dietary 
cholesterol to levels below 200 mg/day and saturated fat intake to levels below 7% of 
TCI (ADA 2008), and, according to Student’s t-test, both groups of patients in this study 
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had significantly higher intakes of both types of lipids (P>0.05). Mean total cholesterol 
was above 350 mg for both groups of subjects. Furthermore, controls show a mean 
saturated fat intake of 11.9% of TCI (SD=5.30%) and cases show a mean saturated fat 
intake of 11.5% of TCI (SD=4.91%), with the differences between groups being non-
significant (t(64)=-0.319, P=0.751). Even though monounsaturated and polyunsaturated 
fatty acids still account for the majority of lipid intake in cases and controls, as 
recommended in the literature (Franz et al. 2010), these data suggest that patients 
should adjust their intake in order to have a more cardioprotective eating pattern. 
The fibre intake recorded for both cases and controls is below the recommended intake 
for T2DM patients. Cases showed a mean intake of 18.3g of fibre (SD=8.73), while 
controls showed a mean intake of 17.7g (SD=8.13). Franz et al. (2010) suggest that diets 
containing 44g to 50g fibre daily improve glycaemic control, but, as these fibre contents 
are difficult to achieve in a diet with low carbohydrate content, and as they may be 
related with gastrointestinal distress, recommendations for fibre intake in T2DM 
patients are similar to the ones for the general population, indicating an intake of 14g 
of fibre for every 1000 kcal. As alternative for these recommendations, the ADA 
guidelines suggest a daily intake of foods containing 25g to 30g of fibre, with special 
attention given for soluble fibres due to their beneficial effect on lipid profile (ADA 
2008). 
Sodium content is another important characteristic of the nutritional composition of the 
diet in these subjects. When compared to non-diabetic individuals, hypertension in 
diabetes patients is more sodium sensitive and patients show an increased total body 
sodium, an increased renal tubular sodium reabsorption, and an impaired ability to 
excrete sodium (Underwood et al. 2012; Van Buren and Toto 2011). This has led to 
believe that sodium intake in diabetes patients is of major importance for the 
management of hypertension. 
It is recommended that normotensive diabetes patients reduce dietary sodium to 2,300 
mg/day or below, and that patient with hypertensions should aim for a sodium intake 
below 1,500 mg/day (ADA 2008). The effects of lowering intake levels below 1,500 
Chapter 4: Discussion 
149 
 
mg/day have been demonstrated in the DASH study, which reports effects similar to 
antihypertensive pharmacological therapy (F. M. Sacks et al. 2001). The different diets 
used in the DASH study lowered blood pressure by reducing sodium intakes to 3,500 
mg/day, 2,300 mg/day, and 1,150 mg/day. Blood pressure reductions were recorded 
among both hypertensive and non-hypertensive subjects, although the effects were 
greater among hypertensive participants. Subjects in this study showed a high sodium 
intake (P<0.001), recorded for both cases (M=4277.7 mg, SD=2057.04 mg) and controls 
(M=3921 mg, SD=1530.06 mg). Sodium intakes were not significantly different between 
groups (t(64)=0.803, P=0.425) and were not correlated with HbA1c (Pearson’s 
r(66)=0.024, P=0.848), which indicates that this micronutrient, by itself, is not associated 
with glycaemic control. 
Overall, when analysing nutrition composition of the usual diet in the subjects of this 
study, I found that both cases and controls show high intakes of energy, lipids (saturated 
fatty acids and cholesterol, especially), total carbohydrates (with sugars accounting for 
a considerable proportion of carbohydrate excess) and sodium. Sugars seem the type of 
nutrient that most significantly determines glycaemic control, but it also appears likely 
that the total energy intake of the diet outweighs the role of carbohydrate distribution. 
My results support the evidence that glycaemic control may be more associated with 
total energy intake than with macronutrient distribution. 
Lower HbA1c is associated with worst nutrition habits, supporting one of this study’s 
initial research hypothesis (hypothesis number 2, stating that “patients with adequate 
glycaemic control have a better compliance of nutrition recommendations “). 
Nevertheless, as described, the similarities between both groups of subjects in 
nutritional intake and food behaviour are also worthy of note. For instance, both cases 
and controls present a daily median energy intake which is over 200 kcal above 
individual requirements.  Furthermore, both groups also showed a high intake of 
sodium, total cholesterol and saturated fatty acids. These results also seem linked to the 
perceptions of nutritional care and to an unreasonable optimism in regard with diet 
adequacy.  Even subjects with substantially increased BMI and high excess intakes of 
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energy, lipids, and carbohydrates, believe they have an averagely adequate diet, 
independently of previous consultations with a dietitian, type of health advice received, 
any of the anthropometric variables collected, years of diabetes duration, and age at the 
time of diagnosis. 
My results support the reasoning that a diet with a moderate amount of carbohydrates, 
privileging foods with low-sugar content, high soluble fibre, and low fat, distributed in 
adequate portion sizes as to not exceed recommended energy requirements, would 
have the most beneficial potential for glycaemic control in T2DM patients. Both cases 
and controls showed a moderate intake of total carbohydrates, which prompts me to 
believe that the promotion of an adequate diet in T2DM patients must include specific 
education interventions aimed at addressing the carbohydrate quality of the meals, and 
also other aspects of food behaviour that seem related to glycaemic control, like the 
number of meals. According to the data, these interventions, if effective, would benefit 
patients with inadequate glucose control and those with adequate glucose control, as 
the majority of patients in both groups have clinical (LDL cholesterol) and 
anthropometric characteristics (BMI, waist circumference) that the literature relates 
with food behaviour and with diabetes monitoring and control.  
The similarities in the nutritional composition of the diet of cases and controls must be 
further addressed in order to clarify the role that known determinants of food behaviour 
play in glycaemic control. The usual food intake found in both groups pf patients in the 
present study is significantly different from the nutritional recommendations. Subjects 
should receive individualized medical nutrition therapy, as it’s reported that modifying 
intake, specifically the type and amount of dietary carbohydrates, can improve disease 
control (ADA 2008). Foods containing carbohydrates that are slowly digested and 
absorbed, included in a diet that consists largely of fresh, unprocessed fruits and 
vegetables, moderate levels of lean protein and beneficial fats, with minimal amounts 
of processed carbohydrates and saturated and trans fats, can significantly reduce 
postprandial glucose levels related to T2DM complications (ADA 2007). Evidence also 
suggests that dietary measures can be effective in weight reduction and glycaemic 
Chapter 4: Discussion 
151 
 
control irrespective of the macronutrient composition (low fat or low carbohydrate), 
provided that there is adequate energy restriction, reduction of saturated fat to less 
than 7%, and adequate provision of dietary fibre (ADA 2008; Stern et al. 2004) 
Nevertheless, nutrition counselling requires a contextual understanding of the patient’s 
individual situation, in order to support and promote health behaviour change (Morris 
and Wylie-Rosett 2010). Despite the literature may recommend that a stricter 
adherence to existing guidelines and a much stronger attention to the desired 
therapeutic goals will allow a decrease in diabetes costs, morbidity, and mortality 
(Comaschi et al. 2005), the results from the socio-demographic variables I assessed 
provide some indication that educational, cultural or economic characteristics that may 
hinder compliance of nutritional recommendations must be taken into account. 
Another result I propose that must be discussed is the involvement of patients in food 
shopping, which seems related with better glycaemic control (P=0.033). The literature 
on food choice and nutrition interventions has associated the participation in food 
shopping following nutrition counselling with better health education outcomes and 
greater nutrition knowledge, especially in situations where restriction of selected food 
items is encouraged, as in weight management diets (Saarela 2013; Saarela et al. 2013). 
It is suggested that family dynamics has a significant impact in diabetes. Family provides, 
for example, emotional support and economic well-being, but, on the other hand, if 
family life is characterized by stress and conflict, subjects’ health tends to be negatively 
affected (Miller and DiMatteo 2013). Family members of diabetes patients are also 
aware of their supportive role, as they report wanting to be more involved in their care 
(Kovacs Burns et al. 2013). The mechanism by which social support affects adherence to 
diabetes therapy is not yet completely understood, and this can be an area of further 
inquiry in diabetes and nutrition research. 
On the overall, regarding diet and adherence to nutrition recommendations, the results 
in subjects with better glycaemic control show that these patients are also in need of 
effective nutrition education, as they also present a higher than expected agreement 
with some of the barriers presented in the literature as important determinants of 
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glycaemic control and nutrition therapy adherence. Furthermore, although patients 
believe diet is an important element in their self-care, they do not maintain their 
dietitian consultations for long or don’t feel the need for attending any consultations.  
According to my results, I propose that most patients, even if differing in their barriers 
perceptions, fail to comply with the recommendations for proper daily food intake. 
Furthermore, when analysing differences in barriers perceptions, it is of note that even 
with the existence of significant differences, the data that show that subjects with 
proper glycaemic control score several barriers above the classification scale’s midpoint 
should not be disregarded. This means that they too experience those barriers, even if 
with a lower frequency or perceived importance than cases. Conversely, the significant 
differences found in these variables can occur due to the wide classification range 
between cases and controls and not necessarily due to a low perception in controls 
alone. For example, there are significant differences in the perceived effort that a 
balanced and proper diet requires, with cases reporting a higher perceived effort, but 
controls also report perceived mean and median scores indicating a moderate perceived 
effort. These results point to the existence of difficulties in translating for one’s daily 
routine the nutritional recommendations that all patients report having previously 
received.  
The literature refers the difficulties and complexities of the nutritional care process in 
T2DM, proposing that a single, uniform approach is not desirable, due to the intricacies 
of diabetes aetiology, complications, and glycaemia determinants (ADA 2008, 2013a; 
Franz et al. 2010). Recommendations for three to four sessions or consultations with a 
dietitian after diagnosis, each lasting from 45 to 90 minutes (ACD 2008), are difficult to 
upheld, and yearly follow-up to reinforce lifestyle changes and to evaluate and monitor 
outcomes are, in the subjects in this study, non-existent. Even though patients report 
having previously received nutrition recommendations, the prevalence of the feeling of 
confusion with nutritional information is high, especially in subjects with poor glycaemic 
control, which raises questions that are unanswered by this study regarding the nature 
and quality of nutrition recommendations. This, together with the low prevalence of 
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physical activity, nutritional status, and nutritional composition of the diet, allows to 
propose that the effectiveness of nutrition recommendations can be improved, and that 
further research in this field must also focus on assessing the type of counselling and the 
determinants of consultation prevalence.  
Additional empirical observations resulting from the data collection interview raise 
concerns that the cost of consultations can be a barrier to nutrition recommendations, 
even if none of the subjects openly identified this factor as a barrier. Subjects expressed 
concern not only for the actual cost of the consultation, but also concern with indirect 
costs, like the need for transportation. Evidence for the efficacy and cost-benefit of 
nutrition therapy in diabetes is not new, and recent data (Franz et al. 2010; Zhuo et al. 
2013) is in accordance with previous findings stating that over patient’s lifetime, 
effective individualized nutrition interventions can be delivered by experienced 
dietitians with a cost-effective investment of resources, and resulting in substantial long-
term savings in healthcare costs. This cost-effectiveness is enhanced when dietitians are 
engaged in active decision making about interventions based on the patient's needs 
(Franz et al. 1995; Pastors et al. 2002; Sheils et al. 1999). Subjects in the population 
analysed in this study are offered dietitian consultations with prices that imply that 
patients have to pay from around €5 to up to €20. Even this relatively low consultation 
cost seems to be a deterrent for consultation adherence and assessing the determinants 
and context of nutrition consultations is to be suggested for future research in the 
population for this study. Furthermore, the results from the barriers to nutrition therapy 
adherence also reflect patients’ concerns over economic implications of a proper diet. 
Patients in this study, especially cases, believe that a proper diet is more expensive. This 
can be seen even in patients that, based on the assessment of the foods in their usual 
diet, seem to have a food pattern that does not often include highly expensive food 
items, like prime cuts of meat or expensive species of fish. As diabetes is more prevalent 
in older patients who are predominantly retired from their job and subsist on a pension, 
the costs of diabetes therapy, which regularly include poly-pharmacy, can be an 
important determinant of adherence to nutrition care.  
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Some of the barriers for nutrition therapy adherence identified in this study were 
expected, like the perceptions of limited food portions, or the dislike of food in the diet, 
but I did not predict that the economic implications were such an important predictor 
of glycaemic control, despite the fact that it has been described in the literature 
(Gazmararian et al. 2009; Jerant et al. 2005; Toobert et al. 2000; UKPDS Study Group 
1995b; Vijan et al. 2005). We believe that dietitians and other healthcare professionals 
providing care for T2DM patients need to acknowledge the economic burden of diabetes 
when counselling for adequate self-care. In regard to nutrition, it seems important that 
the aim of education interventions must be on ways to properly construct a daily meal 
plan, but also on how to do so economically. 
During the data collection interview, patients also made several comments stating that 
they have to prioritize expenses with their health care, and also stating that medication 
and doctor consultations were considered the most important components of care. The 
literature reports that although patients place a high value in a proper diet, 
pharmacotherapy and clinician advice are more highly regarded therapeutic tools (C. 
Asche et al. 2011a; Cramer 2004; Sabatâe 2003)). As beliefs and knowledge about 
diabetes are considered determinants of glycaemic control (Nam et al. 2011) this can 
explain, in part, the poor risk perception recorded, and why most studies show that 
adhering to a proper diet is generally non-sustainable . 
A proper communication of the risk of diabetes perception and their relationship with 
food intake could be useful in this population, as there is evidence suggesting that an 
appropriate risk communication may help patients to take a more active role in their 
care (Paling 2003; Waldron et al. 2011). However, results from randomized controlled 
trials show that the evidence on the specific impact and effects of risk communication 
on diabetes self-care is still unclear. Risk communication seems helpful in T2DM patients 
(Pijl et al. 2009), but risk perception appears to improve during a short timespan after 
the intervention only to subside after about 12 weeks (Welschen et al. 2012). I suggest 
that the strategies for nutrition education in T2DM and nutrition knowledge in the 
Chapter 4: Discussion 
155 
 
population in this study should be assessed, in order to document the association 
between those variables and risk perception.   
Patient education enables people with diabetes to improve their knowledge, skills and 
confidence, allowing them to self-manage their condition. It’s a critical element in 
diabetes care and can have a strong effect on biomedical outcomes (Funnell et al. 2011; 
Nyenwe et al. 2011). Patient education includes, among other goals, patient 
empowerment to incorporate nutritional management and physical activity into his 
lifestyle and the development of personal strategies to promote health and behaviour 
change (Funnell et al. 2011).  
 
4.4. Consultations with health professionals  
My results show a low prevalence of dietitian consultations. In the last year, only 12.5% 
of cases and 35% of controls sought a dietitian consultation. When compared to 
controls, cases went to less dietitian consultations during the last year (P=0.029), and 
also during all the course of the disease (P= 0.031). Additionally, in cases, a longer time 
since last consultation with a dietitian had passed at the time of data collection 
(P=0.028). These results suggest that, independently of the low prevalence of dietitian 
consultations, having been in a dietitian consultation during the last year is related with 
adequate glycaemic control. The literature describes that changes in nutrition behaviour 
depend on patient motivation and the quality and type of follow-up (Delamater 2006; 
Sabatâe 2003), with results from analytic studies evidencing the importance of low goal 
setting, new stimuli during the behaviour change process, proper social support, and 
long-term contact with therapists (Dalle Grave et al. 2010; Epstein et al. 2012) as 
determinants of therapeutic success. A clinical trial assessing different types of diet and 
their impact in weight reduction and cardiovascular outcomes also shows that, more 
important than the specific diet plan, maintaining adherence to the diet for one year is 
a determinant of weight loss and reduction of cardiovascular risk (Dansinger et al. 2005). 
The authors conclude that it seems plausible that for maintenance of reduced weight, 
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the diet needs to be matched with the patient, by adopting dietary and cognitive-
behavioural strategies that increase dietary adherence. 
In diabetes therapy, intensive nutrition counselling by a dietitian is believed to promote 
a statistically significant HbA1c reduction (Coppell et al. 2010b; UKPDS Study Group 
2000), which is maintained up to 12 months after counselling and despite the use of 
fewer anti-diabetic drugs (Franz et al. 2010; Gæde et al. 2003; Pastors et al. 2003). While 
intensive pharmacological therapy seems to provide mixed results for glycaemic control 
(Holman et al. 2008; Turnbull et al. 2009), the current literature supports that proper 
nutrition is a highly valuable therapeutic tool for improving disease outcomes and 
patients’ quality of life (ADA 2013a; Franz et al. 2008, 2010). The literature also shows 
that, in a primary care setting, management of diabetes guided by a registered dietitian 
can improve glycaemic control in patients with poorly managed disease (Huang et al. 
2010), and have a significant impact in the decrease in mean energy intake at dinner and 
a greater increase in mean vegetable intake for the whole day, breakfast, and lunch 
(Adachi et al. 2013). In my study, both the time since the last consultation with a dietitian 
and the existence of this type of monitoring seems associated with better glycaemic 
control, allowing to infer that consultations with a trained dietitian are recommended 
for T2DM, as proposed by the standards of care for diabetes (ADA 2013a). Nevertheless, 
when considering the results on the prevalence of physical activity, the anthropometric 
indicators of nutritional status, and the nutritional composition of the diet, one must 
question the effectiveness of the recommendations and suggest that the type of 
counselling, the determinants of consultation prevalence, or the determinants of 
adherence to recommendations play a significant role in the results. 
The analysis of the specific reasons for low prevalence of consultations, whether by 
referral or by own initiative, is beyond the scope of this study, but the literature suggests 
that low prevalence in consultations and education interventions is common. Data from 
the USA Diabetes Prevention and Control Programs show that only 54.3% of diabetes 
patients attended some type of diabetes self-management class between 2000 and 
2010 (CDC 2011), and a study analysing dietitian consultations in 18,404 patients reports 
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that only 9.1% had at least one consultation within a 9 year period (Robbins et al. 2008). 
The USA health system implies that diabetes patients have a more direct cost with 
disease treatment and management, but similar results regarding consultation and 
education interventions attendance are found even in publicly-funded health care 
systems, where patients could access these services without direct charges (Cauch-
Dudek et al. 2013). 
One of the biggest therapeutic challenges in T2DM nutrition counselling is to implement 
strategies to assure patient adherence, as diet has significantly less compliance than 
pharmacological therapy (Asche et al. 2011a; Cramer 2004; Sabatâe 2003). My results 
show that, although patients believe diet is an important element in their self-care, they 
do not maintain their dietitian consultations for long or don’t feel the need for attending 
any consultations, independently of their glycaemic control. Patients appear to believe 
they have moderate nutrition knowledge, as this was not clearly identified as a barrier 
to a proper nutrition, but cases feel more confused with the information they received. 
It is possible to infer that the manner in which counselling is made can be improved. 
Nutrition advice can be tailored to address the barriers that are more important to 
subjects with inadequate glucose control, such as the perceived effort, cost and foods 
composition in a proper diet, and the clarity of nutrition information.  
A gradually implemented, patient-centred care, recognizing patient autonomy but 
providing continuity of care with frequent contact with health professionals (Delamater 
2006), could constitute a model for nutrition counselling aimed at sustaining the 
beneficial changes beyond the intervention. 
4.5. Glucose self-monitoring 
Glucose self-monitoring was also similarly infrequent in cases and controls. Although the 
optimal frequency for glucose self-monitoring in T2DM patients who follow a non-
insulin pharmacotherapy is still a topic of debate (ADA 2013a),  it is believed that it 
results in early therapeutic changes and can help prevent asymptomatic hypoglycaemia 
and hyperglycaemia (Garg and Hirsch 2014). 
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In this study, empirical observations resulting from patients’ own anecdotal reports 
during the data collection interview allow to infer that the population under study has 
poor knowledge on how to self-measure blood glucose using a portable glucometer, and 
also lacks the skills to properly interpret the data and to act if the results are too high or 
too low. This can be an important aspect of diabetes care and providing additional 
education on self-monitoring must be considered.  
The self-monitoring of glucose in T2DM patients who are not treated with insulin is still 
a controversial topic in the literature. There is evidence from randomized controlled 
trials (Garcia de la Torre et al. 2013) and different prospective studies (Henderson et al. 
2013; Schnell et al. 2013) stating its efficacy in reducing HbA1c, but also evidence stating 
that the improvements in quality-adjusted life years are not cost-beneficial and that are 
only visible if patients have a high compliance with monitoring (Cameron et al. 2010; 
Simon et al. 2008; Tunis 2011). It seems that the evidence skews on the side of 
supporting glucose monitoring in non-insulin treated patients, mostly due to the 
improvements in diabetes management reported in real world clinical settings (Lalic et 
al. 2012), and also to the fact that patient-obtained glucose readings can provide 
valuable real-time feedback on glycaemic responses to meals and exercise, and provide 
the patient with guidance on the day-to-day management of their disease (Garcia de la 
Torre et al. 2013). Nevertheless, for self-monitoring to be most effective, it should be 
performed in a structured format where information obtained from this measurement 
is used to guide treatment, considering that both patients and health care professionals 
require education on how to respond to the data. 
In Portugal, diabetes patients receive their measuring strips and glucometers almost 
completely funded by the Health Service, with a prescription by a doctor. Data modelling 
for Italy and Spain, where payer reimbursement practices are similar, has provide data 
to consider self-monitoring as cost effective across a 40-year time horizon (Tunis et al. 
2010). This timespan can be a deterrent for promoting widespread self-monitoring in 
T2DM patients not using insulin, but it also must be considered that the benefits of self-
monitoring may not be limited to HbA1c improvements.   
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Integration of glucose self-monitoring into basic T2DM management improves 
glycaemic control, but psychosocial outcomes, such as benefits to self-efficacy and 
diabetes-related distress must also be assessed. Furthermore, the increasing technology 
in glucose monitoring and all the novel care strategies that can improve doctor and 
patient communication may aid to detect clinical outcomes, such as hypoglycaemia, and 
to implement therapeutic changes. Results from self-monitoring may will help clinicians 
to adjust OADA therapy. 
For self-measurement of blood glucose to be successfully incorporated into diabetes 
self-management, health care professionals must also be motivated to explain their 
rationale to patients and also to show them their importance and meaning. The 
literature reports that is not unusual for patients to make a note of glucose 
measurements without really understanding what they mean or how they should use 
the information, and also to feel frustrated when healthcare professionals take little 
interest in their diligence in recording glucose values. Glucose self-monitoring must be 
integrated into a comprehensive and structured training programme in which these 
issues are expressly addressed (Heller 2014; Polonsky et al. 2014) 
Considering the results in the present study, glucose-self monitoring also constitutes the 
only practical way to identify glucose excursions after a meal. Due to the similarities in 
PPG that seem independent of HbA1c, self-monitoring results may help to provide 
clinicians with information that can be used to reduce cardiovascular risk in T2DM 
patients. Further research is needed in order to assess the benefits and costs of glucose 
self-monitoring considering additional outcomes other than improvements in HbA1c 
and also cardiovascular risk. 
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4.5. Perceptions and barriers to nutrition therapy adherence  
As proposed in this study’s hypothesis number 3, patients with poor glycaemic control 
identify barriers to nutrition recommendation compliance differently from those 
identified by patients with adequate glycaemic control (P<0.05). Subjects with poor 
glycaemic control believe that a balanced and proper diet takes too much effort, is more 
expensive than other diets, implies different meals from the rest of the family, and is 
composed by less than enough food. Additionally, they also have an increased 
agreement with the statements indicating that diet doesn’t seems to affect glucose 
control, confusion with nutrition information, and insufficient knowledge about 
nutrition in diabetes. 
The results of the agreement with the statements regarding confusion with the nutrition 
information received and with the need for more advice on what is a proper diet seem 
to reflect a concern of diabetes patients with the knowledge and skills related to self-
care and food intake. Confusion and perceived high complexity of diet is correlated with 
low adherence (Mata et al. 2010) and in the cases in my study agreed more with the 
feeling of confusion with nutrition information. 
The results in this study show evidence of an unreasonable optimism in regard with diet 
adequacy that is visible in cases and in controls, even in individuals with substantially 
increased BMI and high excess intakes of energy, lipids, and carbohydrates, and in 
individuals that seem confused with the nutritional information they received and state 
they would like to know more about nutrition in diabetes. In this study, the existence of 
optimistic bias in perceived diet adequacy is not related to a particular characteristic or 
set of characteristics and the mean difference in the classification of diet adequacy on 
the Likert response scale is not correlated (P>0.05) with consultations with a dietitian, 
HbA1c, BMI, WC, energy intake, carbohydrate intake, duration of diabetes, and age at 
the time of diagnosis.  
It is believed that individuals have a general optimism about the outcome of an event, 
related with a strong but unjustified sense of immunity. When asked to classify their 
agreement with the likelihood of an event, individuals are also more unjustifiably 
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optimistic when they perceive having some form of control over that event  (Neil D. 
Weinstein 1980). This can explain the difference in perceived diet adequacy, as 
individuals have more control over their own diet, and thus perceive the outcomes of 
their diet in a favourable way. According to the literature, the tendency to believe that 
one's own outcomes of an event are more favourable than that of others can partly 
explain why health education messages can be ineffective (Weinstein and Klein 1995). 
As health education can even exacerbate unrealistic optimism (Weinstein and Klein 
1995), the communication of nutrition practices in T2DM should be made with care, by 
skilled professionals.  Diet and proper eating behaviour are widely prevalent diabetes 
counselling topics and, as is shown in my results, even the patients who never had a 
consultation with a dietitian were previously advised to follow a diet or meal plan. I 
propose that, although repeated and intensive counselling can be correlated with better 
disease outcomes (Franz et al. 2010), it should be promoted by skilled nutrition 
professionals (Pastors et al. 2002; Spahn et al. 2010) due to its effectiveness in 
facilitating health and food behaviour change and in improving glycaemic control, but 
also due to its possible association with the accentuation of unrealistic optimism, which, 
in turn, can be a determinant of diabetes self-care (Tahmasebi et al. 2013; Weinstein 
2003). 
 
4.6. Postprandial glycaemia 
In order to assess glucose response, all patients were offered a controlled breakfast, 
constructed according to the dietetic recommendations for patients with T2DM (ADA 
2008; Franz and Bantle 2012), and composed of foods traditionally consumed in a 
Mediterranean culture and obeying to usual eating habits in the region. It was decided 
that the breakfast should account for approximately 400 kcal, based on the prediction 
equations of the IOM (2002) that estimate a daily energy requirement of 2000 Kcal for 
adults over 50 years old with a lifestyle that includes only the light physical activity 
associated with typical day-to-day life, and considering that a nutritionally balanced 
breakfast should account for 20% to 25% of the daily energy intake (Leidy et al. 2009; 
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Leidy 2013; Schusdziarra et al. 2011). In this study, cases and controls did not 
significantly differ in glycaemia up to 120 minutes post-meal (P>0.05). 
In non-diabetic individuals, PPG peaks 60 min after the start of a meal and rarely exceeds 
140 mg/dl, before decreasing to pre-prandial levels within up to 180 minutes (ADA 
2001). This evidence, together with the association of postprandial hyperglycaemia with 
several diabetes complications, like macrovascular disease, increased risk of 
retinopathy, oxidative stress, inflammation, and endothelial dysfunction, has prompted 
the proposal of guidelines suggesting a PPG level below 140 mg/dl for 2 hours after the 
start of a meal as adequate  (Ceriello et al. 2008; Franc et al. 2010). 
All of the subjects in this study presented a PPG level above 140 mg/dl, indicating a 
postprandial glycaemia associated with diabetes complications. Furthermore, it is also 
recommended that the difference between pre-prandial and postprandial glucose 
should not exceed 40 mg/dl (Ceriello et al. 2008). All but 4 subjects (2 cases and 2 
controls) had differences above 40 mg/dl, which can be classified as glucose excursions 
(i.e. elevated differences between pre-prandial and postprandial glucose).  
The previous results in this study indicating that a high proportion of subjects have a 
usual diet that is inadequately high in energy, sugars, total carbohydrates, and lipids, 
besides the correlations these variables showed with HbA1c, lead me to suggest that 
the glucose excursions that resulted from the experimental breakfast may have been 
less pronounced than the ones subjects’ experience in their daily diet. It can be proposed 
that outside the experimental setting for this study, some patients can choose to have 
a breakfast which can be classified as less nutritionally adequate than the one that was 
offered during data collection. Analysis of the dietary data makes it safe to assume that, 
due to the high intake of total carbohydrates and sugars, subjects can experience 
postprandial hyperglycaemia, independently of their perceived glycaemic control, 
measured by HbA1c. As previously reported, excess intakes were common in both cases 
and controls, and excess intake of energy and sugars is associated with poor glycaemic 
control.  
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My results confirm this study’s hypothesis number 1, allowing to conclude that there is 
no significant difference in PPG between patients with adequate glycaemic control and 
those with poor glycaemic control. Mean glycaemia values were similar in cases and 
controls up to 120 minutes after a meal. 
Although the group of subjects in this study is a particular one (doing only metformin as 
OADA), if we consider the high prevalence of excess energy and carbohydrates intake 
reported, diabetes patient’s cardiovascular risk can be high in subjects who, based on 
HbA1c levels, believe themselves in a proper state of glycaemic control. 
Similarities in PPG also extend to the mean difference between pre-prandial and 
postprandial glucose and further studies should be promoted in order to analyse the 
role of different OADA in PPG in subjects with adequate HbA1c. 
The similarities in PPG between the subjects also add to the evidence that HbA1c, 
despite being considered an adequate predictor of glycaemic control that can be used 
for establishing a diagnosis, does not account for daily fluctuations of glucose (S. 
Colagiuri 2011; Sakuma et al. 2011; Woerle et al. 2007).  The mean values for glucose 
excursions in both cases (M=57.1 mg/dl, SD=13.29 mg/dl) and controls (M=63.0 mg/dl, 
SD=19.73 mg/dl) were significantly above the recommendations stating that this value 
should not exceed 40 mg/dl (Ceriello et al. 2008) and may imply an added risk for 
cardiovascular events (Coutinho et al. 1999). Self-measure of blood glucose is the most 
appropriate way to identify PPHG and the results from this study show that patients 
should be empowered to overcome their low prevalence of glucose self-measure, as 
regular data of postprandial glycaemia can help to adjust diabetes care plans. 
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4.7. Diabetes complications perception and glycaemic control  
This section of the data collection interview used a set of questions based on the Risk 
Perception Survey for Diabetes Mellitus (RPS-DM) questionnaire (Walker et al. 2007a). 
This set of questions was analysed prior to its application by a test-retest method, where 
a sample of eight T2DM patients was used to assess its reliability. 
The sample was interviewed using only the set of questions regarding diabetes 
complications perception and, a week after, they were retested with the same version 
of the scale. According to the Wilcoxon signed ranks test for paired samples, the scale’s 
scores did not significantly differ between test and retest moments (P>0.05). The scales 
had an acceptable internal consistency, with Cronbach's alphas between 0.7 and 0.8, 
and all original items were retained because there would be no increase in Cronbach's 
alpha with the deletion of any item (Streiner and Norman 2008).  
Although this adaptation and translation process does not validate the subscales of the 
RPS-DM for this population, I suggest that the items used can be considered reliable and 
allowed to achieve this study’s objectives regarding risk perception. 
One of the determinants of diabetes self-care is the perception of harmful effects 
resulting from the disease and its complications (Day 2000; Frostholm et al. 2007; Griva 
et al. 2000; Tahmasebi et al. 2013).  Although research on diabetes self-care has tried to 
identify determinants for adherence to professional recommendations, there is limited 
evidence on the relationship between risk perceptions and health behaviours that 
reduce the risk of disease (Weinstein 2003). Nevertheless, the literature suggests that 
adherence to treatment and management of T2DM is influenced by patients’ illness 
perception (Harrison et al. 2003). 
In this study, both cases and controls seem to have a biased diabetes complication 
perception, favouring less individual likelihood of diabetes complications. My data 
supports the evidence that diabetes patients significantly underestimate their risk for 
diabetes complications (Calvin et al. 2011; Meltzer and Egleston 2000). The group of 
cases, with mean HbA1c that is associated with higher incidence of macrovascular 
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disease, appears to believe that they are less likely to experience diabetes complication. 
When analysing the agreement with a lower likelihood of serious health problems, and 
not only diabetes complications, the results are similar. 
A bias in perceived risk, reflecting an unreasonable optimism can be inferred by the 
results, with cases appearing to have a poorer awareness of the complications of 
diabetes and of the risk of other serious health problems. When considering the 
perception of individual disease risk, both cases and controls also reflect a biased 
assessment, with a predominance of the perception that they have “almost no risk” or 
“slight risk” for several health outcomes. 
The biased risk perception in the subjects is also reflected in their environmental risk. 
The events or outcomes analysed in this type of risk where considered moderately 
probable, with a mean score for environmental disease risk that is statistically similar 
(P>0.05) to the mean score for personal disease risk, in both cases (mean personal 
disease risk=1.9 and environmental disease risk=2.2) and controls (mean personal 
disease risk=2.0 and environmental disease risk=2.1). 
The high perceived health risk from pesticides and extreme weather reflects current 
knowledge on risk perception, stating that individuals tend to attribute a higher risk to 
situations which they cannot control and that associated to a greater sense of dread 
(Brewer et al. 2007; Walker et al. 2007b), like the effects of extreme weather, that are 
usually presented as catastrophic.  
The optimistic bias subscale in the set of questions used to assess diabetes complications 
perception has a high score in both cases (M=3.4) and controls (M=3.3), which indicates 
an unreasonable optimism in diabetes risk perception. 
Cases and controls also score their personal disease risk in a way that indicates low risk 
perception. Cases present a significantly lower risk perception for personal disease 
(P=0.03). These results are incongruent with the physiologic, anthropometric and 
nutritional data I collected, as these indicate a moderate or high risk for diabetes 
complications in most of the subjects. 
Chapter 4: Discussion 
166 
 
The literature reports associations between risk perception and risk knowledge and 
communication (Fischhoff et al. 1993; Fisher et al. 2002). In the subjects of this study, I 
tested for association between previous counselling and risk perception, but did not find 
any significant correlation. 
The associations between risk perception and consultations with health professionals 
are erratic, with negative and positive correlation between the scales of risk perception 
and the same variable (e.g., between nurse consultations in the last year and risk 
perception in controls), with widely varying significance, which I believe to be related 
with the random nature of the measurement. 
My data does not support the evidence in the literature associating lower education 
with a higher optimistic bias (Walker et al. 2007b), but I infer that the homogeneity in 
education in the participants in this study may have led to these results. Approximately 
40% of the subjects had only completed primary education, corresponding to 4 years of 
schooling, and 20% of patients only had 6 years of schooling. The literature suggests that 
individuals with higher education can incur in a more adequate self-care management 
due to a greater knowledge of diabetes (Cauch-Dudek et al. 2013) and, consequently, 
may have a better risk perception for diabetes complications. 
The lack of diabetes symptoms is another factor that the literature associates with poor 
perceived risk for diabetes complications (Frijling et al. 2004), as they are considered 
motivators of protective behaviour (Stover et al. 2001). In the sample, previous 
diagnosis of diabetes complications was low, which may have led subjects to have an 
unreasonably low risk perception, as they feel their disease is under control. 
When assessing the odds ratio for optimistic bias, I found that 65 out of the 66 subjects 
in this study presented an unreasonably optimistic view of their risk for complications 
(value above 2 points in the scale’s score) while the remaining subject was more 
associated with a realistic or pessimist perception (score below 2 points in the optimistic 
bias scale). This implies that I would not find a significant odds associated with 
inadequate glycaemic control due to the high prevalence of optimistic bias in both cases 
and controls.  
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These results further support the need for health education interventions in both 
groups, regarding risk perception and risk knowledge. 
These results confirm this study’s hypothesis numbers 4 and 5. Patients show an 
optimistic bias in the risk perception for diabetes complications, reporting a lower 
likelihood of experiencing diabetes related complications than the likelihood of health 
problems caused by environmental risk factors, like riding an automobile, extreme 
weather, or pesticides. Patients, even those with poor glycaemic control, also report a 
lower individual risk for diabetes complications when asked to compare themselves to 
other patients. 
Nevertheless, as proposed in hypothesis number 5, there is a significant difference in 
risk perception for diabetes complications between patients with adequate glycaemic 
control and those with poor glycaemic control. The optimistic bias recorded in the risk 
perception for personal disease is stronger in subjects with poor glycaemic control. 
More studies on diabetes risk perception are needed to enlighten its role as a 
determinant of glycaemic control, but my results show that patient’s diabetes 
knowledge, together with the way that risk is communicated to patients, must be 
improved. 
 
4.8. Statistical model for prediction of inadequate glucose control  
When analysing risk perception data by creating classification cut-offs in the scales’ 
midpoint and computing the odds ratio associated with the likelihood of being in the 
group of cases, I confirm the results obtained when analysing mean differences in risk 
perception scales indicating that a low personal disease risk perception is associated 
with a poor glycaemic control (section, 3.4., table 32). 
When assessing the odds ratio for optimistic bias, I found that 65 out of the 66 subjects 
in this study presented an unreasonably optimistic view of their risk for complications 
(value above 2 points in the scale’s score) while the remaining subject was more 
associated with a realistic or pessimist perception (score below 2 points in the optimistic 
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bias scale). This implies that I would not find a significant odds associated with 
inadequate glycaemic control due to the high prevalence of optimistic bias in both cases 
and controls.  
These results, together with the associations of glycaemic control with socio-
demographic (age, education), anthropometric (BMI), nutritional (high energy and 
sugars intake), and psycho-behavioural (perceived barriers to proper nutrition, engaging 
in food shopping, and personal disease risk perception) characteristics, prompted me to 
construct a binary logistic regression model, in order to identify  covariates that predict 
poor glycaemic control. 
For this procedure, I first produced a multilevel method, with covariates entered by 
ascending order of the statistical significance previously determined in parametric and 
non-parametric tests for correlations and group comparisons, which resulted in a 
predictive model that did not fit the data. The Hosmer-Lemeshow goodness-of-fit 
statistic was considered non-significant (P=0.321) and I recorded several interactions 
between covariates. One example of such interactions is the confounding effect of age 
in the correlation between occupation and glycaemic control, as previous analysis shows 
that the significant predictor of glycaemic control should be subjects’ age. Older subjects 
are more likely to be retired, resulting in a statistically significant association between 
employment status and glycaemic control when the data are not age adjusted. 
Due to these results and to the exploratory nature of this study, I conducted a backward 
stepwise covariate selection, based on the probability of the likelihood-ratio statistic, as 
proposed by Hosmer and collaborators (Hosmer et al. 2013). From the variables entered 
in the analysis, the most parsimonious resulting model identified age, personal disease 
risk, and BMI above 29 kg/m2 as significant predictors of glycaemic control (table 37):  
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Table 38. Predictors, coefficients, and odds ratio in the logistic regression model for inadequate glycaemic control 
Predictors Beta SE 
Wald 
statistic 
Wald 
statistic 
p-value 
Odds 
ratio 
95% CI for 
odds ratio 
Age at data 
collection 
-0.103 0.041 6.18 0.013* 0.902 0.832 - 0.978 
Personal disease 
risk 
2.801 1.125 6.20 0.013* 0.061 0.007 - 0.551 
BMI above 29 
kg/m2 
1.308 0.616 4.51 0.034* 3.70 1.11 – 12.36 
       
Model constant 11.062 3.730 8.79 0.003* - - 
SE – Standard error 
CI – Confidence interval 
* Statistical significant statistica at the 0.05 probability level 
 
 
I found that the model had a good fit to the data, according to the Hosmer-Lemeshow 
statistic (X2(7)= 14.97, P=0.036), and moderate effect sizes (Cox & Snell R2=0.27, 
Nagelkerke R2=0.36). By assessing the Wald statistic and its significance, I also concluded 
that each covariate has a significant contribution to the prediction of the outcome. 
These results allow to propose that younger subjects, with low individual disease risk 
perception, and BMI above 29 kg/m2 have a high probability of presenting poor 
glycaemic control. The odds ratio values associated with each predictor allows to 
analyse their role in glycaemic control. Increased age is associated with an odds of 0.902 
for the outcome under study, or, conversely, a decrease of approximately 10% 
(considering the difference between 1, the maximum probability of an outcome, and 
0.902) in the predicted probability for inadequate glycaemic control. A good (high) 
perceived personal disease risk implies a decrease of approximately 94% in predicted 
probability for inadequate glycaemic control, while BMI over 29 kg/m2 implies an 
increase of 270% in predicted probability. 
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The logistic regression model provided the predictor coefficients that can be used in the 
logistic equation formula (figure 12), from which probability of an event can be 
predicted. 
 
𝑃(𝑌) =
1
1 + 𝑒−(𝑏0+𝑏1𝑋1𝑖+𝑏2𝑋2𝑖+ … +𝑏𝑛𝑋𝑛𝑖)
 
Figure 12. Logistic regression equation (Hosmer et al. 2013). 
 
Using the equation constant and coefficients, the probability of inadequate glycaemic 
control associated with different values in the predictor covariates can be predicted. For 
example, a 57 year old subject, with a score of 1.57 in personal disease risk, and a BMI 
over 29 kg/m2 is expected to have a probability of 89.5% of having inadequate glycaemic 
control. 
Although this model does not include other variables that appear to be associated with 
group differences, this analysis identified age, personal disease risk, and BMI above 29 
kg/m2 as the strongest predictors of glycaemic control. In previous analyses regarding 
age, both current age and age at the time of T2DM diagnosis seem to be associated with 
glycaemic control and allow the inference that younger patients have higher HbA1c 
levels. Nevertheless, the number of years of disease duration did not correlate with 
glycaemic control nor was a significant predictor in the regression model, which seems 
incoherent with the data from all other age-related variables. Regarding this topic, data 
from the UKPDS describing a patient follow-up for 11 years shows that as disease 
progresses, the prevalence of poor glycaemic control increases (UKPDS Study Group 
1998a). This happens after a period of lower HbA1c, which is thought to be due to 
pharmacotherapy. It is known that patients with an early diagnosis may have a more 
severe form of the disease, as the pathophysiological mechanisms involved with 
diabetes onset are associated with a higher degree of insulin resistance (D’Adamo and 
Caprio 2011). Diabetes treatment aims at normalizing glycaemia and, if successful, 
patients will experience a period of lower HbA1c. As diabetes progresses, most 
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individuals require an increasing number and higher doses of medications to achieve 
glucose, lipid, and blood pressure targets to prevent and/or delay chronic complications. 
This can be a predictor for proper glycaemic control in older individuals, which I could 
not assess in this study due to the sample selection and case-control study design. As 
the mean number of years of diabetes duration were moderately low (6.0 years in cases 
and 6.4 years and controls) and did not significantly differ between groups (t(54)=-0.34, 
P=0.730), the analysis of the impact of years of diabetes duration in glycaemic control 
was not comprehensive. Thus, as diabetes duration in the participants in this study 
presents a mean value around 6.2 years (SD=4.48 years), the regression model is 
believed to be valid if applied to subjects that are in the first decade of disease duration. 
I propose that these results can contribute to the monitoring and counselling of T2DM 
patients, as health professionals can assess in a fast, inexpensive, and non-invasive way 
the predictors identified by the regression analysis. 
 
4.9. Study limitations 
One of the limitations of this work is the fact that I did not assess nutrition knowledge 
and the specific nature and frequency of previous nutrition advice, apart from collection 
of data on the prevalence of dietitian consultations. An analysis of the way that nutrition 
education is offered to these patients could help to further enlighten patient 
motivations and barriers to the adherence to a proper diet.  
The assessment of PPHG was also limited due to the fact that patients did not interrupt 
their usual OADA therapy for the purpose of data collection. The rationale for this 
methodological aspect in this study was that I aimed to replicate as closely as possible 
patient’ daily routine, in order to eliminate bias resulting from the experimental setting. 
I propose that additional data collection moments in these patients, using different 
experimental meals, could have helped to discuss the impact of PPHG on glycaemic 
control, and also of the relation between nutritional composition of the meal and 
glucose excursions.  
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Lastly, I suggest that although this study’s results were obtained in subjects that were 
all selected from the same population, in an effort of assuring that both cases and 
controls share the same opportunity for exposure to the predictor variables under study, 
the sample size can have affected the ability to extrapolate from the data. This study’s 
inclusion criteria implied that subjects must not differ in their pharmacotherapy, in order 
to prevent biases in PPHG. This resulted in a reduced sampling universe, which was 
further reduced by some patients’ refusal in being a part of this study due to the 
expected duration of data collection interview, even if the data collection schedule was 
constructed according to patients’ availability. The fact that the target population is 
composed only of patients receiving metformin or even no OADA restricts the 
applicability of this study’s results to a subset of T2DM patients. Nevertheless, on the 
overall, I propose that this study provides evidence that patients with T2DM should be 
targeted in health education interventions, even the ones with adequate glycaemic 
control, providing that strategies for education must be carefully considered.  
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5.1. Conclusions 
The data analysed in the present study provided answers to the research questions and 
confirmed all research hypotheses.  
I conclude that younger age, high BMI, and biased personal disease risk perceptions are 
important predictors of glycaemic control and should be addressed by education 
interventions. 
I verified that there are no significant differences in PPG between T2DM patients with 
adequate glycaemic control and those with poor glycaemic control. The glucose 
response to a mixed-meal containing 75 of carbohydrates did not significantly differed 
up to 120 minutes after ingestion. I conclude that patients which are considered as 
having a proper glucose control may be unaware that they exceed the recommended 
rise in PPG, and thus may be at a higher than expected risk for macro and microvascular 
events. 
The data from the present study show that the prevalence of blood glucose self-
monitoring is low and independent of glycaemic control, especially in low-schooled, 
older patients. As self-monitoring is the only practical way to detect PPG, efforts should 
be made to promote regular glucose self-monitoring. 
Patients with adequate glycaemic control can be classified has having a better 
compliance of nutrition recommendations, due to their lower intake of energy and 
sugars. Nevertheless, both patients with adequate glycaemic control and patients with 
inadequate glycaemic control present excess intakes of energy, total cholesterol, 
saturated fatty acids, and sugars, when compared with their individual nutritional 
estimates. Additionally, the majority of the subjects were overweight and did not 
engage in recommended levels of physical activity. I conclude that all patients are in 
need of nutrition counselling addressing these issues, even those with apparently 
adequate glycaemic control. 
Inadequate glycaemic control is related to a greater agreement with the existence of 
barriers to the adherence to nutrition recommendations. Subjects with poor glycaemic 
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control believe that a balanced and proper diet takes too much effort, is more expensive 
than other diets, implies different meals from the rest of the family, is composed by less 
than enough food distributed by too many daily meals, is incompatible with social 
gatherings, and doesn’t seems to affect glucose control. These patients are also more 
confused with the nutrition information they have received. 
Both patients with adequate glycaemic control and patients with poor glycaemic control 
show an optimistic bias in their risk assessment of diabetes complications. 
There is a significant difference in risk perception of diabetes complications between 
patients with adequate glycaemic control and those with poor glycaemic control. The 
latter group of patients has a more biased opinion of their likelihood of personal disease 
risk. Additionally, the risk of health complications due to environmental risks is 
perceived similarly to the personal disease risk. Exposures such as medical tests, air 
pollution, pesticides, or household chemicals, are considered as likely to cause health 
problems as several known and common diabetes complications, like high blood 
pressure or cardiovascular disease. 
Overall, adhering to nutrition therapy in T2DM seems to present several challenges, 
especially for patients with inadequate glycaemic control, who seem more prone to 
experience difficulties in integrating the nutrition recommendations into their daily life 
activities.  
I propose that just as it is important for individuals with diabetes to have regular 
consultations with a doctor for assessing health status and disease monitoring, it is also 
important for T2DM patients to receive continuing nutrition education and support for 
lifestyle changes. Consultations with a dietitian are associated with better glycaemic 
control, and so they should be encouraged for all patients with T2DM. Furthermore, 
T2DM management is achieved primarily by patient self-care, and health professionals 
must be aware of the multiplicity of barriers that can constitute an obstacle for self-care.  
Health professionals need to consider specific patient characteristics in order to provide 
proper clinical assessment, treatment, education, and continued medical care. Nutrition 
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education should be tailored to the perceptions of patients and should positively 
discriminate subjects above or below the internationally proposed HbA1c cut-points for 
glycaemic control.  
I conclude that, when counselling individuals to make changes in their nutrition 
behaviour, besides considering food preferences, cultural practices, environmental 
factors, and the patient’s willingness to implement changes, dietetics and nutrition 
professionals must also consider the existence of unreasonable optimism in the 
perception of diabetes complications. 
 
5.2. Recommendations 
Following the analysis of the data and the conclusions that can be drawn, I propose the 
following recommendations, which consist in care practices that currently are not 
common in the Algarve and, in my opinion, can contribute to the improvement of the 
quality of life of T2DM: 
I. All patients should be referred to a dietitian after diagnosis for a set of nutrition 
education sessions, with the first session with the lowest possible cost for the 
patient. Not all patients had a consultation with a dietitian after being diagnosed, 
and if the patient is first diagnosed in the public Health Service, the price of each 
consultation is expected to be around €2.5 for the patient; 
II. Educational materials for quick assessment of overall diet quality should be used 
as a screening tool in diabetic consultations, independently of the health 
professional conducting them. The prevalence of poor eating behaviour is 
expected to be high and this procedure can help clinicians to reassess current 
treatment and plan future interventions. Short, concise questions, currently 
used by skilled dietitians to assess time between meals, number of daily meals, 
and to estimate the number of carbohydrate servings ingested daily, can provide 
valuable information on overall diet quality and can constitute a reproducible 
inquiry tool for use in a structured nutrition education program; 
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III. Structured nutrition education is needed in all patients, independently of 
recorded glycaemic control. A sustained, structured program for nutrition 
education should be put in place and offered to all patients. It is imperative that 
this program is organized in multiple sessions, planned at set time intervals, 
which must also include physical activity promotion, clear information about 
nutrition in diabetes, and how to properly shop and prepare healthy, low-cost 
meals; 
IV. Postprandial glucose measurement should be more thoroughly recommended 
by clinicians and be the subject of additional research. Similarities in subjects 
with different HbA1c makes this the only way to record PPHG and provide data 
for changing the course of treatment and monitoring regimens. All patients 
should be advised to, at least once a day for a period of one to two weeks before 
their consultation with a doctor, record their PPG to properly assess their 
glycaemic control and cardiovascular risk; 
V. Clinicians should ensure that the use of glucometers is adequate and promote 
educational interventions in patients focused on the proper procedure to record 
PPG. 
VI. Health professionals providing diabetes care should be aware of novel 
technologies for glucose monitoring, like phone applications, and consider their 
use.  
VII. Educational interventions must consider that patients have a poor risk 
perception of diabetes complications and a proper risk communication should 
be promoted. 
VIII. Additional research on the determinants for dietitian consultation adherence 
should be encouraged.  
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(ENGLISH) INFORMED CONSENT FORM                   ID:  
You are being invited for a research project regarding nutrition and type 2 diabetes. Please read this form 
carefully and afterwards, place all questions you feel necessary to the researcher providing this document. 
If you agree to be a part of this project, sign your full name in the appropriate space at the bottom. 
1. Purpose of the study: To collect data regarding nutrition in type 2 diabetes and regarding your 
perceptions on health complications;  
2. Procedures: We will offer you a breakfast composed by bread, ham, apple and milk and, after your 
meal, we will measure your blood glucose using a similar device to the one you may have used before 
for self-monitoring. We will measure your blood glucose before breakfast and 30, 60, 90, and 120 
minutes after. Then, we will interview you about your eating habits and lifestyle. Finally, we will 
measure, with your consent, your weight, height, and waist circumference;  
3. Time involved: We expect your participation to last approximately 2 hours and 45 minutes; 
4. Possible risks and discomfort: There will be a minimal risk of discomfort, associated with the 
procedures of glucose measure;  
5. Possible benefits: The data collected in this study may help improve the quality of care provided by 
your healthcare professional. Additionally, immediately after the data collection interview, you may 
place any questions you have regarding nutrition and type 2 diabetes to a registered dietitian; 
6. Costs and compensations: Your collaboration does not imply any costs or any monetary 
compensation for your time; 
7. Confidentiality: Your identity will be kept private and we will not divulge any information that allow 
your identification. All results from this study will not include your name or personal information; 
8. Right to disallow: You may disallow the use of your data at any time, without any consequences. All 
questions regarding your collaboration can be answered at this moment or at a later time, directly 
with the researcher responsible for the study, through the phone number 966 472 993 or through 
the e-mail address epinto@ualg.pt. 
 
  
Your informed consent:                      ID:  
I declare that I have understood the research project outlined above and that I freely consent to collaborate. 
 
Participant’s signature: ________________________________________________________ ____/____/______ 
 
Researcher’s signature: ________________________________________________________ ____/____/______ 
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(PORTUGUÊS) DOCUMENTO DE CONSENTIMENTO INFORMADO               ID:  
Está a ser convidado a participar numa investigação sobre alimentação e diabetes tipo 2. Para aceitar 
participar deve ler a descrição da sua colaboração até ao fim e assinar no espaço apropriado, por favor.  
1. Propósito do estudo: Recolher informação para estudar a alimentação na diabetes tipo 2; 
2. Procedimento: Vai ser-lhe realizada uma entrevista sobre os seus hábitos alimentares e opinião 
sobre a diabetes e registado o seu peso, altura e circunferência da cintura. Depois, vamos pedir-
lhe que ingira um pequeno-almoço composto por pão com fiambre, leite e maçã e que consinta 
que, após 30, 60, 90 e 120 minutos lhe façamos uma punção capilar para obtenção da glicemia 
pós-prandial em aparelho portátil. 
3. Tempo envolvido: Prevê-se que a sua participação demore 2 horas e 45 minutos; 
4. Possíveis riscos e desconforto: Há riscos e desconforto mínimos associados à sua participação, 
relacionados com a medição da glicemia;  
5. Possíveis benefícios: A informação recolhida neste estudo poderá ajudar o seu prestador de 
cuidados de saúde; Para além disso, no final da entrevista poderá colocar todas as questões que 
considerar pertinentes acerca da alimentação na diabetes a um dietista. 
6. Considerações financeiras: A sua colaboração não implica compensação nem tem custos 
associados; 
7. Confidencialidade: A sua identidade é confidencial e não será divulgada informação que 
comprometa o seu anonimato. Todos os resultados deste trabalho, como eventuais publicações 
científicas, não incluirão o seu nome ou outra informação pessoal; 
8. Os seus direitos: Se decidir participar tem o direito de retirar o seu consentimento a qualquer 
altura, sem qualquer prejuízo ou consequência. Todas as questões ou dúvidas sobre a sua 
participação podem ser esclarecidas agora, diretamente com o responsável, ou através do 
telefone 966 472 993 ou endereço de correio eletrónico epinto@ualg.pt. 
 
 
  
Consentimento:                     ID:  
Declaro que li e compreendi este documento e que participo voluntariamente na investigação. 
 
Assinatura do participante: _________________________________________  ____/____/______ 
 
Assinatura do responsável: _________________________________________  ____/____/______ 
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Cranfield, 
Bedfordshire, 
MK43 0AL, England 
Tel +44 (0) 1234 
758349 
Fax +44 (0) 1234 
758380 
www.cranfield.ac.uk 
 
 
 
 
Date  21st March 2015 
 
 
 
 
 
 
 
 
 
 
 
 
Dear Dr Newman 
 
Project Reference No 13/15:   Glycaemic control: The role of nutritional intake, 
postprandial glycaemia, nutrition therapy adherence and diabetes complications. 
 
Thank you for submitting the CUHREC approval form.   
 
I can confirm that your study has been granted retrospective ethical approval from the 
CUHREC Committee. 
 
Subsequent to approval being given by the committee, applicants are responsible for: 
 
 Destruction of personal data within the specified time period.   
 
 
Yours sincerely 
 
 
 
Dr Ruth Bevan 
Vice Chairman  
Cranfield University Health Ethics Committee 
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ENGLISH TRANSLATION OF THE TEXT OF THE ETHICS COMITTE APPROVAL FROM THE 
ALGARVE HEALTH DIRECTORATE 
 
 
 
11-01-2012 
SUBJECT: Submission for approval of a research project on nutritional intake, 
perceptions, and behaviour in patients with T2DM 
 
The present letter intends to report that the Directive Council of the ARS Algarve has 
analysed your submission and the report of the Ethics Commission regarding the 
proposed study and decided to authorize the research project, as stated in the excerpt 
of the meeting transcription presented below: 
 
“…The request for the conduction of the study was approved by unanimity, considering 
that all of the required legal and ethical conditions are guaranteed”. 
 
Kindest regards, 
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1. Study title 
The intended study is titled “Dietary intake, postprandial glucose and nutrition therapy 
adherence in T2DM patients” 
 
2. Project background 
Treatment and prevention approaches for type 2 diabetes (T2DM) focus on achieving glycaemic 
control, in order to manage the disease and to prevent or slow its related health complications. 
General management of patients with diabetes consist of patient education, medical nutrition 
therapy, physical activity, and pharmacological therapy with oral hypoglycaemic agents or 
insulin [1] 
Patient education enables people with diabetes to improve their knowledge, skills and 
confidence, allowing them to self-manage their condition. It’s a critical element in diabetes care 
and can have a strong effect on biomedical outcomes [1, 2]. Patient education, defined as 
diabetes self-management education (DSME) by a task force jointly convened by the American 
Association of Diabetes Educators and the American Diabetes Association, consists in “the on-
going process of facilitating the knowledge, skill, and ability necessary for diabetes self-care”, 
and includes, among other goals, patient empowerment to incorporate nutritional management 
and physical activity into his lifestyle and the development of personal strategies to promote 
health and behaviour change [2]. 
Individuals who have diabetes should also receive individualized medical nutrition therapy to 
achieve treatment goals, preferably provided by a registered dietician, familiar with the 
components of diabetes nutrition therapy [3]. Modifying the type and amount of dietary 
carbohydrates can improve disease outcomes. Foods with a lower glycaemic index contain 
carbohydrates that are more slowly digested and absorbed and a diet that consists largely of 
fresh, unprocessed fruits and vegetables, moderate levels of lean protein and beneficial fats, 
minimal amounts of processed carbohydrates and saturated and trans fats can significantly 
reduce postprandial glucose levels [4]. Evidence also suggests that dietary measures can be 
effective in weight reduction and glycaemic control irrespective of the macronutrient 
composition (low fat or low carbohydrate), provided that there is adequate energy restriction, 
reduction in saturated fat to less than 7%, and adequate provision of dietary fibre [3, 5].  
 222 
 
The role of postprandial glycaemia (PPG) in overall glycaemic control and as a risk factor for 
cardiovascular complications has also been considered in the literature, as patients with good 
glycaemic control (measured by HbA1c) can show elevated PPG. According to the American 
Diabetes Association, [6] HbA1c levels below or around 7% are associated with long-term 
reduction in macrovascular disease and a reasonable A1C goal for T2DM adult patients is 7%. A 
2009 review [7] shows that the relative contribution of PPG in the overall glycaemic control is 
around 70% in patients with HbA1c below 7.3%, independently of the timing of the meal during 
the day, stating also that postprandial hyperglycaemia is common in T2DM patients, even in 
those who are considered to have good overall glycaemic control. In fact, achievement of target 
HbA1c and fasting plasma glucose levels does not necessarily indicate that good glycaemic 
control is continuous throughout the day [8]. Furthermore, a meta-analysis by Coutinho et al. 
[9] showed an exponential relationship between the incidence of cardiovascular events and 
elevated glycaemia 2 hours after a meal, resulting in an increased mortality risk, also reported 
in a large European patient sample  [10]. A 2010 review [8] shows that PPG values 1 hour after 
breakfast were predictive of all-cause mortality and suggests that hyperglycaemia after meals is 
associated with increased cardiovascular risk independent of fasting hyperglycaemia, adding to 
the evidence indicating that PPG may be a more dominant cardiovascular risk factor than fasting 
hyperglycaemia. 
International Diabetes Federation has developed clinical guidelines for PPG and recommend 
that 2 hour post-meal glucose levels are kept below 7.8 mmol/L [11] and delta postprandial 
glycaemia is considered normal between 30 and 50 mg /dl [12]. Furthermore, considering PPG 
variations throughout the day and between different meals, inﬂuenced by the blood glucose 
level before the meal, the nature and quantity of carbohydrate consumed or the anti-diabetic 
treatment [8], the management and treatment of T2DM must also consider this important 
marker of diabetes complications [13]. 
Although the goals and objectives of treatment approaches for T2DM are known, their 
translation into daily routine seems difficult. Studies that have evaluated adherence do dietary 
recommendations have shown poor results, especially those with T2DM patients [14, 15], who 
appear to have high calories and saturated fat intakes, accompanied by low fibre intake [16]. In 
fact, self-reported adherence is higher for pharmacological therapy than for a proper diet, even 
if weight loss trough diet and exercise also results in an improved glycaemic control [17]. 
Although medical nutrition therapy can be successful, diabetics treated by diet alone in a general 
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practice setting have significant rates of complications and are less likely than those on 
medication to be adequately monitored [18]. This can imply that compliance with dietary 
recommendations can be improved and that inadequate patient education strategies are being 
used. 
Barriers to chronic disease self-management and to diabetes care have also been identified. Daly 
et al. [19] suggest that the type and duration of diabetes, illness and other health conditions and 
psychosocial factors, medication use, meal plans, exercise and home glucose testing are factors 
that inﬂuence diabetes treatment. Gazmararian et al. [20], using a focus group design, identified 
the emotional toll from the diagnosis and lifestyle changes to treat diabetes, the failure to 
recognize the risks and consequences of an asymptomatic condition, the perception of lack of 
follow-up on patient education interventions (refresher courses, support group discussions, for 
example) and the availability of different education modalities as barriers to diabetes care. 
Despite all these known barriers, few studies have specifically examined the reasons for the low 
adherence to dietetic recommendations or how patients view dietary restrictions [21]. 
Interventions aimed at improving patients’ ability to modify their diet need to consider 
preferences and barriers when setting goals for treatment and more research is needed to 
successfully translate the benefits of interventions to individuals in the community, outside the 
controlled research environment.  [17]. This implies that the assessment of patient’s 
characteristics, their motives and motivations to comply with nutrition therapy, considering also 
the traditional Mediterranean style diet associated with Portugal, may offer some insight into 
the skills and adjustments needed to promote the adequacy of current nutrition therapy 
guidelines in a clinical, on the field, setting. Furthermore, although the health risks of poor 
diabetes care are well known by the scientific community, the general population is yet to fully 
appreciate the hazards of this condition [1]. Additionally, considering the effect of PPG in 
glycaemic control and its role as a cardiovascular risk factor, and that PPG measures provide 
immediate feedback on the effect of foods and meals [22], an investigation considering the 
associations between socio-demographic characteristics, nutrition recommendations 
compliance, meal composition and PPG could contribute to the discussion of the optimal 
nutrition therapy in T2DM and to the design of strategies to reduce the burden of diabetic 
complications. 
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3. Study aims  
The aim of the present study is to undertake a comparative analysis regarding PPG, nutritional 
therapy adherence, and risk perceptions of diabetes complications in patients with T2DM. 
The specific research questions in this research are: 
 Does adherence to nutrition recommendations differ between patients with adequate 
glycaemic control and those with poor glycaemic control? 
 What barriers patients identify in the adherence to nutrition recommendations? 
 What is the association between PPG levels and HbA1c? 
 How do patients with T2DM with different glycaemic control perceive their risk of 
diabetes complications? 
 
4. Recruitment and consent 
4.1. Study population 
The study population is composed by patients with T2DM receiving health care in a Diabetes 
Clinic in the municipality of Faro, in the Portuguese region of the Algarve. The clinic is integrated 
in a regional association of diabetes patients (AEDMADA).  
 
4.2. Inclusion and exclusion criteria 
The inclusion criterion for this study were: 
 Male or female patients with medical diagnosis of T2DM for at least 12 complete weeks, 
obtained by  previous assessment and identification of one or more of the following: 
HbA1c ≥ 6.5%, FPG ≥ 126 mg/dl (7.0 mmol/l), 2h plasma glucose ≥ 200 mg/dl (11.1 
mmol/l) during a OGTT, or presence of classic hyperglycaemia symptoms and a random 
plasma glucose ≥ 200 mg/dl (11.1 mmol/l); 
 Age below 85 years 
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The exclusion criteria were: 
 Undergoing a pharmacotherapy regimen with insulin or any ADOA other than 
metformin; 
 Diagnosis of degenerative disorder of the central nervous system; 
 Following a lactose-free or gluten-free diet; 
 
4.3. Recruitment 
The subjects in the study population will be invited to be a part of this study in the diabetology 
consultations in the AEDMADA Diabetes Clinic. Patients who conform to the inclusion criteria 
will be approached by the physician conducting the consultations, who will briefly explain the 
study and ask for patient permission to a later contact by the researcher. Having been provided 
with the contact details by the physician, the researcher will contact the patients by telephone 
and explain the study, setting up an individual appointment with each patient that manifests 
interest in being recruited. In this initial contact, patients will informed that they should attend 
the appointment before any intake of food and that a breakfast will be provided, free of charge, 
whether they accept or not to be a part of the study. Furthermore, it will be clearly stated at this 
time that participants will not be compensated monetarily for their collaboration or reimbursed 
for their expenses with any trips to attend the appointment. 
The individual appointments will be held in the School of Health of the University of Algarve, 
conducted solely by the researcher. In this appointment, the study protocol will be discussed 
thoroughly with each patient and the final consent will be taken through an informed consent 
form. Annex 1 presents the informed consent form in Portuguese and in English. 
For this inquiry to take place, it was recommended by the AEDMADA clinic that a written 
approval by the Regional Health Directorate should be sought. A copy of this study protocol was 
submitted for evaluation and the Regional Health Directorate gave its approval to the study. The 
written approval is presented in Annex 2, in its original form and translated into English by the 
researcher, as the Regional Health Directorate stated that an English version could not be 
provided. 
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5. Study methodology 
The data for this study will be collected during an individual interview conducted by the 
researcher, predicted to last between 150 minutes and 180 minutes and to start between 8:00h 
A.M. and 9:00h A.M, according to patients’ convenience. The interviews will be conducted 
according a previously prepared interview script and will follow a semi-structured pattern. 
Annex 3 presents a copy of the interview script, in Portuguese and in English. 
The interviews will be held in a consultation office. 
The inquiry will include the collection of data under five categories: 
VI. Clinical and socio-demographic data 
VII. Anthropometric assessment; 
VIII. Glucose response to a meal; 
IX. Lifestyle and care assessment; 
X. Risk perception of diabetes complications and optimistic bias. 
 
5.1. Clinical and socio-demographic data 
Clinical data on the patient will be collected from the clinical file of the patient that exists at the 
AEDMADA diabetes clinic. This will be done on the day of the interview but after it has been held 
and after patient consent. This data will include the date of diagnosis, previous diagnosis of 
diabetes related complications, lipid profile levels, and the HbA1c level. Lipid profile (total 
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides) and HbA1c are routinely 
measured in each patient consultation at the diabetes clinic, which are held once in every 
trimester for all of the patients. The HbA1c assays are done by an accredited laboratory under 
the guidelines proposed by the Portuguese Ministry of Health for all assays in the National 
Health System and for all Clinical Laboratories [23]. This guideline directs that blood samples 
must processed by the same laboratory, with a method certified by the National 
Glycohemoglobin Standardization Program and calibrated according to the standards of the 
International Federation of Clinical Chemistry and Laboratory Medicine. 
During the course of the interview, patient will also be asked to provide some socio-
demographic data, namely age, gender, marital status, number of persons living in the 
household, occupation, and years of schooling. 
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5.2. Anthropometry and blood pressure assessment 
During the interview, patients will be asked consent for the interviewer to measure their height 
to the nearest centimetre and weight to the nearest 0.1kg, using a stadiometer (Seca, Model 
217, Seca, United Kingdom) and a scale (Seca, Model 899, Seca, United Kingdom), appropriated 
for medical use and calibrated according to the manufacturer’s instructions. Waist 
circumference will also be measured, using an extensible measuring tape (Seca, Model 218, 
Seca, United Kingdom). 
All the measurements will follow the International Standards for Anthropometric Assessment 
procedures [24], following also the guidelines for patients’ intimacy and comfort. 
Blood pressure will also be collected during this stage, using a digital sphygmomanometer 
(OMRON, M6 Confort, OMRON Healthcare Co., Ltd., Japan) for upper-arm measurements, 
validated for clinical use in adults through the European Society of Hypertension International 
Protocol [25]. Patients will be seated and the left arm will be used for blood pressure 
measurement. Three blood pressure measurements will be conducted and the data used in this 
study will correspond to the mean value of the three measurements.  
 
5.3. Glucose response to a meal 
In order to assess glucose response, all patients will be offered a controlled breakfast, 
constructed according to the dietetic recommendations for patients with T2DM [26, 27], and 
composed of foods traditionally consumed in a Mediterranean culture and obeying to usual 
eating habits in the region.  
The experimental meal will have the following nutritional composition (table 1): 
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Table 1. Foods and nutritional values for the experimental breakfast 
Food 
Amount 
(g) 
Energy 
(Kcal) 
Protein 
(g) 
Fat 
(g) 
Carbohydrates 
(g) 
Sugars 
(g) 
Wheat bread 80 231.13 6.72 1.76 45.84 1.68 
Ham 30 90.98 5.40 7.65 0.15 0.15 
Milk 200 93.68 6.60 3.20 9.80 9.80 
Apple 135 76.78 0.27 0.68 18.09 18.09 
 Total 492.6 19.0 13.3 73.9 29.7 
 
Glucose will be measured with a portable blood glucose monitoring system (Freestyle Lite, MK-
23, Abbot, USA) before breakfast and then in 30 minute intervals, up to 120 minutes after 
breakfast. 
The same device will be used for all patients to minimize variability and test strips will be from 
the same batch. The blood samples for testing will be obtained by puncture in the fingers of the 
left hand and all the strictest safety and hygiene procedures will be assured. 
 
5.4. Lifestyle and care assessment 
The interview will also include questions on dietary and physical activity habits, and assessment 
of tobacco and alcohol use.  
Physical activity will be assessed with the short-form version of the International Physical 
Activity Questionnaire (IPAQ) [28], translated to Portuguese [29]. 
This assessment of food intake will be achieved by the recall of all the food items ingested by 
the patient in the previous day, plus questions regarding usual eating habits, both aided by the 
use of images representing usual food items and different portions [30], which were presented 
to the patients for clarification of their description. 
Patients will also be enquired regarding their agreement with different barriers to nutrition 
therapy adherence identified in the literature [17, 20, 21, 31, 32]. The data will be collected using 
a Likert-type scale with 5 points and, also, with an open-ended question, in order to collect data 
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on the views of this specific population on the barriers to a proper diet and on the reasons 
behind the adherence to nutrition therapy. 
 
5.5. Risk perception of diabetes complication and optimistic bias 
The interview will included items adapted from the in-person completion form of the Risk 
Perception Survey for Diabetes Mellitus (RPS-DM) questionnaire [33]. The items were translated 
and adapted into Portuguese and face validity of the subscales was ensured by translating the 
original English version into European Portuguese according to recommendations for cross-
cultural research [34]. The scales were translated and then back-translated by two independent 
translators, without access to the original version. These versions were evaluated by a 
Psychology and Linguistics expert with English skills, in order to ensure the accuracy of the final 
version.  All the items in this scale have a straightforward translation, due to the fact that literal 
equivalents exist in Portuguese. 
 
5.6. Interview and data collection steps 
The flow of the interview will be as follows: first, the patient will be explained the purpose of 
the study and read the informed consent form. Those who choose to be a part of the study will 
have their blood glucose measured and then offered the experimental breakfast. Patients who 
decline participation will be thanked for their time and provided with a free breakfast voucher, 
to be used inside the university’s grounds. 
Participants will go through the anthropometric assessment and afterwards offered the 
experimental breakfast in a room next to the interview room. They will have their breakfast 
seating down, alone. After breakfast, they will be conducted to the interview room and the data 
collection interview will proceed. The interviewer will be monitoring the time and, at the 
designated hours for glucose monitoring, will stop the interview and proceed with the glucose 
assessment. 
The last data to be collected will be regarding blood pressure. 
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6. Data analysis 
Data will be analysed with IBM-SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA). Patient 
description and characterization will be presented as mean values, median values, and standard 
deviations. 
The Kolmogorov-Smirnov test will be used to assess adherence to the Normal distribution and, 
accordingly, parametric or non-parametric statistical procedures will be used to compare 
groups. For comparisons between two groups, Student’s t-test or Mann-Whitney test will be 
used computed, while a one-way analysis of variance (ANOVA) with Bonferroni post-hoc 
correction is intended for multiple group comparisons. 
The statistical procedure for analysing the differences between cases and controls in qualitative 
variables is expected to be the chi-square test, or Fisher’s exact test, were applicable. 
Statistical significance in all procedures will be determined by two-tailed analysis and set at 0.05. 
 
7. Dissemination of information 
All the resulting information from this study can eventually be published in peer-reviewed 
journals, after following all patient anonymity and confidentiality requirements. Furthermore, 
the researcher will also write a brief report on the nutritional analysis that each patient dataset 
will be subjected and deliver it in a signed and sealed envelope directly to the physician 
responsible for the diabetes consultations at the AEDMADA clinic. In this way, participants and 
their physician will be informed of the results of the nutritional assessment. 
 
8. Ethical issues 
This study implies a slight discomfort for the participants, associated with the finger punctures 
needed to assess glucose on the day of data collection. Nevertheless, as this measurement can 
constitute a usual disease self-monitoring behaviour for some of the patients, it is expected the 
discomfort to be minimal. 
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9. Data protection 
Only the physician responsible for the diabetes consultations will know the identity of the 
participants and, at the end of the study, will be given access to the data regarding nutritional 
assessment. 
The collection of data from the patients’ clinical files will be conducted after a written formal 
consent is given and only the researcher will have access to the files. 
Throughout all of the study, only the researcher will be responsible for coding the informed 
consent forms and for data collection, and will be the only one who will have access to the entire 
dataset. 
The dataset will be stored in a password protected computer belonging to the University of 
Algarve, exclusively used by the researcher. When the data is no longer needed, the researcher 
will ensure the safe deletion of the data file. 
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